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Chapter I 
1. Hereditary cancer syndromes 
Neoplastic disease in humans may occur sporadically, that is without a clear familial disposition, or 
less commonly as an inherited disease. Several distinct familial cancer syndromes are known and the 
underlying genetic cause has been identified of a number of these 46. The tumours in these syndromes 
are usually phenotypically identical to their sporadically occurring counterparts. Both syndromes with 
benign and with malignant tumours are known. In cancer syndromes tumours generally develop at a 
younger age than those seen in the non-familial setting and are often multiple 101. Most inherited 
cancer syndromes with an autosomal dominant inheritance pattern are caused by mutations in tumour 
suppressor genes. Far fewer inherited cancer syndromes are caused by mutations in (proto-)oncogenes, 
notably mUltiple endocrine neoplaSia type 2 and familial medullary thyroid cancer caused by 
mutations in the RET gene 99, 107, hereditary papillary renal cell carcinoma caused by mutations in the 
MET gene 124 and some cases of familial melanoma caused by mutations in the CDK4 gene 165. In 
addition to the classical tumour suppressor genes and proto-oncogenes, other genes involved in 
hereditary cancer are DNA repair genes. 
1.1 oncogenes 
Oncogenes are the mutated counterparts of cellular genes, proto-oncogenes, that physiologically 
function as regulators of cell proliferation and programmed cell death (apoptosis). The products of 
oncogenes, also known as oncoproteins, act as growth factors, growth factor receptors, proteins 
involved in intracellular signal transduction and proteins involved in apoptosis 101. Mutations in 
oncogenes are of a dominant nature, resulting in gain of function and loss of susceptibility to control. 
The oncogene concept was formed after the discovery that in animals retroviral gene integration in 
host DNA could lead to tumour formation 153. Two mechanisms may lead to transformation by 
retroviral oncogenesis. Firstly, a viral oncogene (v-onc) may be inserted in the host DNA. In this case 
the viral oncogene is derived from a cellular homologue, c-onc. Alternatively, retroviral insertion of 
DNA may lead to altered expression of cellular proto-oncogenes. In humans retroviral oncogenesis is 
exceedingly rare, in most cases cellular proto-oncogenes are activated by mutations and translocations. 
To date more than 100 (cel1ular) oncogenes have been identified. 
1.2 tumour suppressor genes 
Tumour suppressor genes are cellular genes both alleles of which must be inactivated for oncogenesis. 
Evidence for the existence of tumour suppressor genes came from cell fusion experiments in which the 
tumour-forming capacity of cancer cells was lost after fusion with normal cells or other cancer cells. 
Loss of chromosomes from these hybrid cells could restore the oncogenic nature of cells. Therefore 
loss of or, as would be shown later, inactivation of specific genes could lead to malignant 
transformation of cells 84. The concept of tumour suppressor genes, also called anti-oncogenes, was 
further developed by Knudson by observation of the epidemiology of sporadic (unilateral) and familial 
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(bilateral) cases of retinoblastoma. In this model, called the "two-hit" hypothesis, a germline mutation 
in a tumour suppressor gene (the first hit) is followed by a somatic mutation in a given target cell (the 
second hit), thus resulting in a total lack of functional gene product 78. Although mutations in tumour 
suppressor genes are of a recessive nature, meaning that both alleles must be inactivated for 
tumorigenesis, the resulting inherited phenotypic trait is dominant. To date, at least 12 tumour 
suppressor genes have been identified and partially characterized. However, the frequent observation 
that tumour cells show loss of chromosomes or parts of chromosomes indicates that many more 
tumour suppressor genes exist in the human genome 101. It is most likely that these tumour suppressor 
genes do not lead to inherited cancer syndromes, possibly owing to embryonic lethality with haplo-
insufficiency, but do playa role in multistep carcinogenesis and progression 159. 
1.3 genes involved in genetic integrity 
The DNA of the human genome is constantly threatened by endogenous and exogenous factors. Over 
time a sophisticated system has developed through evolutionary pressure to maintain the integrity of 
the genome. DNA damage leads to mutations. If activating mutations in growth regulating proteins 
(proto-oncogenes) and inactivating mutations in tumour suppressor genes are not corrected by the 
DNA repair machinery, uncontrolled growth, cancer, may ensue. Repair genes, alternatively known as 
mutator genes, encode proteins that function in the proof-reading and correction of replication errors 
in DNA. Two major forms of DNA repair are nucleotide excision repair' (NER) and mismatch repair 
(MMR). Germline defects in NER genes lead to well-defined clinical syndromes, including xeroderma 
pigmentosum. In addition to non-neoplastic features, cancer frequently develops in patients with NER 
defects 155. Mutations in mismatch repair genes result in a dominantly inherited cancer syndrome in 
which the most frequently encountered neoplasm is colon cancer (hereditary non-polyposis colorectal 
cancer, HNPCC). Mutations in several genes engaged in mismatch repair may lead to HNPCC. The 
characteristic feature of this syndrome is found in microsatellite instability, re."iulting from faulty repair 
or replication of di- or trinucleotide repeats 75. In addition to instability caused by NER and MMR 
defects, gross chromosomal abnormalities such as complete loss or gain of chromosomes or parts 
thereof are often seen in cancer. Underlying this phenomenon, named CIN for fhrornosomal 
llstability, may be faults in genes involved in structural organisation of the chromatin, genes coding 
for proteins involved in the mechanics of mitoses (including centrosome formation) and checkpoint 
genes monitoring cell cycle progression 83. 
2. Neurofibromatoses 
The neurofibromatoses are a hereditary group of neurocutaneous disorders (phakomatoses) of which 
the 2 major forms are neurofibromatosis type 1 (NFl), also known as von Recklinghausen's disease, 
and neurofibromatosis type 2 (NF2). Until 1987, NFL and NF2 were considered variants of a single 
form of neurofibromatosis. The first extensive description of neurofibromatosis by Friedrich von 
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Recklinghausen dates from 1882 110 (the history of the neurofibromatoses is reviewed by Ahn 1). 
Features described as characteristic of neurofibromatosis were the numerous skin tumours, often 
leading to severe malformation. In a minority of neurofibromatosis patients the disease was dominated 
by intra-cranial tumours with few or no skin manifestations. This "central" form of neurofibromatosis 
(as distinct from "peripheral" neurofibromatosis) was first described by Wishart in 1822 in a patient 
with bilateral tumours at the cerebello-pontine angle 160. In addition to these bilateral cerebello-
pontine tumours, Wishart described other intracranial tumours connected to the meninges. These 
tumours are now known as meningiomas. The familial nature of neurofibromatosis was noted soon 
after the first description by von Recklinghausen. An extensive survey of patients with bilateral 
cerebella-pontine angle tumours by Gardner and Frazier in 1930 confirmed the dominant inheritance 
pattern of central neurofibromatosis 49. Furthermore, it was found that only approximately 1 in 20 
patients with neurofibromatosis presented with the central form. Despite these findings the central 
from of neurofibromatosis was regarded as a variant and not as a distinct disease. In 1987 linkage 
analysis assigned the NFl gene locus to the pericentromeric region on chromosome 17 10, /29 whilst in 
the same year the NF2 gene locus was mapped to chromosome 22 JJ4, providing definitive proof for 
segregation of these diseases. 
2.1 neurofibromatosis type 1 
NF 1 is a hereditary disease with an autosomal dominant inheritance pattern in which the main 
symptoms are caused by hamartomatous, dysplastic and benign neoplastic lesions which may 
occasionaI1y undergo malignant transformation. 
2.1.1 epidemiology 
The incidence of NFL is estimated at 1 :3000 66 . A minor reduction in the life span was found in one 
study. However, the cause of death did not differ significantly from that of the general population. 
Some rare diseases, including juvenile chronic myeloid leukemia and pheochromocytoma are seen 
with an increased frequency in individuals affected by NFl 140. Genetic fitness is reduced in NFl 
patients. 
2.1.2 clinical signs and symptoms 
The diagnostic criteria for NFl have been established by the National Institute of Health 104. Common 
findings in NFl are cafe-au-lait spots, neurofibromas, Lisch nodules and skin-fold freckling 56. Cafe-
au-Iait spots are pigmented skin macules characterized by increased pigmentation of basal 
keratinocytes. The cafe-au-Iait spots increase in number and size with ageing and are generally the 
first signs to appear in NFl or are present at birth 56. Lisch nodules are hamartomatous lesions of the 
iris, these do not cause any visual impairment. Neurofibromas are benign, nodular, sometimes 
pedunculated, non-encapsulated growths composed of elements similar to those in normal nervous 
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tissue but with a disorganised pattern. Severe malformation and cosmetic problems may be caused by 
plexiform neurofibromas. These tumours diffusely infiltrate large nerve trunks and are composed of 
constituents of normal nerves with a disproportionate amount of matrix substance. Plex iform 
neurofibromas may attain a large size. Additional findings in NFl patients include intellectual 
impairment, macrocephaly, dysplastic bone lesions, short stature, hypertelorism and the presence of 
high-signal-intensity lesions on magnetic resonance images in the brain 56, 67. Complications resulting 
from plexiform neurofibromas, skeletal malformation and brain tumours include scoliosis, epilepsy, 
endocrinological abnormalities and an increased risk of malignant tumours 34. 
To date there is no cure for NFl. Surgery may be necessary for neurofibromas, which owing to their 
disfiguring nature may lead to psychosocial problems. The complete removal of plexiform 
neurofibromas is often not possible because of their large size and infiltrative growth characteristics. 
NFl patients are best managed by a multidisciplinary team, with a single co-ordinator who may 
involve other specialist team-members when the need arises 67. 
2. /.3 the NFl gene and protein 
Cloning of the NFl gene was accomplished in 1990 29,154,156. The gene spans 300kb and consists of 
59 exons separated by 58 introns. Embedded within an intron in the NFl gene are 3 other genes which 
are transcribed in the opposite direction of the NFl gene. After splicing an 11-13kb NFl mRNA is 
formed 85. The mutation rate of the NFl gene is higher than would be expected on statistical grounds, 
even when the large size of the gene is taken into account 34. The large size of the NFl gene hampers 
mutation detection in affected and at risk individuals. However, analysis of mutations in the NFl gene 
has confirmed its role as a tumour suppressor gene. In NFl disease severity varies widely and is 
unpredictable even within a single affected family. This disease heterogeneity is likely to be caused by 
modifier genes 41. 
The NFl gene encodes a 2818 aminoacid protein, named neurofibromin. This protein contains a GAP 
(QTPase ~ctivating nrotein) related domain (GRD) and acts as a negative regulator for the RAS signal 
transduction pathway 47. However, the exact mechanism of tumour formation by lack of 
neurofibromin remains to be resolved. 
2.2 neurofibromatosis type 2 (NF2) 
NF2 is now recognised as a distinct clinical entity. This is reflected in the names by which NF2 was 
previously referred to: bilateral acoustic neurofibromatosis (BANF), central neurofibromatosis, 
hereditary bilateral vestibular-schwannoma syndrome and Wishart-Gardner-Eldridge syndrome 1, 67. 
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2.2.1 epidemiology 
NF2 is about 10 times rarer than NFl with an incidence of about 1:33.000-1:40.000 live births. Mean 
survival after diagnosis is 15 years; first signs and symptoms usually present in the second or third 
decade. Penetrance is close to 100% at 60 years 42. 43. 
2.2.2 clinical signs and symptoms 
The distinguishing feature of NF2 are bilateral vestibular schwannomas, previously referred to as 
acoustic neuromas. These occur in over 98% of NF2 patients 105. These neoplasms are benign 
proliferations of Schwann cells, with a characteristic histological appearance and originating from the 
nerve sheath. Although schwannomas are located eccentric to the nerve proper and do not directly 
involve the nerve fibers they produce symptoms through pressure effects, especially in confined 
spaces. The schwannomas in NF2 develop on the vestibular branch of the eighth cranial nerve. In a 
population-based study 43 first symptoms were deafness in 44% of patients, tinnitus in 10% and 
balance problems in 8%; in the remaining patients presenting symptoms were caused by other central 
nervous system tumours. 
Approximately half of NF2 patients develop meningiomas 43, 105. Like schwannomas, these are benign 
tumours which probably arise from arachnoidal cells in the meninges 4. 17. Symptoms caused by these 
tumours result from their space-occupying nature and include headaches and seizures. In addition to 
these neoplastic features NF2 patients have ocular disease manifestations of which only (sub)capsular 
cataracts cause symptoms 22, 72, 74. 82. 
Apart from vestibular schwannomas, schwannomas may develop in other sites in NF2 patients 
including other cranial nerves, skin and in particular along spinal nerve roots 19,43.93.94. 
The diagnostic criteria for neurofibromatosis type 2 (NF2) were established in 1988 104. Slight 
modifications were introduced in 1997 (Table I) 56. 
Epidemiological and clinical data indicated that 2 clinical forms of NF2 could be discerned. The more 
clinically severe form, called the Wishart type, has an early age of onset, rapid disease course, multiple 
meningiomas and bilateral VS's; the latter less often as presenting sign. A milder form named the 
Gardner type, has a later onset and presents with VS's and fewer meningiomas. Disease progression is 
slower 67. 
2.2.3 NF2 gene and genetics 
Genetic linkage analysis located the NF2 gene on chromosome 22 in 1987 114. After narrowing down 
the region with new markers (reviewed by Bijlsma 18) the gene was cloned 1993 113, 147. 
2.2.3.1 human, mouse, rat and Drosophila NF2 
The human NF2 gene, consisting of 17 exons, is located on the long arm of chromosome 22 and spans 
approximately lOOkb 113.147. Two major splice variants are known: in isoform I exon 16 is skipped 
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and all aminoacids encoded by exon 17 are included, generating a 595 aminoacid protein, in isoform II 
exon 16 containing an in-frame stop codon is included, producing a 590 arninoacid protein with 11 
new C-terminal aminoacids 14, 109. The isoforms thus differ in their C-terminal composition, whereby 
the isoform I C-terminus has a predicted helical configuration and is more hydrophobic than isoform 
II. No functional specificity is known for the isoforms. In northern blots a predominant 4.5kb mRNA 
was seen in a wide range of tissues, together with weaker messenger signals at 2.6 and 7kb 113. 147. In 
addition to these variants, several other less prominent splice variants have been described 63. 109. 
Table I. Diagnostic criteria for NF2 56 
Individuals with the following clinical features have confirmed (definite) NF2: 
I. bilateral vestibular schwannoma (VS), or 
II. family history of NF2 (first-degree family relative) plus: 
1. unilateral VS under 30 years of age, or 
2. any 2 of the following: meningioma, glioma, schwannoma, juvenile posterior subcapsular 
lenticular opacities / juvenile cortical cataract. 
Individuals with the following clinical features should be evaluated for NF2 (presumptive or probable 
NF2): 
1. unilateral VS under the age of 30 years plus at least one of the following: meningioma, 
glioma, schwannoma, juvenile posterior subcapsular lenticular opacitiesl juvenile cortical 
cataract. 
II. Multiple meningiomas (:::: 2) plus unilateral VS under 30 years of age or one of the following 
glioma, schwannoma, juvenile posterior subcapsular lenticular opacities/ juvenile cortical 
cataract. 
The protein encoded by the NF2 gene is homologous to a family of proteins of which the principal 
members are ezrin, radixin and moesin. This homology is reflected in one of the names suggested for 
the NF2 protein, merlin, for moesin, ezrin and radixin like protein 147. Alternatively, the NF2 protein is 
known as schwannomin /13. Ezrin, moesin and radixin (collectively the ERM proteins) are part of a 
superfamily related to the erythrocyte band 4.1 protein. 
Phylogenetic conservation has been proven for the NF2 gene, with murine and rat NF2 homologues 
sharing 90% sequence identity with human NF2 and 98% identity on protein level. Northern blotting 
and RT -PCR analysis revealed the presence of transcripts in a wide variety of tissues 31, 32, 58-60. 68. 76. 
In Drosophila a NF2 homologue has been described with 55% sequence identity with human NF2. 
Although the homology of Drosophila NF2 is greatest in the N-terminus, the C-terminal Similarity is 
of note as this region of NF2 shows less overlap with other homologous proteins (see below, 4. ERM 
and related proteins) 81. 95. 
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2.2.3.2 mutations in NF2 related- and sporadic vestibular schwannomas and meningiomas 
Mutation detection in the NF2 gene is hampered by the relatively low sensitivity of the techniques 
employed, single strand conformational polymorphism (SSCP) analysis and denaturing gradient gel 
electrophoresis (DGGE). Theoretically DGGE should have a high sensitivity for mutations in the NF2 
gene. However, intronic mutations and deletions of complete exons are not uncovered by this 
technique. In addition, mosaicism will hamper detection by DGGE. Maximal sensitivity of SSCP and 
DGGE is at best 60% for the NF2 gene. Alternative techniques such as southern blotting or the protein 
truncation test (PIT), may be more sensitive but are more labour intensive or may not be consistently 
successful because of technical difficulties (19; personal observation). Using SSCP and DGGE 
mutations have been detected in NF2 gene that segregate with the disease 166(and references herein). 
Most mutations found in the NF2 gene lead to truncation of the NF2 protein, suggesting inactivation. 
Truncating mutations have likewise been described in sporadically occurring schwannomas and 
meningiomas. The frequent loss of the second NF2 allele in sporadic and NF2 related tumours 
confirms the NF2 gene as a classical tumour suppressor gene. No clear mutation hotspots are present 
in the NF2 gene, although combining published data and taking the effects of mutations on secondary 
structure into account indicate that the distribution of mutations is not random 55, ISO, 166. 
2.2.3.3 genotype-phenotype correlation 
Analysis of mutations segregating in NF2 families shows that a clear genotype-phenotype correlation 
exists in NF2. Mutations resulting in NF2 protein truncation more often lead to severe (Wishart) 
phenotype, whilst missense mutations are most often associated with a mild (Gardner) phenotype 44, 
lUI, 166. In theory the association of truncating mutations with the severe NF2 phenotype could be 
caused by a dominant negative effect. However, several mutations described in the literature lead to 
severe truncation of the NF2 protein. It is questionable whether the resulting extremely short proteins 
retain any biological activity 166. It seems more likely that truncating mutations result in an unstable 
NF2 protein that is rapidly degraded 57. Conversely, missense mutations may result in either a less 
stable NF2 protein ·or in a NF2 protein that is functionally less effective. In this setting complete 
absence of NF2 protein resulting from accelerated degradation would lead to a severe phenotype as 
seen in NF2 patients with truncating mutations and some missense mutations. Most patients with 
missense mutations presenting with a mild phenotype would harbour a NF2 protein with diminished 
function. However, identical mutations have been identified in patients with distinct clinical subtypes 
21, 127. In addition, phenotypic variation has been observed in monozygotic twins, although 
concordance for disease severity (in severe and mild forms) was preserved ll. Also, in patients with 
mild phenotypes splice-site mutations theoretically leading to truncated proteins and whole gene 
deletions leading to an absence of NF2 protein have been described. 27,98,120,158, this thesis, chapter 
VI). It is possible that mosaicism underlies some cases of phenotypic variation 21, 77. Alternatively, 
modifier genes may cause disease variation in selected cases 27, although the phenotypic variation 
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within families does not support the idea of their existence in NF2. In splice-site mutations some 
residual wild-type protein is likely to be formed, thus leading to a mild phenotype. 
2.2.3.4 NF2 mutations in other tumours 
Several different types of human neoplasms that show loss of chromosome 22 markers have been 
screened for NF2 mutations. Apart from in pleural mesotheliomas and melanoma metastases, NF2 
mutations have only sporadically been detected in other tumour types 8,15, 16, 36, 37, 64, 71. 76, 102, 116,117, 
130,138,141,157. 
2.2.3.5 NF2 mouse models 
Attempts to generate a mouse (knock-out) model for NF2 have yielded some surprising results. 
Homozygous NF2 knock-out mice fail at the gastrulation stage, whilst heterozygotes develop 
metastatic epithelial and mesenchymal tumours 96, 97. No schwannomas or meningiomas were 
observed. Recently, NF2 transgenic mice were generated with mutant NF2 genes under control of the 
Schwann cell specific PO promoter 52, Mice carrying a transgene with an internal deletion (aminoacids 
39-121) demonstrated generalised Schwann cell hyperplasia (schwannosis) and Schwann cell derived 
tumours. Conversely, mice transgenic for a NF2 gene with a C-terminal deletion developed 
comparable to non-transgenic littermates and did not show evidence of Schwann cell hyperplasia or 
schwannomas, In both transgenic strains the mutant protein was detected along with endogenous wild-
type NF2 protein, The latter finding is surprising considering the unstable nature of mutant NF2 
protein in humans. Given the fact that both normal and mutant NF2 protein is detected, it is suggested 
that the mutant NF2 protein may function in a dominant negative way. 
2,3 other neurofibromatoses 
A further sub-classification of neurofibromatosis was suggested by Riccardi 112 giving 7 distinct 
neurofibromatosis subgroups based on clinical findings, The identification of the NFl and NF2 genes 
and the clinical segregation of NFl and NF2 using diagnostic criteria set out by the NIH render a 
further sub-classification of neurofibromatosis of little use. Nevertheless, some forms of 
neurofibromatosis may present as an overlap syndrome with features of NFl and NF2, possibly 
meriting a distinct class. 
3. The cytoskeleton 
The identification of the NF2 gene and the realisation that its protein product resembled cytoskeleton 
interacting proteins led to the assuption that the NF2 protein would also function in association with 
the cytoskeleton, 
The cytoskeleton is a filamentous structure involved in virtually all cellular processes and is not, as 
frequently and erroneously portrayed, simply a rigid scaffold, There are 3 major distinct cytoskeletal 
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systems: 1) the actin-based cytoskeletal system, also known as microfilaments; 2) intermediate 
filaments and 3) microtubules. As a general rule the proteins constituting the cytoskeleton are 
considered resistant to lysis and solubilisation with non-denaturing detergents. 
3.1 actin cytoskeleton 
The actin-based cytoskeletal system is a highly dynamic structure with a key function in cell shape and 
motility. The major protein in this system is actin present either as monomers, G- (for globular) actin, 
or as a polymerised form, denoted F- (filamentous) actin. The polymerisationlde-polymerisation 
process is the key mechanism underlying the dynamics of the actin system. Specialized cell surface 
extensions such as lamellipodia, microvilli and microspikes are formed by discrete aggregations of 
actin molecules. In addition a sub-membranous crosslinked actin network constitutes the cell cortex. 
F-actin, but not G-actin, resists extraction by non-ionic detergents. The actin cytoskeletal system is 
supplemented by a great number of binding proteins and interacts with the other elements of !he 
cytoskeleton. The organisation and induction of specialised actin-containing membrane protrusions is 
under control of a group of ras related proteins (small G-proteins), in particular Rho, Rac and Cdc42 2. 
80.139. 
3.2 intermediate filaments (IF) 
So named because of their intermediate size when compared to actin (microfilaments) and 
microtubules ("macrofilaments"), the IF's are a heterogeneous group of proteins with a common 
molecular arrangement. The exact function ofIF's is unknown, although they do provide resistance to 
mechanical stress. Intermediate filaments are highly resistant to solubilisation and are formed by 
polymerisation of (soluble) tetrameric precursors IW. 
3.3 microtubules 
Microtubules are formed from polymerised heterodimers of u- and ~-tubulin and associated proteins 
(microtubule f!ssociated Qroteins, MAP's). In contrast to the actin and IF cytoskeleton, microtubules 
are not attached to the cell membrane. Microtubules function in maintaining the overall architecture of 
the cytoplasm and thus are co-determinants of cell shape. In addition, microtubules form a major 
component of cilia and flagella and are essential parts of the mitotic spindle. Like other cytoskeletal 
elements the dynamics of microtubules are governed by polymerisation. In contrast to micro-filaments 
(actin) and intermediate filaments, microtubules do not resist extraction by non-ionic detergents. 
4. ERM alld related proteills 
The ezrin-radixin-moesin (ERM) proteins, with which the NF2 protein shares considerable homology, 
are a group of proteins with sequence, structural and functional similarity, acting in close concert with 
cytoskeletal and membrane proteins. As a group the ERM proteins are related to the erythrocyte 
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cytoskeletal protein band 4.1 and are part of a large superfamily of interrelated proteins 30, J52, To 
extend the family connection it has recently been suggested that the ERM family should be renamed 
FERM ("F" for 4.1) 30, Alternatively, the homOlogy of the NF2 protein has led to the suggestion of 
renaming the family MERM ("M" for merlin)8,s', 
4.1 ezrin, radixin and moesin 
The molecular build of ERM proteins is structurally similar. A globular N-terminal domain of about 
300 aminoacids is fonowed by an extensive alpha-helical segment of 160-170 aminoacids and a 
charged C-terminal segment of approximately 100 aminoacids with the variable presence of a proline 
rich stretch (Fig I), ERM proteins are highly homologous and share many functional similarities 
resulting to a certain extent in functional redundancy, This is in part reflected by: a) their ability to 
form homo- and heterotypic interactions, 7, 51, 150, b) the observation that the intracellular 
concentration of aU three ERM proteins ezrin, moesin and radixin needs to be reduced before cell-
morphological changes are observed 144 and c) the fact that moesin knockout mice develop normally 
without obvious cytoskeletal dysfunction 39, However, several findings indicate that the individu~l 
ERM proteins do in part function independently, For instance, radix in, unlike moesin, ezrin and the 
NF2 protein binds to the barbed end of actin fibers and is located at the cleavage furrow during 
cytokinesis 48, 122,148. 
Furthermore, the tissue distribution of ERM proteins is partly non-overlapping 5, 6, 12. 91, 126, 135, the 
ERM proteins exhibit a distinct receptor specific phosphorYlation pattern 45 and ERM family members 
differ in their sensitivity to calpain mediated cleavage 108, 135. From an evolutionary point of view it 
appears that there exists considerable pressure to withstand change in the composition of ERM 
proteins, indicating functional constraint. In addition, the 
similarity of ERM proteins to each other, coupled with this evolutionary constraint, indicates that 
individual ERM proteins have at least some distinct properties 150, 
4.1,1 ezrin 
The biological characteristics of ezrin are the subject of ongoing investigations and are thought to be 
representative of other ERM proteins, The 585 aminoacid ezrin protein has been localised to actin-
containing structures including membrane ruffles, microvilli, filopodia and possibly cell-to-cell 
contact points 5, 12, 23, 26, 54. There is strong evidence that ezrin is a regulator of cell morphology and is 
itself controlled by homotypic inter- and intramolecular interaction and possibly by heterotypic 
interactions, Regulation of ezrin and its effect on cell morphology was demonstrated by addition of 
epidermal growth factor to A-431 cells. This resulted in recruitment of ezrin to microvilli and 
membrane lUffles with concomitant phosphorylation on tyrosine residues 24. Initial experiments failed 
to demonstrate strong ezrin-actin-interaction 23, However, it was later shown that ezrin contains a C-
terminal actin-binding domain that is masked by the N-terminus through intramolecular and possibly 
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intermolecular interaction 3, 50, 51, 151. The C-terminal actin-binding domain was also shown to be 
present in other ERM proteins, but not in the NF2 protein 106, Actin-association was further 
substantiated by immunoelectron-microscopy, demonstrating localisation of actin along the length of 
the microvillus 12. Apart from the C-terminal actin-binding domains in ezrin an internal F-actin 
binding domain has been identified with the use of a solid phase assay, This domain is located 
between aminoacids 1-310, In addition in this assay it was found that aminoacids 13-30 are also 
important for actin-binding and that low affinity binding of G-actin is also seen in ezrin 115. 
Elimination of ERM proteins results in loss of microvilli and cell-cell contacts 144, whilst transfection 
of C-terminal ezrin domains induces the formation of cell surface extensions in Sf9 cells 89, Moreover, 
these morphological effects of C-terrninal ezrin domains are negatively regulated by head-to-tail (N-
terminal - C-terminal) interaction 35, 89, 90. The N- and C- terminal association domains involved in 
this interaction, termed N- and C-ERMAD for s:zrin-radixin-moesin £!ssociation Qomains, have 
subsequently been confirmed by other techniques 13. More recent experiments with deletion constructs 
show that additional domains in ezrin are involved in morphological changes, indicating that the 
situation is more complex than had been thought 26, 90. 
A working model has been proposed whereby ezrin is thought to be predominantly present in the 
resting cell in an inactive "dormant" state with masked C- and N-terminal ERMADs and F-actin 
binding sites. Activation of ezrin, probably involving phosphorylation, on serine and/or threonine 
. residues, results in relaxation of the protein structure with exposure of actin-binding sites 25, 26. 137. 
4.2 ERM effectors 
Previous observations have identified the Rho protein family as important regulators of cytoskeletal 
organisation (reviewed by Aspenstrom and Sasaki 9, 121). Recently it was shown that ERM proteins are 
phosphorylated in-vitro by Rho-kinase in a Rho dependent way 92. In addition, it has been shown that 
redistribution of ERM proteins in actin-containing membrane protrusions is Rho dependent and that 
this redistribution is preceded by phosphorylation of ERM proteins 132. Furthermore, the formation of 
stress fibers, focal adhesions and other actin-containing structures is dependent on an intact Rho 
pathway and the presence of moesin 87. Taken together, it seems likely that cytoskeletal organisation 
involves interplay ofERM- and Rho protein families. 
Studies on non-cytoskeletal ERM binding proteins are ongoing. Proteins that may interact with ezrin 
and other ERM proteins include CD44, ICAM-l, ICAM-2 and ICAM-3, CD43, protein kinase C, 
protein kinase A, Rho GDP dissociation inhibitor (RhoGDI), a regulatory protein for the NHE3 
Na+lH+ exchanger named E3KARP and a homologous phosphoprotein dubbed EBPSO (for s:zrin 
binding Qhosphoprotein 50) 40, 61, 62, 131, 142,149, /52, 163,164. 
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Co-localisation and interaction with CD44 has been documented for all three ERM proteins and has 
also been shown for the NF2 protein J 19, The interaction of ERM proteins with the cytoplasmic tail of 
CD44 appears to require phosphoinositol biphosphate (PIP]) 62. 103, Integrating the experimental data 
suggests that ERM proteins may have multiple activities including: 
1. Regulation of cell surface topography 
2, Regulation/relocation/concentration of integral membrane proteins (ICAM, CD43, CD44; 
NHE via EBP501E3KARP) 
3, Remodelling of the cytoskeletonlstress fiber induction (via Rho signalling) 
4, Indirect effects on transcription through the RhoIRac/Cdc42 pathway 
These effects are likely to be governed by homo- and/or heterodimerization / oligomerization, residue 
specific phosphorylation and phosphoinositides 25,26,88. 152, 
4.3 ezrill, radixill and moesin in neoplastic disease 
Despite the seemingly important role of ERM proteins in the cell, no direct links of ezrin, radixin and 
moesin with malignant transformation are known. Indirect evidence for involvement of ERM proteins 
in malignancy is found in cell transformation by overexpression of ezrin in-vitro and the high levels of 
ezrin found in hemangioblastoma 20, 73, In addition, moesin upregulation has been found to be 
associated with the estrogen receptor-negative breast cancer phenotype; it is suggested that 
upregulation of moesin may be associated with tumour invasiveness and metastasis 28, Conversely, 
decreased moesin expression was observed in cutaneous melanoma 70. 
4.4 ERM related proteins 
Of note is the recent report of a new member of ERM family with characteristics of a tumour 
suppressor gene. This gene, named DAL-l for Qifferentially expressed in §,denocarcinoma of the lung, 
is located on chromosome 18 (band pIl.3) and is expressed in a variety of tissues including intestine, 
kidney, pancreas, brain, lung and testis. The gene encodes a 503 aminoacid protein which localises to 
cell-cell junctions. The homology of DAL-l aminoacids 132-468 to the N-terminus of band 4.1 is 
73%. This region corresponds to the ERM homology (PERM) domain. Re-introduction of DAL-t in 
non-expressing non-small cell lung carcinoma suppressed growth, supporting its function as a tumour 
suppressor gene 146, 
5. The NF2 protein, merlinischwannomill, cytoskeleton and cell biological aspects 
The NF2 gene encodes a 595 aminoacid protein which on the basis of its similarity to the ERM protein 
was thought to function as a membrane-cytoskeleton linking protein 113. 147, A second less abundant 
isoform consists of 590 aminoacids. In western blotting the NF2 protein migrates at approximately 
69kD while its calculated molecular weight is slightly lower (66kD). The NF2 protein frequently 
presents as a doublet in western blots, probably due to phosphorylation (134. 143, our own unpublished 
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observations). The overall homology of the NF2 protein to ERM proteins is greatest in the N-terminal 
globular region. The NF2 protein is 43% homologous to ezrin overall and 61 % in the N-terminal 
domain (for details of the secondary structure of ERM proteins see 150). 
5.1 morphogenetic effects of NF2 expression 
In a similar way to ezrin, modulation of intracellular NF2 protein content may lead to morphological 
changes, although this is not found by all investigators 133. 162. Elongation of cell-processes by 
overexpression of wild-type NF2 constructs was described by Sainio et al. and Koga et al. 79. 119, but 
no induction of specialized cell surface projections was observed. Reducing intracellular NF2 protein 
by introduction of anti-sense oligonucleotides resulted in reversible rounding of cells and loss of 
adhesion to the substratum 69. In addition, overexpression of mutated NF2 constructs likewise induced 
loss of attachment 79. 
Although some functional overlap between NF2 and other ERM proteins is likely, localisation studies 
do not reveal identical spatial localisation for NF2 and other ERM proteins. A relationship between of 
ezrin and NF2 is indicated by redistribution of ezrin by over-expressed NF2 protein in cells 119, but 
immunofluorescent staining demonstrates distinct sub-cellular localisation. Moreover, the NF2 
protein, in contrast to ezrin is not found in microvilli. Co-localisation with moesin was found in 
fibroblasts 125, but not in cultured meningioma cells 53. 
5.2 sub-cellular localisation, actin binding 
Initial studies focused on confirming the proposed role for the NF2 protein as a membrane organizing 
protein (work described in this thesis, chapter 1 and 2). Subcellular localisation studies have been 
performed in transfected cells and in cells endogenously expressing the NF2 gene. A general finding is 
sub-membranous NF2 protein localisation and diffuse cytoplasmic presence. In addition, NF2 protein 
appears to be concentrated in membrane ruffles and other specialized membrane structures, but not in 
microvilli where ezrin in particular is found 33, 38. 53, 79, fI9, 123, 125. 133, /62. 
5,3 NF2 associating proteins 
Co-localisation studies in conjunction with GST pull-down experiments support interaction of the NF2 
protein with CD44 as has been demonstrated for ezrin 119, 149, Other candidate NF2-associating 
proteins have also been identified. Using the yeast 2-hybrid system Scoles et al. identified the actin-
binding protein ~II-spectrin (fodrin) as a NF2 interacting protein 128, The interaction was strongest for 
the type 2 NF2 isoform, possibly owing to masking of binding sequences in the type 1 isoform by 
intra- or inter-molecular association (see below). In addition, it was shown that naturally occurring 
missense mutants have a reduced affinity for ~II-spectrin, It is possible that the association of NF2 
protein with spectrin constitutes the NF2-F-actin link, 
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In rat Schwann cells NF2 protein was found to co-localise with Rho at paranodes 123. Rho is an 
attractive partner for NF2 considering its role in signal transduction and cytoskeletal arrangement and 
the documented interaction of ezrin with RhoGD!. 
Another putative binding partner for the NF2 protein uncovered by the yeast 2-hybrid system is a 
regulatory cofactor for the Na+lH+ exchanger (NHE-RF) 100. It was shown that this protein co-
localised with the NF2 protein to actin-rich cytoskeletal structures where it also co-localised with 
moesin. In GST pull-down experiments NHE-RF bound to N-terminus of the NF2 protein. The inter-
relatedness of ERM proteins, including NF2, is further substantiated by the independent finding that 
ezrin similarly binds NHE-RF, called EBP-50 by Reczek et al. Ill. 
In addition to these cytosolic and membrane proteins, other cytoskeletal proteins may interact with the 
NF2 protein. Conformation-dependent binding of NF2 protein to microtubules has been described, 
with localisation of the binding domain in the amino-terminal half 57, 161. That additional NF2-
interacting proteins may exist is indicated by the report of at least 5 associating proteins identified in 
GST pull down experiments 143. 
5.4 intra- and intermolecular association 
It has become clear that, similar to ezrin, homotypic and heterotypic interactions govern NF2 
functioning. Whilst introduction of NF2 mutants and isoform 2 in tumorigenic cell1ines fail to induce 
growth suppression, this can be achieved by the introduction of wild-type isoform 1 NF2 57, 69, 86, 145, 
(our unpublished observations). Furthermore, deletion of C-terminal aminoacids abolished the growth 
suppressive action. Neither a N-terminal or C-terrninal construct alone could induce growth 
suppression but when combined, growth is suppressed, indicating that N- and C- termini interact 136, 
The interaction of NF2 amino-terminal and carboxy-terminal sequences is confirmed by in-vitro GST-
binding assays and the yeast 2-hybrid system 57. In addition, homotypic interaction of C-terminal NF2 
sequences is also detected which are dependent on sequences distinct from those required for N-
terminal C-terminal interaction 65. However, convincing demonstration of NF2-NF2 interaction in-
vivo has not yet been achieved. 
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6. Scope of this thesis 
The cloning of the NF2 gene in 1993 revealed its similarity to the band 4.1-related proteins ezrin, 
radixin and moesin. On the basis of the homology to these membrane-organising proteins, it was 
postUlated that the NF2 protein likewise would function as a membrane-cytoskeleton linking protein. 
The general aim of the work described in this thesis was to gain insight into functioning of the NF2 
protein and characterise the role of the NF2 protein in tumorigenesis. In addition, we aimed to 
determine in which human tissues the NF2 gene is expressed and to compare the expression pattern of 
the NF2 gene with other ERM proteins. The specific goals were to: 
1) Find evidence for and, if present, characterise a NF2-cytoskeletal association. 
2) Document the presence of NF2 protein in normal human tissue 
3) Detect (mutated) NF2 protein from tumours and determine the effect of mutations on 
cytoskeletal interaction. 
To study the NF2 protein in cells and in tissues we chose to generate pOlyclonal and monoclonal 
antibodies. To this end we adopted the use of synthetic peptides to avoid homologous stretches in 
other ERM proteins. In anticipation of detecting truncated NF2 proteins the synthetic peptides were 
selected along the length of the protein from the N-terminus to the C-terminus. To determine the sub-
cellular localisation of NF2 protein we transiently transfected COS cells with NF2 eDNA isolated 
from a human fetal brain library. In addition to immunofluorescent staining with anti~NF2 antibodies, 
the putative cytoskeletal association was studied by detergent extraction and cytochalasin treatment of 
cells. The generation of antibodies and the sub-cellular localisation studies are described in chapters II 
and III. The elucidation of a putative cytoskeletal attachment region in the NF2 protein using detergent 
extraction of mutant NF2 protein, is described in chapter IV. Immunohistochemical- and mRNA-ISH 
staining techniques were adopted to determine the presence of NF2 protein in human tissues and 
cullured human cells, this work is discussed in chapters II, III and 
V. Mutations in the NF2 gene theoretically lead to protein truncation in a large number of cases. In 
chapter VI an example of an intronic mutation segregating in a family with a mild phenotype is 
described. This mutation theoretically results in a truncated NF2 protein. The observed mild 
phenotype probably results from a degree of residual wild-type splicing in tumour cells. In chapter VII 
investigations are described aimed at detecting truncated NF2 protein in meningiomas and 
schwannomas. 
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Chapter 1I 
Abstract 
Neurofibromatosis type 2 (NF2) is a disease resulting in the formation of schwannomas of the eighth 
cranial nerve, and other central nervous system tumours. A tumour suppressor gene has been found to 
be responsible for this disorder. The 595 amino add NF2 protein shows a great deal of homology to a 
supeifamily of membrane organizing proteins. To generate antibodies against (he NF2 protein four 
synthetic peptides (SP) were injected in rabbits. COS cells transfected with an NF2 cDNA construct in 
an expression vector were used for immunocytochemical staining experiments; lysates of transfected 
cos cells were used for western blotting experiments, as were lysates of E.coli cuitures transformed 
with an NF2 cDNA construct suhcloned in a prokaryotic expression vector. In western blots all sera 
detected a hand indicating the appropriate molecular weight in lysates of transfected cos cells and 
E.coli. Immunocytochemical staining experiments indicate that the NF2 protein localizes in or near 
the cell membrane. Immunohistochemical staining of human tissue sections demonstrates the presence 
of the NF2 protein in muscle-, and SchWalm cells. These results support the hypothesis that the NF2 
protein functions as a membrane organizing element. 
Introduction 
The neurofibromatoses comprise a group of two clinically and genetically distinct disorders 24, 25, 29. 31, 
Neurofibromatosis type 1, otherwise known as Von Recklinghausen's disease, is characterized by 
areas of localized skin pigmentation (cafe-au-Iait spots), multiple cutaneous neurofibromas, and 
hamartomas of the iris (Lisch nodules). The gene for Neurofibromatosis type 1 maps to chromosome 
17, and codes for a protein named neurofibromin, probably functioning in the RAS signal transduction 
pathway 10. II. 20. 39. The distinguishing feature of Neurofibromatosis type 2, is the- bilateral 
development of schwannomas of the vestibular branch of the eighth cranial nerve, occurring in over 
85% of the patients H, Other characteristics of this disorder are the development of schwannomas on 
other (peripheral) nerves and spinal nerve roots, the occurrence of intracranial, or spinal neoplasms 
such as meningiomas (often multiple), ependymomas, and gliomas 7.22. A non-tumour feature are the 
posterior lens capsule opacities, which occur in up to 80% of NF2 patients 16, 27. Additional ocular 
manifestations, in the form of pigment epithelial and retinal hamartomas, and epirelinal membranes, 
have been described in NF2 18, The incidence of NF2 has been estimated at ranging from 1:33.000 to 
1 :40.000; average age at diagnosis is in the second or third decade 8. The gene responsible for NF2 has 
been identified and maps to chromosome 22, band ql2 32. 37, The autosomal dominant inheritance 
pattern, loss of heterozygosity studies and analysis of the NF2 gene in tumours have shown that 
aberrations of both NF2 alleles are common in NF2 related tumours and also in a variety of non-NF2 
related tumours. Mutations in the NF2 gene have been found in sporadic meningiomas, sporadic 
schwannomas, and melanomas. 4. 14. 15, 19, 33, 34. 38. This data indicates that the NF2 gene acts as a 
tumour suppressor gene, 
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The NF2 gene codes for a protein of 595 amino acids, designated "merlin" 37 or "schwannomin" 32. 
The coding sequence of the gene is divided over 16 exons. Alternative splicing of the gene has been 
described 3, 28. Northern blotting and reverse transcriptase mediated PCR (RT-PCR) experiments, have 
demonstrated that the NF2 gene is highly conserved, and is expressed in a variety of human tissues 4, 6, 
12,32,37. The protein, with a calculated molecular weight of 66kDa, shows a great deal of homology to 
the erythrocyte band 4.1 related superfamily of membrane organizing proteins. Three proteins in 
particular, Ezrin, Radixin, and Moesin, referred to as the ERM family 35 share a great deal of 
homOlogy with the NF2 protein, The homology is greatest in the first 350 amino acids, reaching 63%. 
Extending the homology to the functional level results in the postulation that the NF2 protein might 
also act as a membrane organizing protein, functioning as a link between the cell membrane, and the 
cytoskeleton 32, 37, However, these postulations await confirmation. As a first step it is essential that 
the putative localization of the NF2 protein is confirmed, To determine the (sub)cellular localization of 
the NF2 protein by immunocytochemistry, we have generated antibodies against specific regions of 
the NF2 protein, Furthermore we demonstrate the localization of the NF2 protein in human tissue 
sections. To avoid cross-reaction with homologous proteins the synthetic peptide approach was used. 
Four synthetic peptides were selected for synthesis. A model system for immunocytochemistry, and 
western blotting was developed using NF2 transfected COS cells. 
Results 
In order to determine the sub-cel1ular localisation of the NF2 protein, by immunocytochemistry, we 
developed polyclonal antibodies against 4 different synthetic NF2 peptides (table 1). 
Table 1. Synthetic NF2 peptides 
Synthetic 
peptide 
SP276 
SP277 
SP278 
SP279 
amino acid sequence 
YAEHRGRARDEAEMEYLK-C 
KMAEESERRAKEADQLKQDLQEAREAE-C 
DFKDTDMKRLSMEIEKEKVEYMEKSK-C 
C-LHNENSDRGGSSKHNTIK 
po.<;ition" lenght poly-
AA AA clonal anti-
(N7) body 
192-209 18 1395NF2 
(574-627) 1396NF2 
439-465 27 1397NF2 
(1315-1395) 1399NF2 
508-533 26 1398NF2 
(1522-1599) 1400NF2 
561-578 18 1401NF2 
(1681-1734) 1402NF2 
a AA are amino acids, NT are nucleotides. Numbers denote the position from the initiation codon ATG (A~l), or 
first amino acid residue. 
b C is a cysteine residue added for coupling purposes 
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Eight rabbits immunized with synthetic NF2 peptides demonstrated a specific immune response after 
the first boost, when tested in a dot-immunobinding assay, with increased titers after the second boost 
(data not shown). As a control, sera were tested in a dot-immunobinding assay against a non-relevant 
NF2 synthetic peptide. 
To test the sera on the complete NF2 protein, rather than on the synthetic peptides, an assay was set up 
based on transfected COS cells. An NF2 eDNA clone, containing the complete open reading frame, 
subcloned in a eukaryotic expression vector, in the sense-, and antisense orientation, was used for 
transfection experiments in COS cells, and for the generation of a fusion protein in E.coli. 
A s A s A s 
2 3 4 
1396 1397 1398 1401 
Figure 1 
Western blots containing Iysates of NF2 transfected COS cells, and B.coli lysates. 
a) Results from three antisera, obtained after the second boost are shown: I 396NF2, 1397NF2, and 
1398NF2, representing 3 synthetic peptides. Non-specific bands are detected in sense-, and antisense 
transfected cells. "A"=NF2 antisense transfected COS cell lysate; "S"=NF2 sense transiected COS cell 
lysate. The position of the 69kDa molecular weight marker is shown. All sera arc diluted 1 :750. 
b) Results obtained with polyclonal serum 1401NF2, diluted 1:5000. Lane 1 contains E.coli lysates 
carrying the NF2-pGEX plasmid. Lanes 2 and 3 contain sense-, and antisense transfected COS cells 
respectively. In lane 4 a molecular weight marker is shown. 
Dilutions of sera from alI immunised animals, obtained after the second boost detected an 
approximately 70kDa band on western blots containing lysates of NF2 sense-transfected COS cells. 
This band was absent when the blot was incubated with presera from the same animals, nor was a 
similar band observed on western blots containing lysates of NF2 antisense-, or non-transfected COS 
cells, when these blots were incubated with serum obtained after the second boost. (fig. la,b). On 
western blots containing lysales of isopropyl D-D-thiogalactopyranoside (IPTG) induced cultures 
containing the NF2-pGEX-3X plasmid (see material and methods) a band of approximately 90kDa is 
observed, representing the NF2 fusion protein (fig. Ib). This band is absent in non-induced cultures, or 
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when the blot is incubated with presera from the same animal, in the same dilution. To test the 
specificity of the immune serum, blocking experiments were carried out, by pre-incubating the serum 
with the synthetic peptide against which antibodies had been raised. As a control another NF2 
synthetic peptide was used. On western blots complete absence of the signal was observed when the 
immune serum pre-incubated with the relevant peptide was used. Pre-incubation with an irrelevant 
NF2 peptide did not result in loss of signal (results not shown). 
To establish the expression of the NF2 protein in human tissues, immunoprecipitation experiments 
with polyclonal sera were carried out. Polyclonal sera 1396NF2, 1397NF2, 1398NF2, and 1401NF2, 
representing antibodies against all four synthetic peptides, were used. All sera precipitated an 
approximately 55kDa protein from human prostate tissue (fig. 2). The 55kDa protein precipitated by 
any of the four sera could be detected by all four sera on blots. A 55kDa protein was also precipitated 
in a lysate of human myometrial tissue by sera 1397NF2, 1398NF2, and 140lNF2 (data not shown). 
Figure 2 
2 Immunoprecipitation of a 55kDa protein with 3 4 5 6 7 8 9 10 
four antisera. Human pro..<;tate lysate was used 
for the imrnunoprecipitation. Detection of the 
precipitated protein is shown here by antiserum 
1397NF2. Absence of the 55kDa band is shown 
in lanes 1-4, incubated with presera. The arrow 
denotes the position of the immunoglobulins 
precipitated by the Sepharose-protein A 
conjugates, and detected by the secondary goat-
anti-rabbit antibody. Lane 1, 2, 3, and 4 contain 
immunoprecipitates, precipitated by respectively 
1401NF2, 1398NF2, JJ97NF2, and 1396NF2, 
incubated in presera 1397NF2. Lane 5 portrays a 
molecular weight marker. Lanes 6, 7, 8, and 9 1397 1397 
contain the same precipitates as lanes 1-4, 0 2 incubated in serum 1397NF2 taken after the 
second boost. Both presera and inunune sera 
were diluted 1 :2500. Lane 10 contains a NF2 sense 
transfected COS cell lysate. 
To determine the staining properties of the polyclonal sera, transfected COS cells were used for 
immunocytochemical staining experiments. The staining pattern appears to be membrane bound. With 
immunofluorescent staining of COS cells discrete local punctate areas of staining were observed, in 
addition to overall staining of the membrane (fig. 3). Peri-nuclear staining was observed in a small 
subset of cells. Non-transfected cells show slight background staining, comparable to staining 
produced by presera (not shown). In order to visualize the NF2 protein in human tissues, we se1ected 
acetone fixed frozen sections of human colon for immunostaining purposes. In the first experiments 
human colon was selected for the variety of cell types present in this tissue. 
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Six of the eight sera, representing all four peptide epitopes, showed an identical staining pattern on 
human colon sections. Non-specific staining was observed with serum from two animals. 
Figure 3 
Immunofluorescent staining of NF2 transfected COS 
cells. 
NF2 transfected COS cells were stained using an 
indirect avidin-biotin method. For the 
immunofluorescent staining experiments sera 1401NF2 
was used. Note punctate, and membranous staining 
pattern. 
Specific staining was observed in the smooth muscle layers of the muscularis mucosae and muscularis 
externa as well as in the smooth muscle layer surrounding blood vessels (results not shown). No 
staining was observed in lymphoid tissue. Non-specific staining of mucus in goblet cells in the villi 
was observed with immune and non-inunune sera, and phosphate buffered saline (PBS) controls. 
Inunune sera 1396NF2 and 1 398NF2, raised against respectively SP276 and SP278 were used for 
immunohistochemical staining of human prostate cryostat sections. 
Figure 4 
Immunohistochemical staining of formalin fixed paraffin embedded sections of human colon. Sections were not 
counterstained. Sera were diluted I :800. The size bar represents 200)lm. 
a) Negative control, incubation with presera 1398NF2. 
b) Incubation with serum 1398NF2 obtained after the second boost. Smooth muscle cells of the tunica 
media and lamina propria show an intense staining. 
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Both sera stained smooth muscle fibers in the stroma. Less intense staining of the epithelium was also 
observed (results not shown).Formalin fixed paraffin embedded sections of cardiac-, and skeletal 
muscle, prostate and colon were stained with sera 1396NF2, 1397NF2, 1398NF2, and 1402NF2. 
Staining of smooth muscle cells surrounding blood vessels, smooth muscle cells of the muscularis 
mucosae and muscularis externa of the colon (fig. 4a,b), and smooth muscle cells present in the 
prostate was observed. Less intense staining of skeletal and cardiac muscle was also observed (results 
not shown). No staining of epithelial cells of the prostate or colonic mucosa was observed, nor of the 
endothelial cells lining the blood vessels, in the paraffin embedded sections. Staining of paraffin 
embedded sections of human sympathetic trunk was performed with sera 1396NF2, 1397NF2, and 
1401NF2. Both sera 1396NF2 and 1397NF2 demonstrate specific staining of Schwann cells, and 
smooth muscle cells surrounding blood vessels present in the sections (fig. 5a,b). No nuclear staining 
was observed in either smooth muscle cells or Schwann cells. Ganglion cells present in the sections 
also appear to stain with immune serum, however due to the presence of Nissl bodies in the cytoplasm 
of these cells, a clear distinction could not be made between specific cytoplasmatic staining and non-
specific colouring of Nissl bodies. Nissl bodies were also coloured with presera, and PBS controls. 
Staining with serum 140lNF2 resulted in high background staining of the complete section. 
Figure 5 
Immunohistochemical staining of paratl1n embedded section of human sympathetic trunk. Sections were not 
counterstained. The size bar represents 100~m. 
a) Negative control, incubation with presera 1397NF2, diluted 1 :400 
b) Incubation with serum 1397NF2 obtained atter the second boost, diluted 1;800. 
Discussion 
The synthetic peptide strategy provides the opportunity to raise antibodies against selected antigenic 
parts of a particular protein of interest, avoiding stretches of homology to other proteins 40. To prevent 
cross-reactions with ERM family members we adopted the synthetic peptide strategy to generate 
antibodies against the NF2 protein. Experiments with antibodies to one of the ERM family members, 
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generated by using purified proteins as imrnunogens, have been hampered by cross~reactions of these 
antibodies with other ERM family members 9.35. 
A potential problem with antibodies raised against synthetic peptides is the failure of these antibodies 
to recognize the native protein. This is especially important if antibodies are to be used for 
irnmunostaining purposes. For evaluation of the antibodies, we therefore devised an assay using 
transfected COS cells and immunocytochemical techniques. After acetone fixation the NF2 protein 
was still detected by all eight sera in COS cells. Six of the eight sera specifically stain smooth muscle 
cells in acetone fixed frozen sections of human colon. This would indicate that these six polyvalent 
sera raised against four synthetic NF2 peptides also show immunoreactivity for the native protein. 
The polyclonal antibodies detect the NF2 protein on western blots containing lysates of NF2 
transfected COS cells. A band indicative for the same molecular weight was observed when the NF2 
construct subcloned in the eukaryotic expression vector was used for in vitro translation experiments 
(results not shown). 
In immunoprecipitation experiments, using lysates of human tissue, which in staining experiments had 
been shown to express the NF2 protein, a shorter band of approximately 55kDa is detected. This 
shorter protein might represent tissue specific alternative splicing of the NF2 gene resulting in a 
shorter protein. For instance, alternative splice variants lacking exons 2 (126 nucleotides), or 3 (123 
nuc1eotides) would result in a truncated protein of approximately 61kDa. A protein of approximately 
56kDa would be formed as a result of a splice variant lacking both exon 2 and 3 3,28. 
The subcellular localization of the NF2 protein, as judged by immunocytochemistry on COS cells 
supports the hypothesis that the NF2 protein is associated with the cell membrane. The homology of 
the NF2 protein to erythrocyte band 4.1 related proteins and its predicted secondary structure led to the 
postulation that the NF2 protein might function as a membrane organizing protein J, 32.37. Members of 
the band 4.1 superfamily of proteins show a common arrangement. An a-helical stretch is preceded by 
a globular N-terminus, and followed by a hydrophillic C-terminus 30. The association of band 4.1 
related proteins with the ceIl membrane has been demonstrated 2.5,23. Band 4.1 itself has been shown 
to associate with the membrane proteins gJycophorin C and the anion channel band 3 21. On the 
grounds of these homologies the theory has been put forward that the NF2 protein interacts with 
membrane proteins, possibly integrins, by means of its globular amino-terminal domain, similar to 
Ezrin. Interaction with cytoskeletal elements could take place through its a-helical domain, or its 
charged carboxy-terminus J. 
We could not detect the presence of the NF2 protein in non-transfected COS cells by 
immunocytochemistry, with any of the sera. This would indicate that the NF2 protein is not 
endogenously expressed in COS ceIls, or that the homology between the monkey NF2 protein and the 
human NF2 protein is limited. The latter possibility seems unlikely, considering the phylogenetic 
conservation of the NF2 gene 6. In immunofluorescent stained NF2 transfected COS cells, a punctate 
40 
subcellular localization and expression in muscle cells 
staining pattern is observed, possibly representing discrete local concentrations of NF2 protein. These 
focal staining intensities might be due to overexpression of the NF2 construct from the eukaryotic 
expression vector. In this vector the NF2 cDNA is under control of the cytomegalovirus (CMV) 
promoter. Expression of the cDNA under control of this promoter might lead to an aspecific 
localization of the protein in the cell. Conversely the staining pattern might represent a 50 far 
undefined NF2 related 5ubce11ular structure, for instance vesicles, or cytoskeleton related structures. 
Experiments with antibodies to Ezrin, used for immunocytocheniical staining of overexpressed Ezrin 
protein, in transfected CVl cells, indicate that the SUb-cellular distribution of this protein is not 
modified in these cells 2. In addition, these authors show a punctate localisation of the Ezrin protein in 
these cells, similar to our results. Therefore it seems likely that the distribution of the NF2 protein 
observed in COS cells represents the natural situation. 
The mechanism by which mutations in the NF2 gene cause schwannomas and other tumours remains 
to be elucidated. Loss of cell-cell contact possibly resulting from mutations in the NF2 gene in 
Schwann cells could result in loss of growth inhibition, favouring tumour formation. Mutations of the 
NF2 gene that have been described would lead to the formation of a truncated protein, probably unable 
to fulfil its putative membrane organizing function. Further experiments are needed to confirm the co-
localization, and direct association of the NF2 protein with cytoskeletal proteins. 
The staining of smooth muscle cells of human intestine, prostate, and blood vessels indicates that these 
cells expresses the NF2 protein at high levels. The staining pattern of cardiac and skeletal muscle is 
less intense, possibly indicating a lower level of expression in these tissues. Forces generated in 
muscle cells are transmitted to the surrounding environment through interactions between the 
contractile elements, cytoskeleton, cell membrane, lamina basalis and reticular fibres of the 
surrounding connective tissue. Proteins mediating the interaction between the cell membrane and 
cytoskeleton thus play an important role in muscle cells. The staining of Schwann cells, in sections 
taken from the human sympathetic trunk, confirms the presence of the NF2 gene product in cells of the 
type which give rise to vestibular schwannommas, the hallmark of NF2. Further immunohistochemical 
staining experiments with these sera will have to demonstrate the absence of the NF2 protein in NF2 
related tumours. 
NF2 expression has been found to be present in a large number of tissues by northern blot analysis and 
RT-PCR 4, 6. 12, 32. 37. Apart from the smooth muscle layers in the human colon, and the muscle fibers 
in the stroma of the prostate, the smooth muscle layers of blood vessels in the tissue sections also stain 
with six of the eight sera. Although further immunohistochemical staining experiments on various 
tissues remain to be done, it is possible that the ubiquitous expression of the NF2 gene, found by other 
groups, is in fact a result of detecting NF2 mRNA transcripts originating from smooth muscle cells in 
blood vessel walls; blood vessels being present in all tissues analyzed so far. Expression of the NF2 
gene could, in this respect, be restricted to far fewer tissues, or cell types, than as suggested by other 
workers. 
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Materials and Methods 
Selection and synthesis of peptides. 
Selection and synthesis of the peptides were performed essentially as described by Zegers et ai. 40 
With the aid of a computer prediction program (Genetics computer group, Wisconsin, USA), the NF2 
cDNA sequence was screened for stretches of amino acids with a high antigenic index. The selection 
was based on hydrophilicity, protein surface probability, and expected flexibility. Furthermore, 
peptides with a high degree of homology to other proteins were rejected as candidates for synthesis. 
Coordinates and sequence data of the peptides are given in table I. Synthesis of the peptides was 
performed on a Milligen 9050 pepsynthesizer. An extra cysteine residue was added to the N-terminus 
of SP276, SP277, and SP278 ; and to the C-terminus of SP279 for coupling purposes. Coupling of the 
peptides to Keyhole Limpet Hemocyanin (Calbiochem, La Jolla, USA) was achieved with m-
Maleimidobenzoyl-N-hydroxysuccinimide (MBS) ester. Purification of the peptides was by high 
performance liquid chromatography (HPLC) 
Imrnunisations 
250).1g of each peptide coupled to Keyhole Limpet Hemocyanin was diluted in 250).11 of PBS and 
mixed with an equal volume of complete Freunds adjuvant (Difco laboratories, Detroit, USA). Each 
peptide was injected intraderrnally in 2 rabbits. All animals were boosted twice with three weekly 
intervals. For the first and second boosts incomplete Freunds adjuvant was substituted for the 
complete Freunds adjuvant. Blood samples were taken after the first and second boosts. Blood samples 
were allowed to clot for I hour at 37°C. After loosening of the clot, samples were centrifuged at 
2500rpm, serum was collected, and stored in aliqouts at -20°C. 
Dot-imrnunobinding assay 
The dot-immunobinding assay was performed essentially as described by Hawkes 13. A 5mrn grid was 
drawn on a sheet of virgin nitrocellulose (Schleicher and Schuell Co., Dassel, Germany), the 
nitrocellulose was floated on Phosphate buffered saline (PBS) and allowed to hydrate for 20 minutes. 
After excess moisture had been drained from the sheet, it was incubated in a peptide solution (0.1 
mlIcm2 nitrocellulose; l).!g SP/ml PBS) for 1 hour. After incubation the membrane was air dried. A 3% 
Bovine Serum Albumin (BSA) solution in PBS (fraction V, Boehringer Mannheim, Germany) was 
used to block remaining sites on the membrane. Filters were either used directly, or stored aE -20°C. 
Dilutions of immune-sera and sera from pre-bleeds were spotted directly on the membrane, which had 
been placed on a sheet of damp blotting paper. After 1 hour of incubation the sheet was washed 3 
times in PBS. A second incubation was carried out with a peroxidase conjugated goat-anti-rabbit 
secondary antibody (DAKO, Glostrup, Denmark) for 30 minutes at room temperature. After washing 3 
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times with PBS, 0.06% (w/v) 3,3'diaminobenzidine (DAB, Sigma, Brussels, Belgium) and 0.01 % 
H20 2 was added as a substrate. The reaction was stopped by washing the membrane in water. 
Isolation of cDNA clones. and subcloning of the expression constructs. 
1 x 106 plaque forming units from a Human Fetal Brain cDNA library in lambda Zap (Stratagene, La 
Jolla, USA) were hybridized with an NF2 PCR probe, generated using primers 5m4 and 3m6 for RT-
PCR. (Bianchi et al., 1994). The cDNA was subcIoned in the pBluescript plasmid, using the in-vivo 
excision method (Stratagene, La Jolla USA). An approximately 2kb NF2 cDNA clone containing the 
complete open reading frame together with parts of the 5' and 3' untranslated regions was subcloned in 
the EcoRI site of the multiple cloning site of the pcDNA-3 eukaryotic expression vector (Invitrogen, 
San Diego, USA). The vector was transfected to COS cells by electroporation (200V, 500j..lF). After 
48 hours of culture the COS cells were either harvested, lysed in sodium dodecyl sulfate 
polyacrYlamide gel electrophoresis (SDS-PAGE) buffer 17 and used for western blotting, or if grown 
on microscope slides, acetone fixed and used for immunocytochemical staining, either directly or after 
storage at _20°C. A SmaI-EcoRI fragment of the NF2 cDNA was inserted in frame in the pGEX-3X 
vector (Pharmacia, Uppsala, Sweden). As a result of the cloning procedure 18 nucleotides prior to the 
ATG codon were incorporated in the insert. A fusion protein of approximately 90kDa was expected, 
consisting of the NF2 protein (65kDa), glutathion-S-transferase (GST, 26kOa) from the vector, and 6 
amino acids incorporated from the NF2 cDNA prior to the ATG initiation codon. Cultures of E.coh 
strain PC2495 transformed with the pGEX-NF2 construct were grown until the optical density was 
0.3-0.5 prior to induction with IPTG. After induction the cultures were grown for another 2 hours. 
Aliqouts of the culture were lysed in SDSmPAGE buffer, and used for western blotting, 
Western blotting 
Samples oftransfected COS cells, and bacterial cultures were lysed in SDS-PAGE buffer, boiled for 5 
min, and sheared through a 26-gauge needle. Prior to loading the samples on the gel, these were boiled 
for 5 min, Samples were separated on a 7.5% polyacrylamide slab gel. Electrophoresis and 
electroblotting to nitrocellulose, were carried out according to the manufacturer's recommendations 
(Biorad mini-protean 2D cell; BioRad, Hercules, CA, USA), Visualisation of transferred protein was 
performed by incubating the membrane in Ponceau red (Sigma). Blocking the membrane was achieved 
by incubation for 2 hours in a 3% BSA (Fraction V, Boehringer Mannheim) solution in PBS, pH 7.4. 
Primary antibodies were diluted in the blocking solution. Incubations were carried out at room 
temperature for 2 hours, or at 4°C overnight. After washing, detection was accomplished with a 
secondary alkaline phosphatase conjugated goat-anti-rabbit antibody (1:2000 TAGO, Burlingame, 
USA). As a substrate 4-nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl-phosphate 
(Boehringer Mannheim), or Naphtol AS-MX phosphate and 4-aminodiphenylamine-diazonium sulfate 
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(Sigma) was used. Blocking experiments were performed by pre-incubating serum dilutions with 20J.1g 
of synthetic peptide, overnight at 4°C with continuous agitation. In a separate experiment the serum 
was also pre-incubated with a non-relevant NF2 synthetic peptide as a control. 
Immunoprecipitation 
2.5 grams of human prostate obtained from a radical prostatectomy. The tissue sample was taken from 
an area not involved in the disease process. Myometrial tissue was obtained from a hysterectomy 
specimen. The tissues were homogenized in a buffer containing IS0mM NaCI, SOmM Tris, 1 % 
Nonidet P-40, O.S% Sodium Deoxycholate, 0.1% Sodium Dodecyl Sulfate. Insoluble debris was 
removed by centrifugation at 9000g for S min. Pefabloc (Boehringer Mannheim) to ImM was added to 
the supernatant. The imrnunoprecipitation experiments were performed essentially as described by 
Pakkanen for ezrin 26, except that in the wash buffers 1 % Nonidet P-40 was substituted for Triton X-
114. After the inununoprecipitation the samples were suspended in SDS-PAGE buffer and 
fractionated on a 7.S% polyacrylamide gel. Western blotting was performed as described above. 
lnununohistochemical staining. 
Transfected COS cells, frozen tissue sections, and paraffin embedded tissue sections were stained 
using a standard peroxidase-antt-peroxidase technique 36. Transfected COS cells, and frozen sections 
were fixed in acetone. After fixation, sections were rinsed with PBS. Blocking of endogenous 
peroxidase was not performed. Formalin fixed, paraffine embedded sections were subjected to 
protease treatment (pronase E, Sigma) for 10 minutes at 37°C, prior to incubations. Blocking of 
endogenous peroxidase activity was accomplished by incubation in 3% H20 2 in methanol for 15 
minutes. Following pre-incubation with 10% normal goat serum (DAKO), incubation with the primary 
antibodies was carried out, either at room temperature for 2 hours, or at 4°C overnight. After washing, 
incubation with unconjugated goat-anti-rabbit (DAKO) antibodies was carried out for 30 minutes at 
room temperature, followed by washing and incubation with the rabbit peroxidase-anti-peroxidase 
complex (DAKO). DAB supplemented with H20 2 was used as chromogen. If applicable, Mayer's 
haematoxylin was used as a nuclear counterstain. 
lnununofluorescence microscopy 
Acetone fixed COS-cells or frozen tissue sections were sequentially pre-incubated with 10% normal 
goat serum (DAKO), followed by incubation with the primary antibodies, diluted in 3% BSA in PBS 
for 2 hours at room temperature. After washing the slides were incubated in biotinylated goat-anti-
rabbit antibodies (l :400, DAKO), after washing, fluorescein isothiocyanate (FITC) conjugated to 
avidine (1 :200) Vector laboratories, Burlingame, USA) was added for 20 minutes. Amplification of 
the signal was achieved by subsequent incubation for 20 minutes in biotinylated goat-anti-avidine 
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antibodies (Vector laboratories), followed by a second incubation in FITC conjugated avidine for 20 
minutes. Between incubations slides were washed S times for S minutes in PBS. Slides were mounted 
in Gelvatol. Fluorescence was observed with a Zeiss epifluorescence microscope, fitted with the 4F 
fluorescence kit. Detection of FITC fluorescence was achieved with a 4S0-500nm excitation filter, an 
LP 515 longpass filter, an Ff510 dichroic mirror, and an Osram SOW mercury vapour lightsource. 
Results were photographed on Kodak Ektachrome 160 (EPT 135-36) film. 
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Abstract 
The product of the neurofibromatosis type 2 (NF2) tumor suppressor gene is a 595 amino acid protein 
bearing resemblance to afamUy of band 4.1 related proteins. These proteins, including ezrin, radixin, and 
moesin (ERM), probably junction as molecular linking proteins, connecting the cytoskeleton to the cell 
membrane. On the grounds of the homology to the ERM proteins and on the basis of its predicted 
secondaJY structure, the NF2 protein is also thought to act as a cytoskeleton-cell membrane linking 
protein. Using monoclonal antibodies to N- and C-terminal synthetic NF2 peptides we demonstrate the 
co-localization of the NF2 protein with elements of the cytoskeleton in a COS cell model system and in 
cultured human cells. Furthermore, the presence of the NF2 protein in tissue sections is shown. The 
monoclonal antibodies specifically stain smooth muscle cells and the stratum granulosum of the human 
epidermis. In cultured smooth muscle cell~' the NF2 protein co-localizes with actin stress fibers. Immuno-
electron microscopy demonstrates the presence of the NF2 protein associated with keratohyalin granules 
and to a lesser extent with intermediate filaments in the human epidermis. We conclude that the NF2 
protein is indeed associated with multiple elements of the cytoskeleton. 
Introduction 
Neurofibromatosis type 2 (NF2) is a disease resulting in the formation of bilateral vestibular 
schwannomas. These tumors occur in over 98% of NF2 patients 1. Additional manifestations of the 
disease are posterior lens capsule opacities, retinal abnormalities and schwannomas of spinal nerve roots 
2-8. In contrast to Neurofibromatosis type 1 patients (NFl; von Recklinghausen's disease). patients 
suffering from NF2 have few skin disorders 9.10. Skin manifestations occurring in NF2 include cutaneous 
schwannomas, neurofibromas and a third pigmented, hairy lesion with a roughened skin surface 2. 
Neurofibromatosis type 2 has been subdivided in 2 clinical subtypes, a more severe phenotype designated 
the Wishart type and a milder variant, the Gardner subtype 1,2.11. The gene responsible for NF2 has been 
identified and has been shown to act as a classical tumor suppressor gene n.lJ. The gene, located on 
chromosome 22 band q12, has also been implicated in sporadic schwannomas and sporadic meningiomas 
14.19. Expression of the NF2 gene has been found in many human tissues by reverse transcriptase mediated 
PCR (RT -PCR) and northern blotting experiments 12,/3.19.2°. The product of the NF2 gene, called merlin lJ 
or schwannomin 12, is a 595 amino acid protein belonging to a band 4.1 related subset of proteins. These 
proteins, ezrin, radixin and moesin are referred to as the ERM family 21. Several other proteins, including 
talin, share a common design to the ERM proteins, but show a more limited homology. The ERM proteins 
are thought to function as molecular linkers, connecting the cytoskeleton to the plasma membrane 22. A 
similar role has been postulated for the NF2 protein, based on the high degree of homology with the ERM 
proteins 12,lJ. The ERM and related proteins, including the NF2 protein, all share a central a-helical part 
that is preceded by a globular N-terminus, and followed by a charged C-terminus. Apart from moesin the 
ERM and NF2 proteins also contain a proline rich stretch at the C-terminus. It has been postulated that the 
NF2 protein is an F-actin associated protein, based on its homology to ERM proteins. Recently, it has 
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been shown that ERl\I1 family members contain a C-terminal actin-binding site. However, this actin-
binding site is not present in the NF2 protein 23,24. We have recently shown that the NF2 protein is highly 
expressed in smooth muscle cells, and to a lesser extent in other muscle cell types and in Schwann cells 25. 
In Ras transformed NIHI3T3 cells it has been shown that the NF2 protein can reverse the malignant 
phenotype 26. The same properties have been observed for other actin-binding proteins 27"29. The NF2 
protein is unique in the sense that it is the first of the ERM related plasma membrane cytoskeletallinking 
proteins implicated in human disease. We here demonstrate, with the use of monoclonal antibodies to 
synthetic NF2 peptides, the co-localization of the NF2 protein with F-actin. In addition we provide 
evidence for the association of the NF2 protein with other components of the cytoskeleton. Furthermore, 
the association of the NF2 protein with the cytoskeleton was confirmed by detergent extraction of cellular 
proteins. 
Material and methods 
Cell culture, detergent extraction and cytochalasin D treatment. 
COS-l cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% 
fetal calf serum and antibiotics. Human intestinal smooth muscle (HISM) cells (ATCC CRL-1692, 
American type culture collection, Rockville, MD, USA) were maintained in DMEM supplemented with 
10% fetal calf serum and antibiotics. The X63Ag8.653 myeloma cells 30 and hybridomas were cultured in 
Roswell Park Memorial Institute 1640 (RPMI 1640) medium supplemented with 10% fetal calf serum and 
antibiotics. All cell cultures were maintained in a humidified 5% CO2 atmosphere. Cytochalasin D 
treatment of HISM cells was performed by culturing cells on slides in medium containing 2.5~ 
cytochalasin D (Sigma, St.Louis, USA) for 20 minutes at 37°C. The slides were fixed immediately in 
acetone, and used for immunostaining. The detergent extraction of COS and HISM cells was carried out 
essentially as described by Kreis 31 and Algrain 23. The extraction buffer contained 80mM Pipes-KOH pH 
6.4, 5mMEGTA, ImMMgCl" and 0.5% Triton X-IOO. 
Peptide synthesis, generation and characterization of monoclonal antibodies. 
The N-terminal SP-O (RAIASRl\I1SFSSLKRKQPKTF-C) peptide was synthesized essentially as 
described .12, the terminal cysteine re-<;idue was added for coupling purposes. Peptide SP279 has been 
described in detail elsewhere 25. Female BALB/C mice were immunized intraperitoneally with 50).lg of 
synthetic peptide coupled to keyhole limpet hemocyanin suspended in 250J.lJ of phosphate buffered saline 
(PBS) and mixed with 2S0j.l1 of complete Freunds adjuvant. The mice were boosted twice at 2 weekly 
intervals; for the boosts incomplete Freunds adjuvant was substituted for the complete Freunds adjuvant. 
To determine if an immune response had developed, test bleeds were obtained after the second boost. The 
sera were tested in an immunocytochemical assay on NF2 transfected COS cells. The mouse displaying 
the highest antibody titer was used for the production of hybridomas. Three days prior to the fusion the 
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mouse was boosted a third time with 50~g of synthetic peptide suspended in 500~1 of PBS. On the day of 
the fusion the mouse was sacrificed and the spleen was aseptically removed. Subsequent fusion with the 
X63Ag8.653 myeloma cell line, and cell culture was essentially carried out as described 33. After 10 to 14 
days of culture in selective medium clones were screened for antibody production using the dot-
irnmunobinding assay for SP279 essentially as described by Hawkes .14. A total of 70 positive dones were 
identified for SP279. These 70 clones were subjected to a second round of screening using an 
immunocytochemical assay on NF2 transfected COS cells. Three clones were identified (UC2, MH3 and 
KFlO) which specifically stained transfected COS cells. These clones were subjected to limiting dilution 
cloning, followed by expansion and cryopreservation. The KFI0 clone was subsequently cultured in the 
Tecnomouse (Tecnomara, Integra Biosciences, Switzerland) under serum-free conditions, generating a 
high titer antiserum. 
Culture supernatants of clones identified in the SP-O fusion were pooled in groups of 5 and tested directly 
on transfected COS cells. One clone, I5H3, was identified which exclusively stained transfected COS 
cens. The isotype of the monoclonal antibodies was detennined with the Isostrip isotyping kit (Boehringer 
Mannheim, Germany). ELISA was performed by coating 96 wen PVC plates with synthetic peptide. The 
wells were blocked with a 3% bovine serum albumin (BSA; fraction V, Boehringer Mannheim) solution 
in PBS for 2 hours at room temperature. After incubation with culture supernatants and washing with 
PBS, incubation with a secondary peroxidase conjugated rabbit anti-mouse antibody (DAKO, Glostrup, 
Denmark) was performed. After washing, visualisation of positive wells was achieved by incubation with 
o-phenylenediamine (Eastman Kodak Co., Rochester, USA) and H20 2• 
Construction of expression vector, transfection and western blotting. 
The cloning of the NF2 cDNA, subcloning of the cDNA in the eukm'yolic expression vector pCDNA3, 
and transfection of the vector to COS-l cells were performed as described previously 25. Lysates of COS 
cells and protein precipitates of detergent extractions were fractionated under reducing conditions, and 
electroblotted to nitrocellulose according to the manufacturers recommendations (Bio-Rad mini-protean 
2D cell; BioRad, Hercules, CA, USA). Protein blots were blocked with a 3%BSA solution in PBS for 2 
hours at room temperature or overnight at 4°C. The blots were incubated with the KFlO antibody at a 
1:1000 dilution in PBS for I hour at room temperature. After washing with PBS, bands were visualised 
with a secondary alkaline phosphatase conjugated goat anti-rabbit antibody (TAGO, Burlingame, USA). 
As a substrate 4-nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl-phosphate (Boehringer 
Mannheim), or Naphtol AS-MX phosphate and 4-aminodiphenylamine-diazonium sulfate (Sigma, 
St.Louis, USA) was used. 
Immunolabelling studies and competition assays. 
Transfected COS cells and HISM cells were grown on microscope slides. After 48 hours of growth after 
transfection (COS cells), or at 50% confluency (HISM cells) the slides were washed once in PBS and 
so 
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fixed in acetone for 5 minutes at room temperature. The slides were air dried and used for staining 
purposes immediately or stored at room temperature. Cryostat sections mounted on 3-aminopropyl-
triethoxy-silane (Sigma) coated slides, were air dried for 20 minutes after sectioning and sUbsequently 
fixed in acetone for 10 minutes at room temperature. Human tissues were fixed in phosphate buffered 
formaldehyde 4%, pH7.2, embedded and following sectioning mounted, on coated slides. 
Immunostaining of COS cells, cryostat sections, and paraffin-embedded sections was accomplished with 
the KF 10 antibody at a 1 :50 dilution. For immunostaining with monoclonal antibodies DC2, MH3 and 
15H3 undiluted culture supernatant was used. Human tissues were stained with a standard peroxidase-
anti-peroxidase (pAP) method 35. A protease pre-treatment (pronase E, Sigma) was required for the 
paraffin-embedded tissue sections. Endogenous peroxidase activity was quenched with 3% HzOz in 
methanol for 20 minutes at room temperature. Mayer's hematoxylin was used as a nuclear counterstain if 
applicable. Immunofluorescent staining was accomplished with the KFlO antibody at a 1:300 dilution and 
a secondary fluorescein isothiocyanate(FITC)-conjugated goat anti-mouse or tetramethyl rhodamine 
isothiocyanate(TRITC)-conjugated rabbit anti-mouse antibody (DAKO). Phalloidin-FITC staining was 
accomplished by incubating slides in a 5mglml solution of phalloidin-FITC (Fluka, Buchs, Switzerland) 
for 10 minutes at room temperature. If applicable, propidium iodide was used as a nuclear counterstain. 
Slides were mounted in Mowiol (Hoechst, Germany) containing 2.5% 1,4-diazobicyclo-[2.2.2]-octane 
(DABCO; Fluka) to reduce fading, and were examined with a Zeiss epifluorescence microscope fitted 
with the 4F fluorescence kit. Results were photographed on Kodak Ektachrome 160 (EPT 135-36) film. 
Confocal laser scanning microscopy was performed on a Bio-Rad MRClOOO employing the advanced 
:xz..scanning option. Immuno-electron microscopy was performed with the KFI0 antibody as described 
36, The competition studies were performed by diluting KFIO in a 40mM SP279 solution in PBS, and 
mixing overnight at 4°C. As a control a 4DmM solution of another synthetic NF2 peptide was used 
(SP277 or SP278 25). After the pre-incubation the solutions were used for immunostaining and immuno-
electron microscopy. 
Results 
Three monoclonal antibodies were raised against a C-terminal NF2 synthetic peptide SP279 (C-
LHNENSDRGGSSKHNTIK). Two of the antibodies, KFI0 and UC2, reacted similar with regard to 
staining properties while the third antibody, MH3, displayed a more restricted staining pattern. One 
monoclonal antibody, 15H3, was raised against a N-terminal peptide SP-D. The imrnunostaining 
properties of this antibody were identical to the KFIO and De2 antibodies. All four monoclonal 
antibodies were of the IgG I isotype with a K-light chain. The specificity of the antibodies was checked by 
ELISA. The KFIO antibody was only reactive to SP279 and not to any of the other NF2 synthetic peptides 
(SP-O, SP276, SP277 and SP278). Likewise the I5H3 antibody exclusively reacted to SP-O. 
The presence of the NF2 protein in normal human tissues was investigated by immunostaining of 
formalin-fixed, paraffin-embedded tissue sections, and of frozen sections. A panel of human tissues was 
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selected including all three types of human muscle, which have been shown to express the NF2 protein. 
Exclusive staining of smooth muscle cells was observed with the KFIO, DC2 and ISH3 antibodies, but 
not with the MH3 antibody. No staining of skeletal or cardiac muscle was observed (not shown). Vascular 
and visceral smooth muscle showed an intense cytoplasmic staining pattern (figure Ib). In addition, 
myoepithelial cells in sections of breast tissue, salivary gland tissue and around merocrine sweat glands in 
the skin, also stained with the monoclonal antibodies. No difference in staining was observed between 
frozen sections and paraffin embedded sections. 
Staining of the epidermis was also observed with all four antibodies (figure lc). An intense granular 
staining pattern was observed in the stratum granulosum, decreasing in intensity towards the more basal 
ceI1layers. Very weak staining was observed in the stratum corneum. The granular staining pattern of the 
stratum granulosum was further investigated by immuno-electron microscopy, using the KFIO antibody 
and secondary antibodies conjugated to lOnm gold particles. Specific staining was found of the keratohy-
alin granules in the stratum granulosum of the epidermis (figure Id). Less intense staining was found 
associated with intermediate filaments in the more basal layers (stratum spinosum and stratum basale 
epidermidis). To rule out non-specific interactions of the KFIO antibody and components of the 
keratohyalin granules incubations were pelformed in the presence of O.ISM NaCI and O.SM NaCI, or in 
PBS containing 0.5% Triton X-tOO. No loss of signal strength was observed by light microscopy of the 
stratum granulosum and musculus arrector pilli. In addition, competition experiments were performed. 
The staining pattern of the monoclonal antibodies as observed by light microscopy, and the labelling of 
the keratohyalin granules in immuno-electron microscopy, could be completely abolished by pre-incuba-
tion of a working solution of the antibody with the synthetic peptide against which it had been raised (not 
shown). Pre-incubation with different NF2 peptides did not result in loss of staining. 
Figure 1 
Immunohistochemical staining with the KFlO monoclonal antibOOy. 
a. Counterstained section of the human parotid salivary gland containing branches of the 7th cranial nerve. Note 
cytoplasmic staining of Schwann cells. Magnification 400x. 
b. Counterstained section of human ileum. Staining of the muscularis externa, muscularis mucosae and tunica 
media of the blood vessels is observed. Structures staining in the serosal tissue arc tangentially sectioned vessel 
walls. Magnification SOx. 
c. Counterstained section of the human skin, stained with the KFIO antibody. Note the staining orthe suprabasa! 
layers of the epidermis, musculus arrector pilli and tunica media around the blood vessels. Magnification lOOx 
d. Immuno-electron micrograph of the human epidermis stained with the KFI0 antibody. Specific labeling of a 
keratohyalin granule is observcd. Magnification 30,OOOx. 
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To determine if the monoclonal antibodies could detect the NF2 protein in Schwarm cells, the cells giving 
rise to the vestibular schwannomas, several tissue sections were included containing peripheral or cranial 
nerves. In peripheral nerves no staining of Schwmm cells was observed. 
Branches of the facial nerve (7th cranial nerve) present in a section of a parotid salivary gland were seen to 
stain with the KFIO antibody. Distinct cytoplasmic staining of the Schwann cells was observed in several 
branches (figure Ia). 
To further evaluate the NF2 expression in smooth muscle we used a smooth muscle cell line derived from 
human intestine 37. Immunofluorescent staining of these cells with the KFlO antibody revealed a pattern 
resembling that of actin stress fibers. Double-staining of HISM cells with the KFIO antibody and FITC-
conjugated phalloidin resulted in complete overlap of the staining patterns (figure 2a,b). Treatment of 
HISM cells with cytochalasin D resulted in disruption of the stress fibers as evidenced by phalloidin 
staining. The staining patterns produced by KFlO and phalloidin after cylochalasin D treatment did not 
overlap. Both staining patterns were of a punctate nature, with occasional stress fibers still present (figure 
2c,d). Detergent extraction of HISM cells did not interfere with the staining pattern produced by 
phalloidin or KFlO (not shown). 
To study the role of the NF2 protein with respect to its putative membrane-cytoskeletal organising 
function we used a model system based on NF2 transfected COS cells. Immunocytochemical staining of 
the transfected COS cells confirmed the punctate staining pattern previously observed with the polyclonal 
sera. Immunofluorescent staining of the transfected COS cells was used in conjunction with confocal laser 
scanning microscopy (CLSM) to determine a more precise localization of the NF2 protein in the COS 
cells (figure 3a,b). Optical sections perpendicular to the culture slide demonstrated a specific membrane 
bound localization. Furthermore staining was only detected on the dorsal cell membrane, the ventral cell 
membrane did not stain. A non-continuous distribution of the antigen was observed. Focal staining 
intensities and non-staining patches were observed. The cytoskeletal association of the NF2 protein was 
further studied by performing detergent extraction ofNF2 transfected COS cells. COS cells extracted with 
the non-ionic detergent Triton X-1OO were analyzed by western blotting and immunocytochemical 
staining. 
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Figure 2 
Double-immunoOuorescent staining of HISM cells, using the KFIO antibody and TRlTC-conjugated secondary 
antil:xxlies (a,e) and mC-conjugated phalloidin (b,d); the sections were not counterstained. 
a. Phalloidin staining. 
b. KFIO staining. Note complete overlap of the staining patterns in a and b, Magnification lOOOx. 
c. Phalloidin staining of cytochalasin D treated HISM cells. 
d. KFlO staining pattern after cytochalasin D treatment of HISM cells. The staining patterns in c and d no longer 
overlap. Magnification 630x. 
After detergent extraction of the COS cells, the staining pattern was virtually unimpaired, and staining 
intensity was completely retained (not shown). Immunoblotting analysis of the extracted protein and non-
extracted protein indicated that the NF2 protein is associated with the non-extractable portion of the 
cellular proteins (figure 4). 
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Figure 3 
A B 
Immunofluorescent staining ofNF2 transfected COS cells with the KFIO antibody. 
a. Conventional fluoresence microscopy; note the punctate staining pattern. Propidium iodide counlerstained 
section. 
b. XZ-scanning CLSM microb'Taph of a stained COS cell expressing NF2, stained with the KFlO antibody, 
revealing a membrane bound punctate staining pattern. No signa! is detected on the ventra! cell membrane. 
Discussion 
To study the NF2 protein in normal human tissues and cultured cells we produced monoclonal antibodies 
to synthetic NF2 peptides. The N-terrninal part of the NF2 protein is highly homologous to ERM proteins, 
the homology reaching 63% in amino acids 25-342, and 48% for the whole protein n.l.? To avoid possible 
cross-reactivity of antibodies we therefore adopted the synthetic peptide approach 32 to immunize mice for 
the production of monoclonal antibodies. The N-terminal peptide SP-O does not bear homology to any of 
the ERM proteins, ruling out the possibility of cross~reactivity with ERM proteins. Peptide SP279 has 7 of 
its 18 amino acids in common with ezrin, 4 of which occur at a single stretch. Generally a stretch of 6 
amino acids is considered the shortest stretch constituting an epitope .lB, making cross-reactivity with the 
ERM proteins unlikely. The identical staining patterns produced by 15H3 and KFIO indeed indicate that 
the KFlO antibody is specific for the NF2 protein only. 
175 -
2 3 
83 -
47.5 -
32.5 -
4 Figure 4 
Western blot analysis of detergent soluble, and insoluble proteins from 
NF2 transfeeted COS cells. Detected with the KFlO antibody. The 
postion of the molecular weight markers is indicated. Lane 1, insoluble 
protein fracLion; 2, acetone precipitate of extracted protein fraction; 3, 
total COS cell lysate; 4, lysate of mock-trans fee ted COS cells. 
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The hallmark of NF2 is the development of bilateral vestibular schwannomas. Schwannomas of other 
cranial-, and peripheral nerves have also been reported 2. A subset of the dermal abnormalities found in 
NF2 patients are also schwannomas. The NF2 gene product thus most likely plays an important role in 
Schwann cells. With the monoclonal antibody KFlO we could only detect the NF2 protein in Schwann 
cells in a section containing branches of the facial nerve (7th cranial nerve). It is possible that the SP279 
epitope is shielded by other proteins binding to the NF2 protein. Proteins interacting with the NF2 protein 
have been identified J9. Conversely, alternative splicing of the NF2 gene, or post-translational 
modification of the NF2 protein could result in abrogation of the SP279 epitope. Various alternatively 
spliced transcripts of the NF2 gene have been described 20.40.41. This does however imply that this is not a 
universal event in Schwann cells, as indicated by the staining of the Schwann cells of the facial nerve. It 
seems likely that Schwann cells surrounding specific nerves either produce specific isoforms of the NF2 
protein, or that a distinct subset of NF2 binding proteins is synthesized in different Schwann cells. 
The inununostaining experiments performed on sections of human tissues confirm the presence of the 
NF2 protein in smooth muscle cells. With the monoclonal antibodies we could not detect the NF2 protein 
in either skeletal, or cardiac muscle. The immunostaining experiments further indicate that the tissue 
distribution of the NF2 protein is distinct from that of ezrin and moesin, and possibly partially overlaps 
that of radixin 22.42. 
Having noted the intense staining pattern of smooth muscle cells in tissue sections we studied a human 
smooth muscle cell line. This cell line has been isolated from a section of human jejunum 37. The cell line 
was characterized by its ability to contract in response to cholecystokinin-octapeptide, and by the presence 
of abundant stress fibers. Staining of HISM cells with the KFlO antibody and phalloidin revealed co-
localization of the NF2 protein and actin stress fibers. Detergent extraction of the HISM cells did not 
result in changes of either the KFlO or phalloidin staining pattern. It thus appears that the NF2 protein is 
bound to actin stress fibers in smooth muscle cells. This is supported by the finding that the staining 
patterns produced by KFI0 and phalloidin no longer coincide after cytochalasin D treatment. Phalloidin 
staining after cytochalasin D treatment of the HISM cells shows disruption of the stress fiber an·ays. As a 
result KF 1 0 staining adopts a disorganized punctate configuration, not overlapping with the stress fiber 
distribution pattern, suggesting aggregation of the NF2 protein in the cytoplasm. 
A surprising finding was the specific staining pattern of the monoclonal antibodies of the human 
epidermis, although several band 4.1 related proteins have been identified in the epidermis by cross-
reactivity with antibodies to band 4.1 protein 43. Keratohyalin granules are notorious for their false 
positive staining reactions with various monoclonal antibodies. However, antibody incubations performed 
in high salt conditions, eliminating non-specific electrostatic interactions, or in the presence of non-ionic 
detergents, preventing hydrophobic interactions, did not impair inll11Unostaining. The specificity was 
further substantiated by blocking experiments with synthetic peptides. Immuno-electron microscopy 
analysis demonstrates the association of NF2 protein with keratohyalin granules and intermediate 
filaments in the human epidermis. The contents of the keratohyalin granules include the protein fillagrin 
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which is probably involved in bundling cytokeratin filaments in terminally differentiating keratinocytes 44. 
The presence of the NF2 protein associated with intermediate filaments in the more basal layers of the 
skin, and with keratohyalin granules in the stratum granulosum suggests that the NF2 protein might be 
involved in the terminal differentiation of the human epidermis. Although most of the cutaneous 
manifestations of the NF2 patients do not constitute disorders of keratinization, demonstration of the 
presence of the NF2 protein in the epidermis supports its involvement in the NF2-related skin disorders. 
The localization of the NF2 protein associated with intermediate filaments is unique in the sense that none 
of the ERM proteins has been found associated with intermediate filaments. 
To study the sub-cellular localization of the NF2 protein we used NF2 transfected COS cells. A similar 
system has been used to investigate the cytoske1etal association of ezrin 23, which is endogenously 
expressed in COS cells. The specific localization of the NF2 protein in COS cells at the dorsal cell 
membrane observed with confocal laser scanning microscopy indicates that the NF2 protein is not 
randomly distributed in the COS cells. A staining pattern suggesting discrete accumulations of the NF2 
protein at the dorsal cell membrane, and complete absence of the protein at the ventral cell membrane was 
observed. It does remain possible however that artifacts are created by the overexpression of the NF2 
cDNA under control of the cytomegalovirus (CMV) promoter. It is interesting to note that the NF2 protein 
is not localized on the ventral cell membrane where focal contacts occur. In this respect the NF2 protein 
resembles ezrin and moesin as neither of these proteins is associated with focal adhesions 22. Talin, 
another band 4.1 related protein is specifically located at focal adhesions 4.'0. Apparently the NF2 protein 
does not participate in the formation of focal contacts in COS cells. The NF2 protein also does not seem to 
co-localize with specialized cell surface structures such as microvilli. Ezrin specifically localizes at these 
structures in tissues and cultured cells 22.23. To investigate the association of the NF2 protein with the 
cytoskeleton we performed extraction experiments. The majority of cytoskeletal proteins are not 
solubilized by detergent extraction. Immunoblotting analysis of NF2 transfected COS cell extracts with 
the monoclonal antibodies confirmed the cytoskeletal association of the NF2 protein. A faint band was 
also observed in the extracted protein probably representing non-cytoskeletal associated NF2 protein. The 
overproduction of the NF2 protein in COS cells might lead to spill-over of the protein after saturation of 
NF2 binding sites. Staining of COS cells after detergent extraction did not result in changes of the staining 
pattern, the punctate membrane-bound staining pattern was unaffected. These results indicate that the NF2 
protein is tightly bound to elements of the cytoskeleton. 
We have shown that the NF2 protein is associated with 2 components of the cytoskeleton, the 
microfilament system in smooth muscle cells and the intermediate filament system in the human 
epidermis. Further support for the cytoskeletal association of the NF2 protein is provided by the COS 
model system. The function of the NF2 protein is probably modified and controlled by binding proteins. If 
the NF2 protein acts as membrane-cytoskeletal linking protein, it is likely that amongst these binding 
proteins are integral membrane proteins. 
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Abstract 
Neurofibromatosis type 2 is a hereditary cancer syndrome characterized by the development of 
bilateral vestibular schwannomas. Underlying the disease are inactivating mutations of the NF2 
tumour suppressor gene, located on chromosome 22, encoding a 595 aminoacid protein. The NF2 
protein, also known as merlin or schwannomin, reported to act as a membrane-cytoskeleton linking 
protein. This assumption is based on the homology of the NF2 protein to a group of band 4.1 related 
proteins, ezrin radixin and moesin. The cytoskeletal association of the NF2 protein has in part been 
confirmed by its ability to resist extraction from cells by non-ionic detergents. We peiformed detergent 
extraction on COS cells transfected with NF2 eDNA constructs. The extracts were analyzed by 
western blotting and immunofluorescent staining with monoclonal anti-NF2 antibodies. The results 
provide evidence for a major cytoskeleton attachment domain at aminoacids 27-131 and a putative 
second attachment domain between aminoacids 315 and 475. 
Introduction 
Introduction 
Inactivating mutations of the neurofibromatosis type 2 (NF2) tumour suppressor gene, located on 
chromosome 22, cause the NF2 syndrome, characterized by bilateral vestibular schwannomas 22. 32. 
Other features of NF2 include development of meningiomas, spinal nerve root schwannomas, 
ependymomas and non-neoplastic ocular manifestations J J. In addition to the germline mutations 
found in familial NF2 cases, somatic mutations are found in sporadic schwannomas and meningiomas 
37. Two major isoforms of the NF2 gene are known. Isoform-l lacks exon 16 and contains all 
aminoacids encoded by exon 17. Isoform-2 includes exon 16, which contains an in frame stop codon, 
resulting in a C-terminus with 11 different aminoacids I, 13. The 595-aminoacid NF2 protein, 
alternatively known as merlin or schwannomin, is related to the ezrin-radixin-moesin (ERM)-band 4.1 
family of proteins. These proteins are involved in attachment of integral membrane proteins to 
elements of the cytoskeleton 33, 35. Most mutations in the NF2 gene theoretically result in truncated 
NF2 protein 37. The homology of the NF2 protein to ERM proteins is greatest in the first 300 
aminoacids and includes an extensive alpha helical segment common to ERM proteins 10. The 
similarity of the NF2 protein to ERM family members suggests that it likewise functions as a 
membrane-cytoskeleton linking protein. Evidence has accumulated that the integral membrane protein 
CD44 functions as the membrane bound NF2 associating protein partner 24, 26. An alternative 
membrane protein, the regulatory cofactor of the Na+-H+ exchanger (NHE-RF) has been described as 
a potential NF2 membrane associating protein 21. Several cytoskeletal proteins have been found to 
associate or co-localize with NF2 protein including actin, both as cortical actin fibers and as stress 
fibers, spectrin, tubulin and intermediate filaments 6, 9. 28, 36. Ezrin, an ERM protein specifically 
localizing to actin filaments in specialized membrane structures, has been found to contain an actin 
binding site at the C-terminus, regulated by sequences in the N-terminus 35. Recently an internal F-
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and G-actin binding sequence has been described in ezrin located between aminoacids 281-333 23. 
Although the NF2 protein shares considerable homology with ezrin this is located in the first 300 
aminoacids, the C-terrninal actin binding sequence of ezrin is not present in the NF2 protein. 
Evidence for the cytoskeletaI association of proteins may be obtained by their ability to resist 
extraction from cells by treatment with detergents. We, and others, have previously shown that the 
NF2 protein resists extraction by non-ionic detergents in keeping with its postulated cytoskeletal 
association 4·6, 17, 24, 26, 27. Moreover, immunofluorescent and immuno-electron microscopy 
localization studies have provided further evidence for the function of the NF2 protein as a membrane 
cytoskeleton linker. To determine which domain of the NF2 protein might determine its attachment to 
the cytoskeleton we tested 13 NF2 expression constructs in detergent extraction experiments. Of these 
13 constructs 4 harboured mutations found in NF2 patients, including NF2-220N~ Y, a construct 
based on a aac~tac mutation at nucleotide position 657 found in a NF2 family and resulting in 
substitution of tyrosine for asparagine 20; constructs NF2-deI262-C and NF2-360L~P are both based 
on mutations described in NF2 patients by Rouleau et af. (NF2-deI262-C = EB G and NF2-360L---7P = 
RFlO) 22. The mutation in NF2-del262-C is a t~c mutation in exon 8 at position 784 and introduces a 
stop codon, generating a 261 aminoacid protein. In NF2-360L~P a t~c mutation in exon 11 at 
position 1079 was described causing a proline for leucine substitution. The NF2-de1173-C construct is 
based on a NF2 gene mutation observed in a NF2 family, in which a g~a transition in intron 5 results 
in activation of a cryptic exon. 3, 19. Detergent soluble and insoluble fractions from transiently 
transfected COS cells were analyzed by western blotting using monoclonal anti-NF2 antibodies. In 
addition, visualization of NF2 protein from 6 constructs before and after detergent extraction was 
performed by immunofluorescent staining of cells grown on slides. Our results provide evidence for a 
major cytoskeleton attachment domain between aminoacids 29-131. Furthermore, all mutant NF2 
proteins based on natural mutations in families remained attached to the cytoskeleton in our assays. 
Materials and Methods 
Construction of expression constructs (Fig. 2) 
Cloning and expression of wild-type NF2 isoform 1 (wtNF2isol) has been described previously (den 
Bakker et aI., 1995a). NF2 isoform 2 (wtNF2is02) was kindly provided by Dr. Ramesh (Massachusetts 
General Hospital, Charlestown, MA, USA). All other constructs are based on isoform-l. 
Construction of NF2-220N~Y was achieved by PCR using forward primer 5NFA2-121: 
5'-gcccaagaggaattgcttc-3' and a reverse primer incorporating the changed nucleotides (capitals) and a 
BspEI restriction site (bold): 5' -ttattccggattgcaaagtagATAacaccgt-3'. The PCR product thus produced 
spanned 2 internal BspEI sites. After digestion of wtNF2iso 1 cDNA and the PCR product with BspEI 
(New England Biolabs, Beverly, CA, USA) and agarose gel electrophoresis, the appropriate fragments 
were isolated and ligated. Construction NF2-deI262-C and NF2-360L~P was achieved with the aid of 
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an in-vitro mutagenesis kit (Altered Sites, Promega, Madison, USA). The cloning procedures were 
performed according to the manufacturers recommendations. For NF2-de1262-C forward primer: 
5'-ccccaagatctccttcccgtggaatgaaatcTgaaaca-3' in conjunction with the reverse primer from the kit was 
used. For NF2-360L~P a reverse primer: 5'-aggcCgctgcagatgaaagaagaagcaacaatggccaacga-3' was 
used in combination with a forward primer from the kit. The sequence of mutants NF2-220N~ Y, 
NF2-deI262-C and NF2-360L~P was checked by sequencing using a sequencing kit (pharmacia, 
Uppsala, Sweden). NF2-del341-C was constructed by XhoI digestion (New England Biolabs) of 
pcDNA-3 vector containing the wtNF2isol eDNA, preceding preparative agarose gel electrophoresis, 
fragment isolation and re-ligation of the isolated fragment. Cloning and characterization of construct 
NF2~deIl73-C has been described previously.3 Construction of NF2-de1131-254 and 
NF2-de1l31-254;262-C was achieved by BglII digestion of respectively wtNF2isol cDNA and 
NF2-deI262-C cDNA following subc10ning of the cDNA's from the pcDNA-3 vector to pTZ19 
(Pharmacia, Uppsala, Sweden) to avoid BglII sites in the pcDNA-3 vector. Mter digestion and 
fragment isolation, the inserts were re-inserted in the pcDNA-3 vector. Starting from wtNF2isol 
cloned in the pBluescript plasmid, construction of NF2-delN-28 was achieved by first subcloning the 
cDNA insert in reverse orientation by digestion with EcoRI followed by ligation and selection for the 
appropriate orientation by control digestions. After XhoI digestion, the resulting larger XhoI fragment 
derived from the plasmid was circularly ligated and digested with Ncol. Following isolation of this 
fragment from agarose gel and circular ligation the product was digested with XhoI and treated with 
calf intestinal phosphatase (Boehringer Mannheim, Germany). The second fragment from the initial 
XhoI digestion was isolated from gel and ligated into the modified vector. The resulting insert, now 
lacking sequences coding for the initial 28 arninoacids of the NF2 protein, was isolated by EcoRI 
digestion and inserted in the pcDNA-3 vector. The NF2-deIN-28;262-C construct was made using 
NF2-delN-28 as a starting point and the using the same method as described above for NF2-de1262-C. 
Constructs NF2-delN-320 and NF2-deIN-204;47l-C were constructed by PCR using wtNF2isol 
cDNA as a template. For NF2-delN-320 forward primer FW1168 
5'-ggaattCCACCATGaaagcccaggccagggag-3') and reverse primer RV2004 
(5'-gctctagaCTAgagctcttcaaagaaggccac-3') were used. For NF2-delN-204;471-C forward primer 
FW832 (5'-ggaattCCACCATGgaatatctgaagatagctcaggacc-3') and reverse primer RV1633 
(5'-gctctagaCTActgcttggctcttcgctccg-3') were used. The forward primers incorporated an BcoRI 
restriction endonuclease site (bold) facilitating directional cloning and a Kozak consensus sequence 
flanking an ATG initiation codon (capitals). The reverse primers contained a XbaI restriction 
endonuclease site (bold) and a CTA termination codon (capitals). Amplification was performed under 
standard conditions (Perkin Elmer Gene Amp 9600, The Perkin-Elmer Corporation, Norwalk, USA); 
30 cycles, 95°C 45 sec, 55°C 45 sec, 72°C 2 min) in the presence of 200ng each of the primers and 1 U 
of Taq polymerase (Promega).Ten ,.Ii of the 100111 reaction volume was analyzed by agarose gel 
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electrophoresis, after which the product was digested by EcoRI and XbaI according to the 
manufacturers recommendations (Boehringer Mannheim, Germany). After agarose gel electrophoresis 
the product was isolated and inserted in the pcDNA-3 eukaryotic expression vector (Invitrogen, San 
Diego, USA). All constructs were tested for expression by in-vitro-transcription-translation 
experiments using T7 RNA polymerase and 35S-methionine in the TnT coupled reticulocyte lysate 
system according to the manufacturers recommendations (Promega). Of a 50}.!l reaction 2 }.!I yvas 
analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE; mini-protean 2D 
cell, BioRad, Hercules, CA, USA). After electrophoresis, the gels were dried and analysed by 
autoradiography. 
Cell culture, transfection of constructs, western blotting and immunofluorescent staining of cultured 
cells were performed essentially as described previously (den Bakker ef at., 1995a) Monoclonal 
antibodies used for immunoblotting and staining included FE9, HE?, AHlO and KFlO. Monoclonal 
antibody FE9 was raised against NF2 synthetic peptide SP-O 6. Monoclonal antibodies HB? and ARlO 
were raised against NF2 synthetic peptides SP276 and SP27? respectively (manuscript submitted); 
monoclonal antibody KFlO has been described previously 5. In these experiments detection in western 
blotting was performed by incubation of blots in a cocktail of antibodies (AHI0 1 :1000, FE9 1: 1000, 
HE7 1:1000 and KFlO 1:3000) followed by incubation with peroxidase conjugated goat-antI-mouse 
antibodies. Enhanced chemoluminescence (Pierce, Rockford, USA) with exposure to film was used 
for visualization of bands. For immunofluorescent staining single monoclonal antibodies were used, 
nuclei were counterstained with propidium iodide (Sigma, Brussels, Belgium). 
Detergent extraction was performed according to the method outlined by Sainio et al.. 24 based on the 
method of Bretscher et al. 2. The results were analyzed by western blotting; no densitometric analysis 
was performed. Detergent extracted cells grown on slides were immediately fixed in ice-cold acetone 
and stained. Control experiments included immunofluorescent staining and western blotting of COS 
cells with an anti-cytokeratin antibody (NCL5D3; DAKO Corporation, Glostrup, Denmark). 
Results 
In-vitro-transcription-translation experiments confirmed synthesis of mutant NF2 proteins with 
expected calculated molecular weights (not shown). All constructs could be detected after transfection 
to COS cells, both by immunofluorescent staining and by western blotting. However, transfection 
efficiency of constructs varied considerably, ranging from approximately 1 % to 15% of cells. 
Although some differences in staining patterns were noted for some constructs, these were not found 
to be readily reproducible. In addition, overexpression of eDNA in the pcDNA-3 vector imparts a 
considerable degree of difficulty when interpreting qualitative staining results. Therefore we drew no 
conclusions from the staining patterns. Detergent extraction of cells grown on slides resulted in 
degeneration of morphology with fuzzy nuclear outlines and loss of ceJl shape. However, cell ghosts 
could still be discerned and elements of retained cytoplasm and cytoskeleton were easily recognised 
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with slight loss of fluorescence intensity as compared to non-extracted cells. In control experiments 
with wild-type NF2 (wtNF2isol), and non-transfected COS cells in which intermediate filaments were 
detected with anti-cytokeratin antibodies, a typical filamentous network was observed (Figure la). 
This network, although somewhat distorted, was still present after detergent extraction with minor loss 
of staining intensity (Figure Ib). Immunoblotting with the anti-cytokeratin antibody yielded a 60kD 
band in non-extracted COS cells and only in the insoluble fraction of detergent extracted COS cells 
(Figure 2). Of note is the observation that the proportion of soluble versus insoluble NF2 protein from 
one and the same construct varied from one extraction experiment to another. Some NF2 protein was 
usually found in the soluble fraction. Most likely this results from the overexpression of the cDNA 
construct and subsequent spill-over into the cytoplasm following saturation of cytoskeleton attachment 
sites. Therefore, mutant NF2 protein was only deemed soluble if in repeated experiments the bulk of 
protein was recovered in the soluble fraction. 
NF2 protein resulting from transfection of wild type NF2 eDNA to COS cells, was predominantly 
present in the insoluble fraction. Likewise, isoform-2 NF2 protein was recovered from the insoluble 
fraction. Apart from constructs, NF2-delN-204;471-C and NF2~de1N-320 only minor amounts of 
mutant NF2 protein from the other constructs was detected in the soluble fraction (Figure 2). 
Conversely, the mutant NF2 protein from these constructs was easily detected in the insoluble fraction. 
The molecular weight of the mutant proteins in the extraction experiments was similar to the 
determination in in-vitro-transcription-translation experiments (not shown). Immunofluorescent 
staining of COS cells transfected with constructs other than NF2-delN-104;471-C and NF1-delN-320, 
(wtNF2isol; NFl-210N---7 Y; NFl-360L---7P; NF2-deI161-C) after detergent extraction showed slightly 
diminished staining intensity compared to non-extracted cells, nevertheless, the fluorescent signal 
remained associated with cell ghosts (Figure 1 c,d,e,f,g,h,i,j). 
Figure 1 
Immunofluorescent staining of transfected COS cells with and without detergent extraction. 
a. Staining witli anti-cytokeratin antibody, non-extracted COS cells, lOOOX magnification 
b. Staining with anti-cytokcratin antibody, after detergent extraction of COS cells, lOOOX magnification 
c. wtNF2;sol transfected COS cells stained with KFlO, not-extracted, 200X magnification 
d. wtNFisol transfected COS ceUs stained with KFlO, after detergent extraction, lOOX magnification 
e. Staining ofNF2-220N---7 Y transfected COS cells with KFlO, not-extracted, 400X magnification 
f. Staining of NF2-220N---7 Y transfected COS cells with KFIO, after detergent extraction, 400X magnification 
g. NF2-360L---7P transfcctcd COS cells stained with KFIO, not-extracted, 200X magnification 
h. NF2-360L~P transfected COS cells stained with KFIO, detergent extracted, 200X magnification 
i. NF2-deI262-C transfected COS cells stained with HB7, not extracted, 400X magnification 
j. NF2-deI262-C transfected COS cells stained with HB7, after extraction, 400X magnification 
k. NF2-delN-320 transfected COS cells stained with AHlO, not extracted, 400X magnification 
1. NF2-deIN-320 transfcctcd COS cells stained with AHlO, after extraction, 400X magnification; note minor 
retention of stainable NF2 protein 
m. NF2-deIN-204;471-C transfected COS cells stained with AHlO, not extracted, IOOX magnification 
n. NF2-delN-204;471-C transfected COS cells stained with AHIO, after extraction, 200X magnit1cation 
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The mutant NF2 protein of constructs NF2-deIN-320 and NF2-delN-204;47l-C was predominantly 
present in the detergent soluble fraction as determined by western blotting (Figure 2). No 
immunofluorescence signal was observed in COS cells transfected with these 2 constructs after 
detergent extraction (Figure 1 k,l,m,n). 
Discussion 
The assumption that the NF2 protein is a membrane-cytoskeleton linking protein is based on the 
homology of the NF2 protein to members of the ezrin-radixin-moesin (ERM) family of proteins, in 
turn part of a superfamily of proteins based on the erythrocyte cytoskeleton protein band 4.1. A 
common structure is shared by ERM proteins. A globular N-terminal region is followed by an alpha 
helical stretch and charged C-terminus 33, 35. The cytoskeleton binding capacity of ERM proteins has 
been convincingly demonstrated for ezrin, radixin and moesin, This binding capacity has been shown 
to reside in a 34 aminoacid F-actin binding sequence in the C-terminus, first described for ezrin. '34. 
Although this domain is present in radixin and moesin, it is lacking in the NF2 protein, Using a solid 
phase assay an additional internal actin binding domain has been described By Roy et al. 23 
Interestingly, this domain located between aminoacid residues 281-333, falls within the ERM 
homology region also shared by the NF2 protein, Intermolecular head-to-tail interaction has been 
demonstrated in ezrin in which the C-terminal F-actin binding site is obscured 7. Heterotypic 
interaction has also been demonstrated between moesin and ezrin, further uniting the ERM family as a 
closely related functional group of proteins 8, Recently, the membership of the NF2 protein to this 
family has been further substantiated by the finding that ezrin-NF2 interaction can occur 14 and that 
NF2 isoforml protein also may form inter- and intramolecular association. 14. 24, 30, Sequences 
facilitating this interaction are located in C-terminal aminoacids encoded by exon 17. 
The functional implications of these homotypic interactions have been strengthened by the 
observation that interaction of N-and C-terminal sequences is essential for growth inhibition in 
Schwann cells and that overexpression of the C-terminal sequences solely cause cell death in NIH3T3 
cells 29, 30. It would be of interest to determine the effect of mutations on NF2 homotypic and 
heterotypic interactions in relation to growth inhibition. 
The majority of mutations in the NF2 gene theoretically lead to truncated NF2 protein 37, Truncated 
NF2 protein however, has not yet been conclusively demonstrated in tumours from NF2 patients 12, lf1, 
31; our unpublished observations), although immunohistochemical staining experiments have provided 
some evidence for their existence 15,25, 
Figure 2 
Schematic overview of eDNA constructs and accompanying western blots of soluble (s) and insoluble (I) protein 
extracts. Numbers above diagrams indicate positions of nuc\eotides, numbers in italics below diagrams represent 
aminoacids, Calculated molecular weights are given with construct names. The relative position of peptides to 
which monoclonal antibodies were raised are given with reference to wtNFi''') 
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The lack of detection of truncated NF2 protein may be caused by increased degradation of mutated 
protein, possibly mediated by calpain dependent proteolysis 16. As the NF2 protein is thought to act as 
a linking protein, connecting integral membrane proteins to elements of the cytoskeleton, it would 
naturally fonow that truncated protein would lose the capability to bind to either membrane or 
cytoskeletal proteins. Therefore determination of the functional domains of the NF2 protein may 
indicate which mechanism underlies tumour formation in NF2. We therefore have undertaken 
experiments to establish which domain of the NF2 protein mediates binding to the cytoskeleton. To 
this end we adopted detergent extraction of COS cells transfected with NF2 mutant cDNA constructs, 
4 of which are based on mutations found in NF2 patients. Of note is the finding that the 4 constructs 
harbouring mutations found in NF2 patients do not seem to be impaired in their ability to resist 
detergent extraction and thus attachment to the cytoskeleton. Therefore it may be concluded that loss 
of cytoskeletal interaction by itself is not sufficient to cause NF2. 
The data provided here show that the N-terminal sequences of the NF2 protein harbour a high affinity 
cytoskeleton attachment domain. Constructs NF2-deIN-204;471-C and NF2-delN-320 almost totally 
lose their ability to interact with the cytoskeleton, whilst constructs NF2-del173-C, 
NF2-deI131-254;262-C, NF2-delN-28 and NF2-de1262-C retain resistance to detergent extraction. 
Therefore, we conclude that aminoacids 29-131 harbour a major cytoskeleton attachment domain. At 
present we do not know whether this domain directly interacts with cytoskeletal proteins, such as 
actin, or whether this interaction is indirect. There is considerable data from other groups supporting 
the existence of a cytoskeletal attachment domain in the N terminal region of the protein. In 
concordance with our results, Koga el at. show that several constructs in which C-terminal amino 
acids were deleted are retained in the insoluble fraction upon extraction with Triton X-lOO, with the 
smallest construct representing amino acids 1-173 17. In addition, Scherer et al. show the same for a 
construct deleted following aminoacid 303 26. Shaw el at. show that wild-type NF2 protein and a 
construct containing the N-terminal sequences localise to cortical actin and in particular areas such as 
membrane ruffles- where dynamic actin rearrangements take place 29, 
In addition to this N-terminally located high affinity domain, there is evidence for a second domain 
more C-terminal in the NF2 protein. From our extraction experiments it appeared that although the 
majority of protein from deletion constructs NF2-deLN-204;471-C and NF2-deLN-320 is extracted and 
recovered in the soluble fraction, some protein remained present in the insoluble fraction. We 
hypothesize that this is possibly due to a second lower affinity domain located between aminoacids 
321-470, being the overlap between these two constructs. Evidence for a C-terminal binding domain 
has also been presented by Deguen et al. In their experiments a deletion construct harbouring amino 
acids 251-595 is even exclusively found in the insoluble fraction 4. Further support for a C-terminal 
binding domain is provided by Scherer et at. who show that a protein fragment spanning amino acids 
300-595 is recovered in both detergent soluble- and insoluble fractions 26. Moreover, from other 
experiments it appears that NF2 protein sequences from 178-367 co-sediment with actin 36. 
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Combining these data the results would be compatible with a putative actin binding domain between 
amino acids 321-366 in the NF2 protein. Interestingly, an internal actin binding site was demanstrated 
for the ERM protein ezrin between ezrin amina acids 281-333 23. There is a 30 amina acid overlap 
between the actin binding region in ezrin and the putative NF2 damain. From these 30 amina acids 20 
are identical between both proteins and an additianal 5 are similar. 
Taken tagether, it appears that cytoskeletal assaciation 'Of the NF2 protein is camplex and most likely 
invalves N- and C-terminal sequences. Furthermore, homotypic and heterotypic interactions probably 
influence this interaction. The available data seems ta paint ta a major cytoskeleton association 
domain in the N-terminus 'Of the protein probably regulated by C-terminal sequences. We here provide 
evidence for a major cytoskeletan attachment damain at the N-terminus 'Of the NF2 protein, located 
between aminaacids 29-131 and a putative weaker attachment domain at aminoacids 321-470 possibly 
shared with other ERM prateins. 
References 
1. Bianchi AB, Hara T, Ramesh V, Gao J, Klein-Szanto AJP, Marin F, et al. Mutations in transcript 
isoforms 'Of the neurofibromatosis 2 gene in multiple human tissue types. Nature genetics, 1994. 6: 185-
192. 
2. Bretscher A. Rapid phaspharylation and reorganization of ezrin and speetrin accompany morphalogical 
changes induced in A-43 1 cells by epidermal growth factor. J Cell Biol, 1989. 108(3): 921-30. 
3. De Klcin A, Riegman PH, Bijlsma EK, Heldoorn A, Muijtjens M, den Bakker MA, et al. A G-->A 
transitian creates a branch paint sequence and activatian 'Of a cryptic exan, resulting in the hereditary 
disorder neurofibromatosis 2. Hum Mol Genet, 1998.7(3): 393-8. 
4. Deguen B, Merel P, Goutebroze L, Giovannini M, Reggia H, Arpin M, et al. Impaired interaction of 
naturally occurring mutant NF2 pratein with actin-based cytaskeletan and membrane. Hum Mol Gellet, 
1998.7(2): 217-26. 
5. den Bakker MA, Riegman PlU, Hekman RACP, Boersma W, Janssen P, van de Kwast T, et al. The 
product 'Of the NF2 tumaur suppressor gene localizes ncar the plasma membrane and is highly 
expressed in muscle cells. Oncogene, 1995.10(4): 757-763. 
6. den Bakker MA, Tascilar M, Riegman PlU, Hekman ACP, Baersma W, Janssen PJA, et al. 
Neurofibromatasis type 2 protein co-localizes with elements of the cytoskeleton. Am J Path, 1995. 
147(5): 1339-1349. 
7. Gary Rand Bretscher A Ezrin self-assaciation involves binding of an N-terminal domain to a normally 
masked C-terminal damain that includes the F-actin binding site. Mol Bio! Cell, 1995. 6(8): 1061-75. 
8. Gary Rand Bretscher A Heterotypic and hamotypic associations between ezrin and maesin, two 
putative mcmbrane-cytoskeletallinking prateins. Proc Natl Acad Sci USA, 1993.90(22): 10846-50. 
9. Ganzalez-Agosti C, Xu L, Pinney 0, Beauchamp R, Hobbs W, GuselJa J, et al. The merlin tumor 
suppressor lacalizes preferentially in membrane ruffles. Oncogene, 1996. 13: 1239-1247. 
10. Gronholm M, Sainia M, Zhao F, Heiska L, Vaheri A, and Carp#n O. Hamotypic and heterotypic 
interaetian 'Of the neurofibromatasis 2 tumar suppressar protein merlin and the ERM protein ezrin. J 
Cdl Sci. 1999. 1I2(Pt 6): 895-904. 
II. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation 
and multidisciplinary management 'Of neurofibromatosis I and neurofibromatosis 2 [see camments]. 
Jama, 1997.278(1): 51-7. 
12. Gutmann DH, Giordana MJ, Fishbank AS, and Guha A Loss of merlin expression in sporadic 
meningiomas, ependymomas and schwannomas. Neurology, 1997.49: 267-270. 
13. Hara T, Bianchi AB, Seizinger BR, and Kley N. Molecular claning and characterization of alternatively 
spliced transcripts of the mouse neurofibromatosis 2 gene. Cancer res, 1994, 54: 330-335. 
14. Huang L, Ichimaru E, Pestanjamasp K, Cui X, Nakamura H, La GY, et al. Merlin differs fram moesin 
in binding ta F-actin and in its intra- and intermalecular interactians. Biochem Biophys Res CO/11/J1l1ll, 
1998.248(3): 548-53. 
71 
cytoskeletal attachment domain 
15. Huynh DP, Mautner V, Baser ME, Stavrou D, and Pulst SM. Immunohistochemical detection of 
schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas. 1 
Neuropathol Exp Neurol, 1997.56(4): 382-90. 
16. Kimura Y, Koga H, Araki N, Mugita N, Fujita N, Takeshima H, et al. The involvement of ealpain-
dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat 
Med, 1998.4(8): 915-22. 
17. Koga H, Araki N, Takeshima H, Nishi T, Hirota T, Kimura Y, et a!. Impairment of cell adhesion by 
expression of the mutant neurofibromatosis typc 2 (NF2) genes which lack exons in the ERM-
homology domain. Oncogene, 1998. 17(7): 801-10. 
18. Lee JH, Sundaram V, Stein DJ, Kinney SE, Stacey DW, and Golubic M. Reduced expression of 
schwannomin/merlin in human sporadic meningiomas. Neurosurgey, 1997. 40(3): 578-587. 
19. Lekanne-Deprez RH, Bianchi AB, Groen NA, Seizinger BR, Hagemeijer A, Drunen v, E, et al. 
Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am 1 
Hum Genet, 1994.54: 1022-1029. 
20. MacColiin M, Mohney T, Trofattcr J, Wertelecki W, Ramesh V, and Gusella J. DNA diagnosis of 
neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree 
[published erratum appears in JAMA 1994 Oct 12;272(14):1104]. lama, 1993. 270(19): 2316-20. 
2l. Murthy A, Gonzalez-Agosti C, Cordero E, Pinney D, Candia C, Solomon F, et al. NHE-RF, a 
regulatory cofactor for NA+-H+ exchange, is a common interactor for merlin and ERM proteins. 1 BioI 
Chem, 1998.273(3): 1273-1276. 
22. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman l, Marineau C, et al. Alteration in a new gene 
encoding a putative membrane-organizing protein causes neuro-fibromatosis typc 2 [see comments]. 
Nature, 1993.363(6429)'.515-21. 
23. Roy C, Martin M, and Mangeat P. A dual involvement of the amino-terminal domain of ezrin in F- and 
G-aetin binding. J BioI Chem, 1997. 272: 20088-20095. 
24. Sainio M, Zhao F, Heiska L, Turunen 0, den Bakker M, Zwarthoff E, el al. Neurofibromatosis 2 tumor 
suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. } 
Cell Sci, 1997. 110(18): 2249-2260. 
25. Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, and Pulst SM. Mutations of the 
neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol 
Genet, 1994.3(6): 885-91. 
26. Scherer SS and Gutmann DH. Expression of the neurofibromatosis 2 tumor suppressor gene product, 
merlin, in SchWalm cells. J Net/TOsci ReJ, 1996.46(5): 595-605. 
27. Schmucker B, BaHhausen W, and Kressel M. Subcellular localization and expression pattern of the 
neurofibromatosis type 2 protein merlin/sehwannomin. Eur J Cell BioI, 1997.72: 46-53. 
28. Scoles DR, Huynh DP, Marcos PA, Coulsell ER, Robinson NG, Tamanoi F, e[ al. Neurofibromatosis 2 
tumour suppressor schwannomin interacts with betalI- spcctrin. Nat Genet, 1998. 18(4): 354-9. 
29. Shaw RJ, McClatchey AI, and Jacks T. Localization and functional domains of the neurofibromatosis 
type II tumor suppressor, merlin. Cell Growth Differ, 1998.9(4): 287-96. 
30. Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N, Ponta H, et al. Interdomain binding 
mediates tumor growth suppression by the NF2 gene product. Oncogene, 1997. 15(20): 2505-9. 
31. Stemmer-Raehamimov A, Xu L, Gonzalez-Agosti C, Burwick l, Pinney D, Beauchamp R, et al. 
Universal absence of Merlin but not other ERM family members, in sehwannomas. Am J Pa/h, 1997. 
151(6): 1649-1654. 
32. Trofatter lA, MacColiin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al. A novel Moesin-, 
Ezrin-, Radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell, 1993. 72: 
791-800. 
33. Tsukita S, Yonemura S, and Tsukita S. ERM proteins: head to tail regulation of actin-plasma membrane 
interaction. Trends in Bioi Sci, 1997. 22: 53-58. 
34. Turunen 0, Wahlstrom T, and Vaheri A. Ezrin has a COOH-terminal actin-binding site that is 
conserved in the ezrin protein family. J Cell Biol, 1994.126(6): 1445-53. 
35. Vaheri A, Carpen 0, Heiska L, Helander TS, Jaaskelainen J, Majander-Nordeswan P, et a!. The ezrin 
protein familiy: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Bioi, 
1997. 
36. Xu HM: and Gutmann DH. Merlin differentially associates with the microtubule and actin cytoskeleton. 
J Nellrosci Res, 1998.51(3): 403-15. 
37. ZwarthoffEC. Neurofibromatosis and associated tumour suppressor genes. Parhot Res Pract, 1996. 
192: 647-657. 
72 
CHAPTER V 
Expression of the Neurofibromatosis type 2 gene in human tissues 
Michael A. den Bakker, Kees l Vissers, Anco C, Molijn, J ohan M. Kros 
Ellen C. Zwarthoff and Theo H. van der Kwast. 
Dept. of Pathology, Josephine Nefkens Institute, Erasmus University Rotterdam, 
Rotterdam, The Netherlands 
The Journal of Histochemistry and Cytochemistry 
in press 
73 
NF2 gene expression 
Abstract 
The Neurofibromatosis type 2 tumor suppressor gene is implicated in the hereditary tumor syndrome 
NF2, hallmarked by bilateral vestibular schwannomas, mellingiomas and ocular non-neoplastic 
features. The gene product has characteristics of a membrane-cytoskeleton linking protein, but the 
mechanism of tumor suppression by the NF2 protein remains to be elucidated. The NF2 gene is widely 
expressed in mouse and rat tissues. In humans most of the expression data has accumulated through 
northern blot analysis, RT-PCR and more recently western blot analysis, providing information on 
whole tissues and organs mther than on specijic cell types. We here report an extensive sUlvey of NF2 
gene expression in human tissues using a combination of mRNA in-situ-hybridization (mRNA-ISH) 
and immunohistochemistry (lH) with a panel of monoclonal antibodies, supplemented by tissue 
immunoprecipitation experiments with affinity purified poiyc/onal antibodies. Expression was 
obselved in many different cell types, most of which appear functionally normal in individuals aff-'ected 
by NF2. Surprisingly, expression could not be consistently documented in Schwann cells and 
arachnoidal cells by immunohistochemistry nor by mRNA-ISH in formalin fixed tissue. However, 
consistent immlillostaining of Schwann cells was seen in frozen sections. 
Introduction 
Cloning of the neurofibromatosis type 2 (NF2) gene in 1993 26. J8 led to the decisive segregation of the 
neurofibromatosis type 1 and neurofibromatosis type 2 syndromes. NF2 is characterized by the 
development of bilateral vestibular schwannomas. In addition, other central nervous system tumors, in 
particular meningiomas and to a lesser extent gliomas and ependymomas, occur in NF2 patients 12. 
Spinal tumors observed in a high percentage of cases by neuroimaging studies less commonly lead to 
functional impairment 24. Non-neoplastic features of NF2 include juvenile subcapsular lenticular 
opacities, retinal hamartomas and epiretinal membranes. Mutations in the NF2 gene are detected in 
NF2-related and sporadic schwannomas and meningiomas, supporting its role as a classical tumor 
suppressor gene 43. In addition mutations have been detected in pleural mesotheliomas, a tumor that 
does not occur in NF2 patients 5,22. _H. The 595 aminoacid NF2 protein is homologous to a subgroup of 
band 4.1 proteins, ezrin, radixin and moesin, collectively known as the ERM protein family. ERM 
proteins function as membrane organizing proteins, linking the plasma membrane to the cytoskeleton 
3. 40. Based on the homology of the NF2 protein to the ERM proteins it has been postulated that the 
NF2 protein likewise functions as a membrane-cytoskeleton linking protein. The CD44 glycoprotein 
and a regulatory cofactor of the Na +-H+ exchanger are candidate NF2 associating membrane proteins 
25. 27. It has been shown that the NF2 protein co-localizes with elements of the actin cytoskeleton, 
possibly actin, with reports supporting colocalization with F-actin in stress fibers and subcortical actin 
fibers 10. ll. Other reported putative NF2 associating cytoskeletal proteins include spectrin 32, RhoA 30 
and tubulin 42. To date, localization studies and biochemical approaches thus support the postulated 
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role of the NF2 protein, although conclusive evidence is still lacking and the method of tumor 
suppression is unclear. 
The expression of the NF2 gene has been extensively studied in mouse and rat tissues using various 
techniques, including mRNA-in-situ hybridization (mRNA-ISH), RT-PCR, immunohistochemistry 
and western blotting 6·8. lJ. 14. 19.11. Expression studies of the NF2 gene in human tissue are limited and 
are mainly based on RT-PCR and northern blotting 2.4. /7. lX, 26.18. 34-36. 311. These approaches provide a 
general overview of gene expression. Detailed expression studies with visualization at the cel1ular 
level may be performed by immunohistochemistry or mRNA-ISH. Immunohistochemical detection of 
the NF2 protein relies on the availability of suitable antibodies and the accessibility of the epitope in 
the tissue. Previously, we have performed immunohistochemical detection of the NF2 protein in 
selected human tissue samples9. /0. We here present a detailed expression study of the NF2 gene in 
human tissue combining mRNA-ISH and immunohistochemical staining with a panel of monoclonal 
anti-NF2 antibodies. This approach was adopted in favor of immunohistochemistry solely, to avoid 
epitope masking problems which, with respect to ERM proteins, appear to prohibit an adequate 
inventory 29. 
Materials and methods 
Tissue samples and sections. 
For rnRNA-ISH and immunohistochemistry experiments formalin fixed paraffin embedded archival 
tissue blocks from surgical specimens were used. All brain sections were obtained from an autopsy in 
which there was no neurological disease. Following fixation in neutral buffered 10% formalin and 
paraffin wax embedding, 51lm sections were cut and mounted on 3-aminopropyltriethoxysilane coated 
slides (Sigma, Chemlcal Co., St.Louis, MO, USA). Glassware and solutions were autoclaved to inhibit 
RNase activity; non-autoclavable material was soaked in O.2M HCl. All manipUlations were 
performed under RNase free conditions. 
In-situ-hybridization probes 
Digoxigenin (DIG) labelled riboprobes BAK3AS (antisense) and BAK3S (sense) were transcribed 
from a subcloned 291 bp PstI fragment of the NF2 cDNA (positions 1085-1376 from the ATG 
initiation codon; Fig. 1). The fragment was subcloned in the pTZ-19 vector (Pharmacia, Uppsala, 
Sweden) in 2 orientations. After linearization of the plasmid, transcription and digoxigenin-Iabelling 
was performed according to the manufacturers recommendations (Boehringer Mannheim, Mannheim, 
Germany) using T7 RNA-polymerase. The BAK2S and BAK2AS probes (235bp, positions 1376-1611 
from the ATG initiation codon; Fig. 1) were transcribed from peR generated DNA templates. A 
consensus T7 RNA polymerase binding sequence was incorporated in the primer sets. The antisense 
BAK2 probe was transcribed from a DNA template generated with primers PI (5'-
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aggaagcacgcgaggcgga-3', forward) and P2T? (5'-'tgcttgctcttttccatggcatcctaatacgactcactatagg-3', 
reverse). 
For the sense BAK2 probe primers T?PI (5'-gcatcctaatacgactcactataggaggaagcacgcgaggcgga-3', 
forward) and P2 (5-'tgcttgctcttttccatg-3', reverse) were used. The peR products were purified 
(Qiaquick spin column, Qiagen GmbH, Hilden, Germany) and used for transcription. Transcribed 
riboprobes were checked by agarose gel electrophoresis and ethidium bromide staining and spot-
blotting. Initial hybridization experiments performed on parallel tissue sections with BAK3AS/S and 
BAK2AS/S indicated that the results with these 2 probe sets were comparable with the BAK3AS/S 
probe set general1y generating a stronger signal, all further hybridizations were carried out with probe 
set BAK3AS/S. 
In-situ hybridization 
mRNA-in-situ hybridization was performed essentially as described by Lindenbergh et al.· 13. 
Hybridization was performed at 53°C (2xSSC, 50% formamide) in a humid chamber overnight with a 
final probe concentration of 100ng/ml. Posthybridization washes were carried out at 45°C. 
Visualization of RNA hybrids was achieved by incubation with alkaline phosphatase conjugated anti-
digoxigenin antibodies (Fab fragments, Boehringer Mannheim); 4-nitroblue tetrazolium chloride 
(NBT) and 5-bromo-chloro-indolyl-phosphate (BCIP) were used as substrate. The colour development 
was performed in the dark with periodic visual inspection. The reaction was terminated when a 
sufficiently strong signal was observed. The sections were counterstained with nuclear fast red, 
dehydrated through ethanol gradients and mounted with Euparal (Chroma-Gesel1schaft, Stuttgart, 
Germany). Control hybridizations were performed in selected cases with the DIG-labelled insulin-like-
growth-factor-binding-protein-5 (IGF-BP5) probe 31, kindly provided by D.Lindenbergh-Kortleve. 
Control slides were treated with DNase or RNase prior to hybridization as controls. NF2 transfected 
COS cells were used as hybridization controls; transfection and cell culture were performed as 
described previously 10. 
Antibodies and immunohistochemistry 
The production of the monoclonal anti-NF2 antibody KFlO has been described previously 10. 
Production of monoclonal antibodies FE9, HB? and AHIO, immunohistochemistry and ELISA were 
performed as described previously 10. In ELISA and immunohistochemistry control experiments 
culture supernatant from the IgGl secreting myeloma parent cell line (P3-X63Ag8) was used. 
Monoclonal antibody FE9 was raised against synthetic peptide SPNF2-0 10 and monoclonal antibodies 
HB? and AHlO were raised against synthetic peptides SP2?6 and SP2?? respectively (Fig. 1) 9. The 
isotype of the monoclonal antibodies was determined with the use of the Isostrip isotyping kit 
(Boehringer Mannheim, Germany). Primary monoclonal antibodies AH 1 0 and HB? were used as 
undiluted culture supernatants FE9 and KFIO were used at 1:50 to 1: 100 dilutions from culture 
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supernatants from a Tecnomouse incubator (Tecnomara, Integra Biosciences, Wallisellen, 
Switzerland); all antibody incubations were performed overnight at 4°C. For immunoperoxidase 
staining the peroxidase-anti-peroxidase (PAP) method was used. Staining intensity for FE9 was 
improved by wet heat (microwave antigen retrieval) pre-treatment. As a chromogen diaminobenzidine 
(DAB) was used. Sections were incubated in the chromogen solution with hydrogen peroxide as a 
substrate for no longer than 7 minutes in the dark with gentle agitation. After rinsing, sections were 
counterstained with hematoxylin. No enhancement techniques were used. Negative controls included 
omission of the primary antibody, staining of parallel sections with undiluted culture supernatant from 
the myeloma parent cell line which secretes an IgGl antibody, and staining with a commercially 
available anti prostate specific antigen (PSA) antibody (clone 8, IgGl, Sanbio, Uden, The 
Netherlands). The polyclonal antiserum 1399NF2 9 was affinity purified using synthetic peptide 
SP277 coupled to an immobilized matrix (Sulfolink, Pierce, Rockford, IL, USA) through its terminal 
cysteine residue according to the manufacturers specifications. The antibody containing fractions were 
pooled and concentrated by ultrafiltration (Diaflow ultrafiltration membrane PMlO, Amicon Corp. 
Beverly, MA, USA). 
Immunoprecipitation 
Normal human tissue was obtained from surgical specimens submitted for pathological diagnosis. The 
samples were analyzed histologically to avoid abnormal tissue. Tissue samples were lysed by mincing 
in 5 volumes immunoprecipitation buffer (1 % NP40; 50mM TRIS-HC1, pHS.O; 150mM NaCI; SmM 
EGTA; 5rnM EDTA; 15rnM MgC12; 60rnM ~.glycerophosphate; lrnM DTT; O.lrnM NaV04; O.lrnM 
NaF) supplemented with protease inhibitors. The samples were cleared by centrifugation and filtration 
(Super Acrodisc, Gelman Sciences, Ann Arbor, MI, USA). The obtained supernatant was precleared 
by adding Sl1g of normal rabbit IgG and incubating for 1 hour at 4DC after which 25111 of a 50% slurry 
of protein-A sepharose (Pharmacia, Uppsala, Sweden) was added to the supernatant and mixed for an 
additional 30 minutes. The beads were spun down and the precleared supernatant was transferred to a 
fresh tube. Ten Jlg of pOlyc1onal antibody 1399A or of the commercially available NF2 antibody A19 
(sc331, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to the lysate and incubated for 1 
hour at 4DC, after which 20111 of protein-A sepharose beads were added. The immunoprecipitate was 
allowed to form for 2 hours at 4 DC or overnight. Following four washes of the immunoprecipitate in 
imrnunoprecipitation buffer and centrifugation, the pellet was resuspended in 50111 of reducing sample 
buffer (Laemlli). Ten III samples were analyzed by western blotting as described previously 10. 
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Figure 1. 
Schematic diagram of the NF2 protein with 
relative positions of synthetic pcptides and 
mRNA-ISH probe sets. 
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Results 
mRNA-in-situ-hybridization and antibody controls 
The specificity of the probes was checked by control hybridizations on NF2- and mock transfected 
COS cells with and without prior DNase or RNase digestion. A strong cytoplasmic hybridization 
signal was observed in approximately 10% of the cells (not shown), no signal was observed after 
RNase digestion, but DNase digestion did not alter staining, indicating that the signal was not due to 
hybridization of the riboprobe to transfected NF2 cDNA. Weak background staining in all COS cells 
was observed with the anti-sense and sense probes in most experiments. 
Antibodies FE9 and AHIO were determined as IgGl(K) antibodies, while HB? presented as an IgM(K) 
antibody. In solid phase assays (ELISA) using synthetic NF2 peptides and non-relevant protein 
(bovine serum albumin) the monoclonal antibodies reacted exclusively to the NF2 peptides to which 
these had been raised. No reactivity in ELISA was seen when culture supernatant from the myeloma 
parent cell line was used. All mono- and affinity purified polyclonal antibodies detected the 69kD 
band in western blots of NF2 transfected COS cells. In western blotting experiments and 
immunocytochemical staining experiments using cultured epithelial cell lines it was found that anti 
sp-o antibody FE9 crossreacts with a low molecular weight cytokeratin (not shown), therefore 
staining of epithelia with this antibody was not interpreted. Staining of nucleoli in some tissue sections 
was seen with the monoclonal antibody AHlO and to a lesser extent a-cellular stroma was stained with 
this antibody. 
Figure 2. 
Immunohistochemical- and mRNA-ISH staining of human tissue. 
a. mRNA-ISH of epidermis, BAK3-AS probe, original magnification 200X 
b. mRNA-ISH of oesophagus, BAK3-AS probe, original magnification lOOX 
c. Immunostaining of epidermis, KFlO antibody, original magniHcation 400X 
d. mRNA-ISH of small intestine, BAK3-AS probe, original magnitlcation lOOX 
e. mRNA-ISH of mesothelial lining of intestine, BAK3-AS probe, original magnification 200X 
f. Immunostaining of pleural aspirate, FE9 antibody, original magnification 400X. Note strong staining of 
mesothelial cells and weaker staining of histiocytes, lymphocytes do not stain. 
g. mRNA-ISH of intestinal ganglion, BAK3-AS probe, original magnif1cation 200X. A clear signal is seen in 
neurons, satellite eells do not stain. 
h. mRNA-ISH of peripheral nerve, BAK3-AS probe, original magnification 200X. ISH staining is seen in 
endothelial cells, Schwann cells are negative. 
i. Immunostaining of cryostat section of peripheral nerve in sub-epicardial connective tissue, FE9 antibody, 
original magnification 200X. Note strong cytoplasmic staining of Schwann cells and weaker staining of 
mesothelial (epicardial) lining. 
j. mRNA-ISH of eNS neurons, BAK3-AS probe, original magniHcation 400X. Very weak staining of glial 
cells is observed in addition to strong cytoplasmic staining of neurons. 
k. mRNA-ISH of Purkinje cells in the cerebellum, BAK3-AS probe, original magnification 400X. 
l. Immunostaining of bloodvessel, KFIO antibody, original magnification 200X. The tunica media is stained, 
the endothelial lining does not stain with this antibody. 
m. mRNA-ISH of bloodvessc1s in loose subserosal tissue in the intestinal tract endothelial, BAK3-AS probe, 
original magnification 200X. Note absence of staining of smooth muscle cells of the tunica media, a strong 
hybridization signal is in endothelial cells. 
n. lmmunostaining of bloodvessel, FE9 antibody, original magnification 200X. Both smooth muscle cells in 
the tunica media and endothelial cells are stained 
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The sections stained with culture supernatant from the myeloma parent cell line demonstrated weak 
non-specific staining that did not overlap with staining patterns achieved by the NF2 monoclonal 
antibodies; no signal was observed in sections stained with anti-PSA antibodies. 
NF2 expression in tissues by mRNA-ISH and immunohistochemistry 
Consistent NF2 gene expression was observed in a number of tissues by mRNA-ISH, 
immunohistochemistry and immunoprecipitation. An overlapping but distinct staining pattern of the 
various anti-NF2 antibodies was found. 
epithelium and mesothelium 
High levels of NF2 gene expression were observed in all layers of the epidermis excluding the a-
cellular cornified layer by in-situ-hybridization (Fig 2a). Non-cornifying stratified epithelium of the 
oesophagus also stained. However, here the ISH signal was limited to the lower layers (Fig 2b). A 
strong ISH-signal was observed in urothelium and in the epithelium of the small intestine. In the small 
intestine the signal was confined to the crypts and diminished towards the tips of the villi (Fig 2d). 
Weak ISH-staining was observed of colonic epithelium, generally located at the basal parts of the 
crypt. Other epithelia in which a weaker InRNA-ISH signal was observed included pseudostratified 
epithelium of the trachea, bronchial epithelium, epithelium of eccrine sweatducts in the skin, the 
acinar cells in the pancreas, cells of the collecting ducts in the kidney and follicular epithelium in the 
thyroid and parathyroid gland. No ISH signal was observed in fat, cardiac muscle, cartilage, liver, 
prostate, adrenal gland, spleen, thymus and peripheral nerve. Immunostaining closely mimicked 
mRNA-ISH staining in stratified epithelia with strong staining by AHlO, HE? and KFlO (Fig 2c). In 
non-stratified epithelia weak immunostaining was observed with AHlO only. 
Hybridization- and immunostaining of peritoneal mesothelial cells was observed, but of variable 
intensity (Fig 2e). Mesothelial cells in other locations, including pleura and epicardium were also 
stained with NF2 antibodies, a stronger cytoplasmic immunohistochemical signal was observed when 
cytological smears from pleural aspirates were used (immunohistochemistry only, Fig. 2f). 
neural tissue 
Strong and consistent immunohistochemical and mRNA-ISH staining was observed of neurons in the 
autonomic ganglia throughout the intestinal tract (Fig 2g). However, Schwann cells and satellite cells 
were negative. Likewise, Schwann cells in other locations, for instance in peripheral nerves or in 
peripheral sections of cranial nerves, did not show any hybridization signal (Fig 2h) and only weak 
and non-consistent immunostaining was seen in paraffin sections. However, immunostaining of 
cryostat sections of peripheral nerve with FE9 was consistently positive (Fig 2i). In the central nervous 
system neurons were consistently positive with mRNA-ISH but no regional differences were noted. 
Cortical neurons, neurons of cranial nerve ganglia and neurons of extra-pyramidal locomotory systems 
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stained with equal intensity (Fig 2j). We did observe diminishing staining intensity towards the deeper 
layers, most likely due to impaired penetration of fixative in the brains after autopsy. Weak and 
inconsistent ISH-staining of glial cells was noted. A weak hybridization signal was observed in 
ependymal cells but arachnoidal cells were negative. Staining of neurons with the monoclonal NF2 
antibodies was not observed and no immunostaining of arachnoidal cells was seen. In the cerebellum 
the Purkinje cells hybridized strongly (Fig 2k) but no ISH-staining of the molecular or granular layer 
was observed. Imrnunostaining of cells in the cerebellum was not seen. In the human eye a 
hybridization signal was observed in amacrine cells in the retina. Very weak ISH-staining was 
observed in the cornea and in lens epithelium while irrununostaining was negative. 
blood vessels 
Variable NF2 gene expression was found in endothelium in bloodvessels. In bloodvessels located in 
the loose subserosal tissue in the intestinal tract and in umbilical cord vessels strong specific 
endothelial ISH- and immunostaining with the FE9 monoclonal antibody was observed but not with 
any of the other antibodies (Fig 2 1,m,n). In other tissues staining of endothelial cells was weak or 
absent. Of note is the very weak or complete absence of a ISH-signal in the smooth muscie cells of the 
tunica media of blood vessels, despite consistent strong positive immunostaining with several 
antibodies (Fig 2 l,m,n). Skeletal and cardiac muscle demonstrated low expression levels with 
immunostaining with 1 antibody (AHIO) but ISH was completely negative. 
other tissues 
No staining was seen of liver including bile duct epithelium, spleen, prostatic epithelium, thymus 
(only staining of Hassal's corpuscles), adrenal gland, pneumocytes, circulating blood cells, fat, 
cartilage, mucus glands in oesophagus and trachea, islet cells and ductular epithelium in the pancreas, 
glomeruli and renal tubules. Imrnuno- and ISH staining was seen of tissue macrophages in various 
tissues; in lymph nodes imrnunostaining was seen of high endothelial venules. 
Immunoprccipitation. 
To confirm the presence of NF2 protein in various tissues we performed imrnunoprecipitation 
experiments with affinity purified anti-NF2 antibodies. Frozen tissue samples were available for 
immunoprecipitalion experiments for a selection of tissues. From all tissue samples NF2 could be 
immunoprecipitated by either of the affinity purified polyclonal antibodies A19 or 1399A (Fig 3). 
Immunoprecipitated protein could be detected with anyone of the monoclonal antibodies and with 
either of the affinity purified polyclonal antibodies. In addition to the expected 69kD band, a slower 
migrating band of approximately 130 kD was observed in most samples and in lysates of oesophagus 
and adrenal gland a band of 250 kD was also seen. These additional bands were detected by several 
NF2 antibodies and therefore possibly represent NF2 dimers. From most lysates the 69kD NF2 band 
presented as a doublet, probably due to phosphorylation. 
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Two human smooth muscle cell lines, one an established smooth muscle cell line derived from the 
muscularis externa of the intestine (human intestinal smooth muscle, HISM (Graham et at. 1984)) and 
a second primary smooth muscle culture from the human airway (kindly supplied by Miss S. McKay, . 
Dept. of Pharmacology, Erasmus University Rotterdam), were used for immunoprecipitation. Both 
cell lines yielded a 69kD band which was detected with monoclonal antibodies raised against distinct 
NF2-peptide 
epitopes (not shown). In some experiments the 69kD band presented as a doublet. 
Figure 3 
Immunoprecipitation of NF2 protein from 
human tissue. Precipitating antibody A19, 
detection with FE9. Lane 1 to 8: small 
intestine, adrenal gland, myometrium, 
myocardium, kidney, oesophageal 
mucosa, epidermis and NF2 transfected 
COS cells. Note the slower migrating 
bands at approximately 130 kD band and 
250 kD. The position of the molecular 
weight markers is indicated on the left. 
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Neurofibromatosis type 2 is characterized by the development of schwannomas of the eighth cranial 
nerves, and meningiomas. Schwannomas are benign tumors arising from neural-crest derived 
Schwann cells, in which the inactivation of the NF2 gene is thought to be paramount in the 
pathogenesis. Therefore expression of the NF2 gene is expected in Schwann and arachnoidal cells. 
To further document NF2 gene expression in human tissue, we performed immunohistochemical and 
mRNA-ISH staining experiments on an extensive panel of human tissues. Although frozen sections 
may provide _ increased sensitivity we used formalin fixed paraffin embedded sections for all 
experiments to ensure a comprehensive tissue panel and optimal morphology after hybridization. An 
exception was made to demonstrate the presence of NF2 protein in Schwann cells in peripheral nerve. 
In this case both formalin fixed and cryostat sections were used for immunohistochemical staining. 
The discrepancy of non-staining tissue in paraffin sections versus clear immunoreactivity in cryostat 
sections is well known. In a number of tissues in the study presented here, including liver, spleen, 
adrenal gland, thymus, fat, prostatic epithelium, cartilage, pneumocytes and circulating blood cells we 
could not document NF2 expression by either mRNA-ISH or IH. It is possible that the sensitivity of 
the employed methods is insufficient to detect the presence of NF2 protein in these tissues. Therefore, 
we interpreted positive immuno- or ISH staining as evidence of NF2 gene expression whilst 
acknowledging that non-staining does not rule out NF2 gene expression below the detection threshold 
levels. 
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Expression studies of the NF2 gene have been performed by a number of techniques including 
northern blotting, RT-PCR, western blotting, mRNA-ISH and immunohistochemistry. Furthermore, 
the majority of these investigations have been performed on non-human tissues, in particular rodent 
tissues and on cell lines 2.4.6·8. ].'1. 14. 17-/9, n 26, 28, 34-36, .'18. A drawback of a number of techniques utilising 
tissues homogenates such as northern blotting, western blotting and RT-PCR, is the inherent lack of 
detail. No information on specific cell types can be inferred from these experiments. Furthermore, 
until evidence exists that the NF2 protein functions similarly in rodent cells and human cells 
comparison of expression studies should be interpreted with care. 
Strong and consistent immuno- and ISH-staining of epithelia, in particular stratified epithelia, was 
observed. Expression was observed both in keratinizing and non-keratinizing stratified epithelium. 
Previously we have documented co-localization of NF2 protein with keratohyalin granules and 
intermediate filaments in keratinocytes /0. Apart from cutaneous schwannomas NF2 patients do not 
develop specific skin disorders. Our findings coincide with immunohistochemical and mRNA-ISH 
data from a developmental study in mice in which expression in keratinocytes in the epidermis was 
described 21. 
NF2 gene mutations have been documented in malignant mesotheliomas 5.22, 3.l, a tumour that is not 
seen with an increased frequency in NF2 patients. In support of the involvement of the NF2 gene in 
the development of malignant mesotheliomas are our findings of NF2 gene expression in pleural, 
epicardial and abdominal mesothelium. It remains to be elucidated if, comparable to epithelium, the 
NF2 protein co-localizes and associates with intermediate filaments in mesothelial cells. 
Schwann cells are derived form the neural crest and form myelin sheaths around axons in the 
peripheral nervous system, Sporadic and NF2 related Schwannomas arise from Schwann cells. 
Therefore, the presence of NF2 protein is expected in Schwann cells. Surprisingly, no signal was 
observed in Schwann cells with either of the hybridization probe sets, while immunostaining was 
weak and variable in paraffin sections. However, strong and consistent positive immunostaining of 
Schwann cells in frozen sections was seen. Approximately half of NF2 patients develop meningiomas. 
These tumors, with variable histological appearances, are generally believed to originate from 
arachnoidal cells in the leptomeninges. Therefore, it is assumed that the NF2 gene is expressed in 
these cells. We were not able to demonstrate NF2 gene expression in arachnoidal cells with mRNA-
ISH. Neither did we detect NF2 protein by immunohistochemical methods with the monoclonal 
antibodies. The lack of reactivity in mRNA-ISH and immunostaining experiments of Schwann- and 
arachnoidal cells may be caused by insufficient sensitivity of the employed methods to detect low 
levels of NF2 mRNA and protein. In previous reports the presence of the NF2 protein in Schwann and 
arachnoidal cells has been demonstrated by immunohistochemical methods 7, III, 28 . . '10. 34, 35. However, 
the results of these experiments are not consistent and staining in some reports has only been achieved 
by very sensitive methods. Investigators using more conventional staining techniques, describe 
cytoplasmic perinuclear staining in some Schwann cells and variable expression in arachnoidal cells in 
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frozen sections of human tissue 34. In addition, fixation time appears critical for immunohistological 
detection of NF2 protein 30 and it appears that detection of NF2 protein in tissues is dependent on the 
epitope to which antibodies are reactive. Several investigators have used cultured Schwann cells to 
detect NF2 protein. It must be borne in mind however, that ERM gene expression may be upregulated 
in cell culture while corresponding endogenous tissue expression has not been documented for the 
particular ERM protein 1.16.39. Previously it has been demonstrated that NF2 gene expression in the 
mouse and possibly in humans is developmentally regulated 21.26. Failure of demonstration of NF2 
expression in the study in adult human tissue could thus be due to physiological down-regulation in 
Schwann and arachnoidal cells. 
As we and others have noted, the NF2 gene is expressed in smooth muscle cells and endothelial cells 7. 
10.34. Therefore, expression studies utilizing RT-PCR, northern blotting and to a certain extent western 
blotting, may erroneously detect NF2 expression originating from blood vessel wall elements in 
tissues not truly expressing the NF2 gene. 
Comparable to rodents, we found a strong ISH signal for the NF2 gene in neurons of the central 
nervous system, including the Purkinje cells in the cerebellum. In contrast, we were not able to detect 
NF2 protein in these cells using antibodies to various epitopes. It is possible that the antibodies we 
employed were directed to masked epitopes. Indeed, a recent report by Stemmer-Rachamimmov 
describes extensive expression of the NF2 gene in the human CNS by immunohistochemical methods 
using a monoclonal antibody directed to C-terminal NF2 sequences 35. In addition to neurons, these 
authors detect NF2 protein in glial and ependymal cells. Although we did occasionally observe a ISH 
signal in glial cells this was not readily reproducible and weak ISH staining was also observed after 
hybridization with sense probes. 
Taken together, it appears that the NF2 gene is expressed in many human tissues, most of which are 
not involved by disease in individuals affected by NF2. NF2 gene mutations in particular affect 
Schwann cells and arachnoidal cells and do not affect other tissues that apparently express the NF2 
gene. It therefore seems plausible that NF2 expression in these tissues may be redundant. Experiments 
providing support for this hypothesis have been performed by Takeuchi, Huyng and Henry 15.20.37. By 
introducing anti-sense NF2 oligonucleotides in the Schwann-celllike cell line STS-26 Huyng et al. 
observed morphological and stimulatory proliferation effects, while Takeuchi showed that inhibition 
of all 3 ERM proteins was required in thymoma and epithelial cells for maximal inhibition of cell 
adhesion and for morphological changes. Why this putative redundancy might fail in Schwann cells 
and arachnoidal cells is not clear. Although cell type specific expression of a single ERM protein 
seems an attractive explanation, Schwann cells have been shown to express moesin 34 as well as NF2 
protein thus excluding this hypothesis. An alternative explanation for the apparent discrepancy 
between NF2 disease symptoms and tissue expression patterns of the NF2 gene may be that, in 
analogy to loss of the retinoblastoma gene in several epithelia, loss of function of NF2 function in 
epithelial cells induces hyperproliferation masked by an increased rate of apoptosis 41. 
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We have provided an inventory of human NF2 gene expression. From this inventory and the available 
literature data, it can be concluded that NF2 and ERM genes are indeed expressed in an partly 
overlapping set of tissues. Additional studies are required to focus on common and distinct NF2 and 
ERM protein functions. 
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Abstract 
We describe a G~A transition within intt'on 5 of the NF2 gene. This mutation creates a consensus 
splice branch point sequence. To our knowledge, this is the first report of a mutation that creates a 
functional branch point sequence in a human hereditary disorder. The new branch point sequence is 
located 18 bp upstream of a consensus splice acceptor site. A consensus splice donor site is found 106 
bp 3' of the acceptor site. As a consequence the G~A transition results in an alternatively spliced 
mRNA containing an additional exon 5a of 106 base pairs derived from intron sequences. We cloned 
the mutant cDNA alld show that due to an in frame stop codon the eDNA codes for a truncated NF2 
protein. The mutation was observed in 3 affected members of a NF2 family. In a tumour of one of the 
family members, both alternatively spliced and wild type mRNA were found, although the wild type 
allele of the gene is absent due to an interstitial deletion on chromosome 22. We also show that 
immunoprecipitations reveal the presence of full length wild type NF2 protein in the tumour lysate. 
These data support the hypothesis that some degree of normal splicing of the mutant precursor RNA is 
taking place. 1t is therefore likely that this residual activity of the mutant allele explains the relatively 
mild phenotype in the family. These data also implicate that complete inactivation of the gene is not 
required for tumourformation. 
Introduction 
Branch point sequences are located 18-40nt upstream of a splice acceptor site which usually is the first 
AG downstream of the branch point sequence. In the branch point consensus sequence, 
Y,N,Y,U,R,A,C (Y=Cff; R=G/A; N=any) the A at position 6 is critical for the formation of a 
mammalian splice intermediate: the lariat structure. In addition, it has been shown that mutation of this 
A residue strongly reduces the splicing efficiency of the downstream exon l.l. In human genetic 
diseases, splicing errors are common, however most of these alterations are due to a mutation of the 
splice donor or acceptor sites. Only two cases have been described so far in which the splicing error 
was the result of a mutation of the invariant A residue of the branch point resulting in reduced usage of 
the downstream exon 12. N. 
Neurofibromatosis type 2 (NF2) predisposes patients to the development of central nervous system 
tumours such as Schwannomas, meningiomas and ependymomas 5. /0. Additional manifestations of the 
disease include peripheral Schwannomas and cataract. NF2 is an autosomal dominant disorder with a 
birth incidence of 1:35,000, The NF2 gene, located on chromosome 22q12, consists of 17 exons of 
which exons 16 and 17 are alternative splice forms leading to different COOH-termini of the NF2 
protein I. l.l. 19, Mutations in the NF2 gene have been found in NF2 family members and in sporadic 
Schwannomas and meningiomas 20. In addition, mutations were found in malignant mesotheliomas, a 
tumour that does not develop in NF2 patients 2, Iii. 
Most of the mutations that have so far been described in the NF2 gene predict that gene function is 
negatively affected. In general, mutations that lead to a truncation of the protein are found more 
90 
Chapter VI 
frequently in patients with the severe form of the disease. In patients with a mild'phenotype missense 
mutations are more frequent. This suggests that there is a correlation between phenotype and genotype 
ll, 16. 20. It has been speculated that the mutations leading to a truncated protein could perhaps function 
as dominant negative mutations in which the truncated protein interferes with the function of the wild 
type gene. The reduced activity of the NF2 protein could then trigger some degree of hyperplasia 
which would increase the chances on a second hit (i.e. loss of the other allele), after which tumour 
formation would ensue. Such a scenario would explain the larger number of tumours in severely 
affected patients. However, this hypothesis remains to be proven. Mutations that affect splice sites are 
encountered in both forms of NF2 and it has been argued that in cases with the mild form of NF2 these 
mutations do not completely prevent normal splicing. However, the effect of the mutation on rnRNA 
and protein is usually not investigated. 
In the current report we describe a G--?A transition which causes NF2 in a Dutch family. The mutation 
creates a consensus splice branch point sequence in intron 5 of the NF2 gene. Due to the presence of 
downstream splice acceptor and donor sites this mutation results in the incorporation of a additional 
exon in the NF2 mRNA. We show that the alternative mRNA codes for a truncated protein. In 
addition, we detected large amounts of wild type mRNA and protein in tumour tissue. This suggests 
that the mutation still allows normal splicing of the mutant allele. This finding might explain the 
relatively mild phenotype in the family and that tumourigenesis does not require a complete absence 
of wild type NF2 protein. 
Results 
Detection of a point mutation in the NF2 gene 
Earlier we reported that in a meningioma from case 2, MN121, the NF2 cDNA contained an extra 
insert of 106 base pairs Ii. The insertion of 106 bp located between exon 5 and exon 6, suggested a 
mutation either in the exon 5 splice donor site or in the exon 6 splice acceptor site. In order to find the 
exact position of the mutation in genomic DNA, we have amplified these exons including the 
exonlintron borders with exon 5 and 6 specific primers 7. No altered migration pattern was observed 
on agarose gels or by SCCA analysis (not shown) nor did the sequence of the 106 bp insertion 
correspond to the reported exon border sequences. These results indicate that mutations in the exon 5 
splice donor or exon 6 splice acceptor sites were not the cause of the insertion, 
To determine the origin of the extra 106 bp at the exon 5 and 6 border in MN12l cDNA, we have 
cloned a 1,Okb PCR fragment encompassing exon 5 and 6 and the intron 5 sequences of the NF2 gene 
from case 2. To locate the 106nt cDNA insertion in the intronic sequences we used the restriction 
enzyme BpmI which has one recognition site in the 106nt insertion. BpmI cuts also once in the 1.0kb 
genomic exon 5-6 fragment. By determining the sizes of the restriction fragments, we were able to 
locate the 106nt insertion 249 bp downstream of exon 5 (Fig. lA). peR, using primers from exon 5 or 
exon 6 in combination with primers derived from the 106nt sequence confirmed the position of the 
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106 bp sequence. These primers were also used for DNA sequencing and the sequence of a 430 bp 
genomic region ofMN121 DNA was determined and compared with normal DNA (Fig. 1). It appears 
that both in control DNA and in DNA of tumour MN121 the sequence of the 106nt insertion is 
present. However, in MN121 there is a G~A point mutation at position 301 (start of exon 5 is 1), 18 
bp upstream of the 106 bp sequence. This is the only difference we could detect in MN121 tumour 
DNA when compared to the control. The point mutation results in the creation of a putative branch 
point site just in front of a putative splice acceptor site (Fig. 1). 
A 8pml 
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Figure 1. 
Identification and position of the G---7A 
mutation and exon 5a relative to exons 5 and 
6 of the NF2 gene. A. Upper drawing: 
location of exon 5a within the intron between 
eXOhS 5 and 6. The EpmI site is indicated. 
The sequenced area is indicated in the 
drawing. In the sequence, exon 5 and 5a are 
in bold letters. Underlined are splice acceptor and donor sites. Bold underlined is the newly created branch point 
sequence, in which the mutant A is in bold and italic. The BpmI site is doubly underlined. B. DNA sequence 
analysis of the area spanning the mutation in control DNA (left) and DNA from MN12l (right). The altered 
nucleotidc is indicated with an asterisk 
The splice acceptor site precedes the genomic copy of the 106 bp insertion. At the 3' end, the 106 bp 
genomic sequence is flanked by a putative splice donor site. We therefore conclude that the point 
mutation creates a new splice branch point sequence, which in combination with already existing 
consensus splice acceptor and donor sites, results in the formation of an extra exon Sa in the NF2 gene. 
Effect of the mutation on the NF2 protein 
To analyse the NF2 protein encoded by eDNA carrying the insertion, we generated an expression 
plasmid (pRI21) containing a cDNA derived from the mutant NF2 transcript from meningioma 
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MN121. This mutant eDNA encodes a putative protein of 23.5 leD consisting of 172 amino acids of 
the normal NF2 protein and 31 amino acids derived from exon Sa. A nonsense codon is present at 
position 412 in exon 5a (see Fig. 1). When clone pR121 was used for in-vitro transcription-translation 
a truncated protein with the expected molecular weight of about 25 leD was found (Fig. 2A). In 
addition, a western blot of a lysate of COS cells transiently transfected with the pRl21 construct, also 
showed a protein of about 25 kD (results not shown). 
A 
wt=: ~ 
-66.4 
-556 
-42.7 
-36.5 
ml- -26.6 
B 
- -165 
-105 wt"* _ ..... -76 
~ 'W -57 
-46.5 
-37.5 
Figure 2. 
Analysis of the NF2 protein. 
A. In-vitro-transcription-translation of 
wild type and mutant (RI2l) cDNA. The 
positions of the wild type (wt) NF2 
protein, which migrates at approximately 
70 kD, and the mutant (mt) 23 kD protein 
are indicated. 
B. Immunoprecipitation of the NF2 
protein from a lysate of meningioma 
MNI21. The wild type NF2 protein 
produced by transfCcted COS cells is 
used as a control for the position of the 
full length NF2 protein. The bands below 
the full length NF2 band in MN121 arc 
from the 'precipitating antibody. The 
identity of the slower migrating band, 
which is sometimes observed in these 
analyses (Den Bakker, unpublished results), is not known at prescnt. The 23 kD mutant NF2 protein cannot be 
seen. The length of the protein markers is shown at the right side of the panels. 
To see whether the truncated protein could be detected in MN121, we used a frozen sample of this 
tumour for immunoprecipitation. Tumour cells were lysed and used for inununoprecipitation with 
antibody A19. Detection of the NF2 proteins was with the same antibody. The results of this analysis 
are shown in figure 2B. As a control, figure 2B shows the position of the wild type NF2 protein, 
transiently expressed in monkey COS cells. In the lane with the immunoprecipitated MN121 sample a 
band migrating at the position of ful1length NF2 is visible, in addition to the bands from the heavy and 
light chains of the precipitating antibody and a slower migrating band of unknown identity. However, 
no truncated mutant protein of the expected size can be detected in tumour MN121. 
Presence of the G.---7A mutation in other members of the NF2 family 
The G.---7A transition that was detected in PBL DNA from case 2, results in the loss of a Bfal site and 
creates a new MaeH site. Both these restriction enzymes were used to detect the mutation in other 
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members of the family and the results are shown in figure 4. Two fragments resulting from a MaeH 
digestion were found in the DNA extracted from peripheral blood lymphocytes of cases 2 and 3, 
together with the undigested band from the wild type allele. Similarly,. two MaeH fragments were also 
found in DNA extracted from meningiomas from case I (MN60) and 2 (MNI21). 
A B 
PEDIGREE OF NF2 FAMILY 121/60 
II 
0¥_'~=_-"64 
Figure 3. 
Diagnostic analysis of the mutation in the family members. A. Pedigree of the family. Individuals with filled 
symbols are affected. Further information: number in the upper right quadrant depicts age of decease; figure in 
the lower left quadrant indicates case number; figure on the right is age of onset of clinical symptoms. B. Maell 
digestion of amplified DNA from MN60, MN121 and PBLs from cases 2-4. DNA from case 5 was analysed 
separately and is not included in this figure. She did not carry the mutation. 
In the DNA of case 4, no new MaeH sites or loss of the Bfal site could be detected (Fig. 3). This 
individual was born in 1938 and has so far not complained of any symptoms reminiscent of NF2, 
although he has not been tested in a clinical setting. In addition, the G-tA transition could not be 
found in control DNAs extracted from peripheral blood lymphocytes of a series of 50 independent 
individuals. These results suggest that the G-tA transition is indeed the causative mutation in this 
family. Case 5 was seen for genetic counselling because she wanted to be informed about her carrier 
status. She was tested according to a presymptomatic counselling protocol. Her DNA was screened 
using the RFLP analysis. She had a wild type genotype (results not shown). 
Discussion 
In this paper we describe a mutation which creates a splice branch point sequence in an intron of the 
NF2 gene. Due to the presence of consensus splice acceptor and donor sites downstream of this 
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mutation, intron sequences are spliced into the NF2 mRNA. Mutations affecting a branch point 
sequence are not frequently encountered and only two cases have been described so far. Putnam et at. 
12 describe a case of congenital contractural arachnodactyly (CCA) in which an A~G mutation 
destroyed the invariant A residue of the branch point preceding eXOn 29 of the FBN2 gene, resulting in 
a reduced usage of the exon. In a family with X-linked hydrocephalus (HSAS) a A~C change 
destroys the branch point of exon R 14. This results in omission of the exon from the mRNA or usage 
of an alternative splice acceptor site 69 nucleotides upstream of the exon. In addition to this normal 
splicing of the mutant allele was also observed. In the affected members of the NF2 family described 
here, the reverse is found: a genuine branch point sequence, -TICTAAC- is created and 106 bp of 
intron sequence are spliced in the mRNA between exons 5 and 6. To our knowledge this is the first 
time such a mutation has been found in a human hereditary disorder. 
Mutations that lead to a putative truncated protein are predominantly found in families with the severe 
form of NF2. In contrast, families with the mild form more often have a missense mutation 20, and 
references therein, II. /6. A special class is formed by the patients in whom a splice site mutation is 
detected, these may be either of the mild or severe phenotype. A possible explanation of the latter 
finding is that the mutation may not always exclusively lead to a mutant transcript but that some 
degree of normal splicing may still be possible. However, the result on mRNA and protein of the 
splice site mutations is usually not investigated. MN121 contains both mutant and considerable 
amounts of wild type transcript as judged from the relative intensities of bands obtained in RT-PCR 
experiments (results not shown). In the tumour, LOB of the wild type allele was observed 9 and 
densitometry of the RFLP data suggests that the tumour sample contained 80-90% tumour cells 
(results not shown; non-tumour cells are presumably derived from blood vessels). Thus, we presume 
that a considerable fraction of the wild type transcript originates from the tumour cells and was 
produced by normal splicing of the mutant transcript. The detection of full length NF2 protein in the 
tumour lysate also supports this hypothesis. Therefore, in this family, the occurrence of some degree 
of normal splicing may explain the relatively mild phenotype. 
The nucleotide sequence of the mutant cDNA predicts that translation of this alternative mRNA stops 
within the insertion at a stop codon located after 31 amino acids within the 106nt fragment. These 
predictions were confirmed by Western blotting of COS cells transfected with a NF2 expression vector 
containing the MN121 mutation and in-vitro transcription-translation of this construct. With both 
analyses we demonstrated the formation of a smaller truncated NF2 protein. In whole cell lysates of 
tumour MN121 the 23 leD mutant NF2 protein could not be detected in contrast to full-length wild 
type protein. This suggests that the truncated 23 leD protein is unstable. It has been suggested by 
several investigators that a mutation leading to a truncated NF2 protein may display a dominant 
negative effect on the product of the wild type allele n. 16. 20. However, so far there is no proof for this 
hypothesis. The data presented in this paper show that we were unable to detect the truncated protein, 
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even when considerable amounts of mutant transcript were present. Therefore it seems that, at least in 
this case, a dominant negative effect of the mutation is unlikely. 
Approximately half of all NF2 patients are severely affected 5. However, 80% of the identified 
mutations are in patients with the severe phenotype. This implicates that there is a bias towards the 
detection of mutations that lead to the severe form of the disease ll, 16, 20 In the group of patients 
described by Parry, germ-line mutations were detected in only 36% of families with a mild phenotype, 
Therefore it is likely that many of the mutations in mildly affected families, are within introns and 
affect splicing of the transcript to some extent. In the family discussed in this paper, a mutation 
affecting splicing was revealed that cannot easily be discovered using SSCA on genomic DNA with 
exon flanking primers, This will also hold for other similar mutations, because it is practically 
impossible to screen each intron of the entire gene. The most optimal approach to detect mutations like 
these is by SSCA on cDNA A problem with this approach is that RNA isolated from lymphoblasts 
cannot be used for such assays, probably because of the low or absent expression of the gene in these 
cells llThe NF2 gene is, however, strongly expressed in the skin 4. Thus, an alternative and perhaps 
better approach for mutation detection in NF2 families, would be to use RNA isolated from skin 
biopsies. 
Materials and methods 
Patients 
The patients mentioned here are members of a family that was described by Delleman et al. .'I as 
having the central form of Von ReckIinghausen disease, Figure 3A depicts the updated pedigree, This 
family is now diagnosed as having NF2, using the current NIH criteria for diagnosis of NFl and NF2 
10. The first generation consisted of three affected and four unaffected sibs. The two affected brothers 
from this generation developed multiple meningiomas and died at ages 70 and 64. The affected sister 
died at age 43. Upon autopsy, multiple meningiomas and bilateral acoustic neurinomas (vestibular 
Schwannomas) were discovered, The second generation members are descendants of one of the 
brothers and comprise 3 affected and (as far as is known) 3 unaffected sibs. Update of the clinical 
record of this generation: 
Case 1. A female patient I (FHI, 4 in Delleman et at.), born in 1942. From 1967 multiple intracranial 
and intraspinal meningiomas were discovered. Several of these were removed by surgery during the 
foIlowing years. The patient died in 199 I. 
Case 2. Sister of case 1 (FIll, 2), was born in 1936, In 1972 a bilateral focal cord paresis and a right-
sided radiculopathy of L4 and L5 were diagnosed, for which, at that time, no explanation could be 
found, In 1979 she presented with hearing loss. A CT -scan showed a right cerebellopontine angle 
tumour besides multiple supra tentorial high density lesions suggestive of meningiomas, The 
cerebellopontine angle tumour was partially removed. Histology: fibrous meningioma. When the 
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tumour recurred in 1992, it was totally removed. The other tumours have not shown progressive 
growth and the clinical condition of the patient has remained stable. 
Case 3. Brother of case 1 (FIII,5), was born in 1944. At age 22 a meningioma was removed from the 
optic nerve sheath. Presently, he has a harsh voice due to unilateral cord paralysis. Because of an 
intrathoracal tumour detected in 1993, he is slightly dyspneic. Since 1994 his visual acuity is 
deteriorating due to cataract. In 1997 he is still able to work. 
Case 4: Brother of case 1, born in 1938, is without symptoms of NF2. 
Case 5. Daughter of case 3. Was healthy at age 19 although she complained of dizziness. 
NF2 mutation detection 
For the detection of NF2 mutations in genomic DNA, DNA was extracted using routine procedures 17 
from MN60 (case 1) and MN121 (case 2) and peripheral blood lymphocytes of the family members 2-
5 and control individuals. Primers flanking the exons of the NF2 gene were kindly supplied by Dr JF 
Gusella 7. These primers were used to amplify exons 5 and 6 of the NF2 gene. PCR conditions: non-
radioactive (50111 containing 100ng genomic DNA; 200 11M dNTP; 7.5 pMol of each primer; O.lU 
SuperTaq DNA polymerase (HT Biotechnology) and Ix PCR buffer (PCR optimizer kit, Invitrogen 
Leek, The Netherlands) or radioactive (15111 : identical with 20 )lM dATP and 0.15 )ll of 32P_a_dATP( 
3000 Cilmmol, Amersham, Little Chalfont, UK». The non-radioactive PCR products were analysed 
on 4% agarose gels and radioactive fragments were used for SSCA on 0.5x MDE gels (JT Baker) 
containing 0%, 5% or 10% glycerol and electrophoresed at 8 Watt at 4 C or RT for 14-19 hours. 
SSCA gels were transferred to blotting paper, dried and exposed to Fuji Medical X-ray film. A 
combination of eXOI1 5 and exon 6 and exon flanking primers 7 was used to amplify the region 
containing the intron sequence. The PCR fragment was subcloned into pCM1mn (TA-cloning kit, 
Invitrogen) and the 5' part of this fragment was sequenced using a T7 DNA sequencing kit 
(Pharmacia, Sweden). For the detection of the G~A transition in the family members and control 
DNAs the primers SaIl (AATCTCCCAGTAAACAGTGT, nt 192-211 in Fig. 1) and 121B 
(CACTGCAAACAGCTCAATTCC, nt 399-379 in Fig. 1) were used to amplify a 206 bp DNA 
fragment. After digestion of the radioactive PCR fragment with the restriction enzymes Bfal or a 
MadI the samples were analysed on 12.5% polyacrylamide gels and exposed to Kodak XAR-5 films. 
Construction of a mutant cDNA expression construct 
The forward primers AIlS' (CATGGCCGGGCCATCGCTICC, nt 219-240, relative to the start 
codon) in combination with the reverse primers A3/3' (CATAAATAGATCATGGITCCCGAT, nt 
1142-1119) 8, flanking the insertion in the NF2 transcript of MN 121 were used to amplify the eDNA 
of MN121. The 1.0 kb PCR product of the primer combination was cloned into plasmid vector 
pCMTMn, using the TA-cloning kit (Invitrogen). A 0.475 kb BglII fragment was isolated and 
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subcloned into a ful11ength NF2 cDNA construct replacing the original 8glII fragment. Clones with a 
properly oriented 8glII fragment were selected by restriction analysis and recloned into a pCDNA3 
mammalian expression vector. The insert of the thus obtained pR121 clone was sequenced using a 
sequence kit (Pharmacia, Sweden). 
Detection of mutant and wild type NF2 protein 
In-vitro transcription-translation was performed using the TnT Coupled Reticulocyte Lysate System 
(Promega, Madison, WI, USA), with the T7 primer, 1 llg of plasmid DNA and 2 )11 of 35S labeled 
methionine (10 mCiJrnl, Amersham, Little Chalfont, UK), under conditions described by the 
manufacturer. Samples were analysed using SDS-PAGE and autoradiography. The expression 
constructs were transfected to COS cells by electroporation (250V, 500)lF). After 48 hours the 
transfected cells were washed with PBS, harvested by scraping with a rubber policeman, lysed in 
reducing sample buffer and used for Western blotting. Immunoprecipitations were performed 
essential1y as described by Fornerod et al. 6. Briefly, tumour tissue of MN121 was homogenized by 
mincing in immunoprecipitation buffer (50 rnM Tris-HCI, pH8.D, 150 rnM NaCl, 1 % Nonidet P40, 
5rnM EGTA, 5rnM EDTA, 15 rnM MgCI" I rnM Dithiotreitol, 0.1 rnM NaV04, 0.1 mM NaP) 
supplemented with protease inhibitors. The crude lysate was centrifuged and filtered trough a 45)1m 
filter. After preclearing, specific antibody (AI9; sc331, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) and 40 )11 of a 50% slun'y of sepharose-protein A were added. After O/N incubation at 4°C, the 
beads were spun down and washed four times in immunoprecipitation buffer. The beads were 
resuspended in reducing sample buffer and the sample was subjected to electrophoresis and blotting as 
described previously 4. Mter blocking, the NF2 protein was detected by incubating the blots with 
antibody A19 , followed by a secondary biotinylated goat-anti-rabbit and peroxidase conjugated 
streptavidin. Bands were visualised by enhanced chemiluminescence and exposure to film. 
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Truncated NF2 proteins are not detected in meningiomas 
and schwannomas. 
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Abstract 
Neurofibromatosis type 2 is caused by mutations in the NF2 tumour suppressor gene. The NF2 gene 
encodes a 595 aminoacid protein, presumably functioning as a membrane organising element. 
Theoretically, the majority of mutations found in the NF2 gene should lead to a truncated protein 
product. Using immunoprecipitation with an antibody raised to N-terminal sequences of the NF2 
protein, we sought to demonstrate the presence o.ftruncated NF2 proteins in tumours. From 17 of 19 
tumours (14 meningiomas and 5 schwannomas), 12 of were shown to harbour truncating NF2 
mutations, wild-type NF2 protein was immunoprecipitated. From 2 tumours 110 protein was 
precipitated. Truncated NF2 proteins were not obselved. We conclude that mutant NF2 proteins are 
ullstable and undergo accelerated degradation. 
Introduction 
Neurofibromatosis type 2 (NF2) is a rare inherited cancer syndrome characterized by the occurrence of 
bilateral vestibular schwannomas. These tumours, also known as neurilemmemomas, are benign 
neoplasms originating from the Schwann cells in the nerve sheath. Other NF2 disease manifestations 
include meningiomas, which are tumours arising from the membranes covering the brain and non-
neoplastic lenticular opacities developing at an early age. The disease is caused by mutations in the 
NF2 tumour suppressor gene, located on chromosome 22. The NF2 gene was cloned in 1993 and 
encodes a 595 aminoacid protein that is believed to interact with integral membrane proteins and the 
cytoskeleton 12. 18. This assumption is based on the homology of the NF2 protein to ezrin, radixin and 
moesin (collectively ERM proteins) which in turn form part of yet a larger superfamily of proteins 
related to the erythrocyte band 4.1 protein. 
Two subforms of NF2 can be discerned, a clinically severe form, called the Wishart type, with an early 
onset of symptoms, multiple meningiomas and accelerated disease course. A second milder form is 
known as the Gardner SUbtype and presents with a delayed disease onset and fewer tumours 4. J 1. 
Mutation analysis has shown that a clear NF2 genotype-phenotype correlation can be deduced. 
Nonsense mutations resulting in a truncated protein are usually associated with a severe phenotype and 
miss-sense mutations resulting in aminoacid substitutions are predominantly associated with the mild 
phenotype 13, 20. Two possibilities exist for tumorigenesis by NF2 gene mutations. Either the mutant 
protein product acts in a dominant negative way over the wild-type protein or alternatively true loss of 
function occurs in which case loss of the remaining wild-type allele is expected in tumours. In either 
case it may be expected that mutant (truncated) NF2 protein is present in tumours. Successful 
immunological detection of truncated protein may simplify the search for NF2 mutations and aid 
diagnosis. 
To detect tlllncated NF2 proteins we performed immunoprecipitation with aN-terminal anti-NF2 
antibody on fresh tumour samples. Nineteen tumours, 5 schwannomas and 14 meningiomas were 
analysed (Table 1). Eight of the 14 meningiomas and 4 of the 5 schwannomas have previously been 
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investigated for NF2 mutations and chromosome 22 copy number 9. Loss of heterozygosity (LOR) for 
chromosome 22 was determined for the remaining 7 tumours using polymorphic microsate11ite 
markers. In addition, these 7 tumours not previously investigated were immunohistochemically stained 
for the endothelial cell marker CD34 and smooth muscle actin (HHF35) to determine residual normal 
tissue in the form of endothelium and smooth muscle cells of the tunica media. 
Materials and Methods 
Fresh tissue samples from operative specimens were snap frozen and stored at -80°C until use. For 
LOR analysis formalin-fixed, paraffin-embedded archival tissue was used. Blocks were selected with 
a minimal amount of residual normal tissue on the basis of H&E-stained sections. 
To evaluate the normal tissues content, sections were stained for the endothelial cell marker CD34 
(Qbend to, Biogenex, San Ramon, CA, USA) and smooth muscle actin (HHF-35, Biogenex). A 
standard streptavidine-biotin-peroxidase method was used (Ultra Vision detection system, Lab vision, 
Fremont, CA, USA) with diaminobenzidine as a chromogen. Normal tissue content was scored 
visually. 
DNA extraction from paraffin blocks was performed by proteinase K (2 mglml) digestion of de-
paraffinized 10 Jlm sections, followed by purification using the Qiagen DNeasy kit (Qiagen, Hilden, 
Germany). Microsatellite primer sequences were obtained form the Cooperative Human Linkage 
Center (http://www.chIc.org/). Six primer pairs were used: D22S444, D22S445, D22S683, D22S684, 
D22S685 and D22S686. Amplification and quantification were performed as described previously 17. 
Frozen tissue samples were thawed and minced in immunoprecipitation buffer. After centrifugation, 
immunoprecipitation and western blotting were performed as previously described 2. An affinity 
purified polyc1onal NF2 antibody was used for immunoprecipitation (A19, sc331, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). This antibody was raised to N-terminal NF2 aminoacids and 
therefore should precipitate all truncated proteins. The ability to immunoprecipitate truncated NF2 
proteins was confirmed using mutant NF2 proteins produced in-vitro. For these experiments cDNA 
constructs NF2-del-341-C and NF2-del-N204A71C were used together with an affinity purified 
polyclonal antibody 1399A raised to synthetic peptide SP277 e, den Bakker submitted; Fig. la,b). In-
vitro-transcription-translation (ITT) reactions were performed as described with 35S-methionine as 
a radio label. For immunological detection on western blots monoclonal anti-NF2 antibodies FE9 and 
KFlO were used 2. 3. FE9 was raised to a synthetic peptide spanning aminoacids 1-20 of the NF2 
protein and therefore should detect all truncated NF2 proteins resolvable by sodium-dodecyl-sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). The KFlO monoclonal antibody was raised to a C-
terminal synthetic peptide and thus only detects full-length NF2 protein. Samples were run on 7.5 and 
12 or 15% slab gels to enhance detection of truncated low molecular weight proteins. In addition, 
multiple exposures of probed western blots were analysed to detect faint bands. Mock 
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immunoprecipitations were performed on tumour tissues samples by omitting the precipitating 
antibody. 
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A. Schematic representation of wt-NF2 protein and cDNA constructs 
with positions of antibody epitopes used for control 
immunoprecipitation experiments. Construct NF2-dcl-341-C lacks 
the C-terminal 255 aminoacids of the NF2 protein. Construct NF2-
del N-204;47l-C is a NF2 construct spanning aminoacids 205-470. 
Calculated molecular weights are given with constructs. 
B. Autoradiogram of a protein blot of immunoprecipitated protein 
produced in-vitro. 
Results 
Lane I: non-immunoprecipitated ITT products, wtNF2 (*), NF2-
del-341-C (**) and NF2-del N-204;471-C (***) 
Lane 2: construct NF2-del N-204;471-C immunoprecipitated by 
1399A 
Lane 3: construct NF2-del N-204;471-C immunoprecipitated by 
AI9 
Lane 4: construct NF2-del-341-C immunoprecipitated by 1399A 
Lane 5: construct NF2-dc1-341-C immunoprecipitated by A19 
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Immunohistochemical staining for the endothelial cell marker CD34 and the anti-smooth muscle 
antibody HHF35 demonstrated a rich vascular network in tumour samples (not shown). However, 
estimated amounts of normal cells (predominantly endothelium and smooth muscle cells) was not 
more than 10% in any sample. Five of the 6 meningiomas and the schwannoma demonstrated allelic 
imbalance for chromosome 22 by PCR with polymorphic microsatellite markers (not shown). From 17 
of the 19 tumours full-length NF2 protein was immunoprecipitated, detectable by both FE9 and KFIO. 
From 2 tumours, both schwannomas, no detectable NF2 protein was precipitated (Table I; Fig 2). 
However, only minor tissue was available from the two tumours from which no NF2 protein was 
precipitated. The immunoprecipitated protein presented as a doublet in virtually all cases. Truncated 
NF2 proteins were not identified. On very long exposures additional bands were observed but these 
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additional bands did not conform to calculated molecular weights resulting from specific mutations in 
selected tumours and were either detected with PE9 or KFlO but never by both antibodies. In addition, 
faster migrating bands were also observed in mock irnmunoprecipitations in very long exposures. Two 
additional bands migrating at approximately 130 and 200kD were consistently observed in several 
samples. We have previously observed these bands in 
irnmunoprecipitates from normal tissue. 
Table 1. Details of tumours and outcome of immunoprecipitations 
Meningiomas chromo #22 NF2 % tumour IF 
99' -22 del 448-467; FS >90 WT 
108* -22 53 CAA-CT; FS >90 WT 
111* -22 del 76; FS >90 WT 
121*# -22 ins 106bp 517; FS >90 WT 
127* -22 1009 CAG-TAG stop >90 WT 
128* diploid del 36-37; FS >90 WT 
del 82bp + 18bp ins 496-
577 
140* -22 deI1223-1236; FS >90 WT 
145* -22 ins 119bp 364; FS >90 WT 
328 LOH 90 WT 
329 LOH >90 WT 
331 no loss 90 WT 
334 LOH >90 WT 
337 LOH >90 WT 
399 LOH >90 WT 
Schwannomas 
340 LOH >90 WT 
106* -22 del 38-58 >90 
110* diploid deI440-492 >90 WT 
111* diploid del 1023-1044 >90 
175 >90 WT 
* Lekanne-Deprez (1994).9 
# meningioma in a NF2 patient 
Discussion 
Mutation analysis in NF2 families and in sporadic schwannomas and meningiomas has confirmed the 
role of the NF2 gene as a classical tumour suppressor gene. Inactivating mutations of both alleles of 
tumour suppressor genes are required for tumorigenesis. In the familial setting a gerrnline mutation 
inactivates the first allele. The second allele is often inactivated by loss of (parts of) the chromosome 
on which the gene is located in target cells. Indeed, in tumours with NF2 mutations the second 
chromosome 22 is usually lost. From these observations it may be expected that loss of functional NF2 
protein results in disease. However, a dominant negative effect before loss of the second allele cannot 
be ruled out. Theoretically, many of the mutations identified in the NF2 gene should result in the 
production of a truncated protein 20. Truncating NF2 mutations are associated with a severe 
phenotype, whilst miss-sense mutations lead to a mild phenotype 13. 20. We sought to demonstrate the 
!O5 
truncated NF2 proteins 
existence of truncated NF2 proteins from tumours with known NF2 mutations. In addition, 
meningiomas evaluated for loss of chromosome 22 were included. It has been shown that most if not 
all meningiomas with chromosome 2210ss, also harbour NF2 mutations 14, 19. 
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Western blots of protein immunoprecipitated from meningiomas and schwannomas by antibody A19. Tumour 
numbers are indicated above the lanes (see Table 1), not shown are MN99, 108 and 128. 
A. Western blot of7.5% slab gel, NF2 protein detection by monoclonal antibody FE9. These samples were 
prepared from tumours with characterised NF2 mutations. COS= direct (non-immunoprecipitated) 
lysate of NF2 transfected COS cells, serving as positive control. The negative control is 127mock, the 
precipitating antibody was omitted in this sample. The bands indicated by * arc immunoglobulins cross-
reacting with the secondary antibody. 
B. Western blot of 12% slab gel, loaded with precipitated protein from tumours not evaluated for 
chromosome 22 loss. Detection by PE9. 
C. Western blot of 15% slab gel loaded with precipitated NF2 protein from 4 sehwannomas with 
characterised NF2 mutations. No truncated NF2 protein is observed. Lane M is a biotinylated molecular 
weight marker. 
Truncated NF2 proteins were not detected in any of the tumour samples investigated. From 2 
schwannoma samples no protein at all was immunoprecipitated. However, wild-type NF2 protein was 
found in all but these 2 schwannomas. Although residual normal tissues was less than 10% in all cases 
it must be assumed that the precipitated wild-type NF2 protein originates from intimal endothelial 
cells and smooth muscle cells of the tunica media of blood vessels. We have previously shown that 
NF2 gene expression is demonstrable in both of these cells types 2. The failure to immunoprecipitate 
NF2 protein from 2 tumours is likely to be the result of the minimal amount of fresh tissue available 
from these tumours for investigation. 
The failure to detect truncated NF2 protein in tumours may result from defective transcription and/or 
translation or from decreased stability of the mutant protein. A failure of translation as a result of 
increased RNA degradation is highly unlikely as RT-PCR analysis is usually performed successfully. 
In addition, cDNA constructs based on mutations found in patients do yield truncated protein in-vitro 
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(den Bakker et al., submitted). It therefore appears that truncated NF2 proteins are unstable and are 
rapidly degraded. There is considerable evidence supporting this mechanism. It has recently been 
shown by Gutmann et al. that truncated NF2 proteins are not produced in-vivo. Efforts to generate 
rat-schwannoma cell lines producing truncated NF2 proteins were unsuccessful despite incorporation 
of the trans gene with detection of transcribed NF2 mRNA. In addition, it was shown that NF2 proteins 
with miss-sense mutations were produced in transgenic cell-lines but these too had a reduced half-life 
compared to wild-type protein 5. NF2 protein has been shown to be sensitive to calpain dependent 
proteolysis and that this proteolytic pathway be excessively activated in meningiomas. In up to 30% of 
meningiomas loss of chromosome 22 is not observed 10. It is conceivable that in these meningiomas 
aberrations of the proteolytic pathway may result in reduced NF2 protein. 
The failure to detect truncated proteins in schwannomas and meningiomas is corroborated by data 
from other investigations 1. 6-8. 15, 16, Quantitative western blot analyses have shown reduced NF2 
protein levels or complete absence of NF2 protein in meningiomas and schwannomas. However, 
quantitative determination of NF2 protein by western blotting should take into account the vascular 
density of the tumour to compensate for NF2 expression in endothelial and smooth muscle cells. In the 
published reports this has not been the case. In none of the reports published to date are truncated NF2 
proteins detected by western blotting. Immunohistochemical staining with antibodies to N- and C-
terminal NF2 epitopes indirectly supports the presence of truncated NF2 proteins in a single report 7 
but these findings are not completely consistent with the molecular data. Our own efforts to detect 
NF2 protein in normal araclmoidal cells have not met with success 2. 
In conclusion, truncated NF2 proteins are not detected in meningiomas and schwannomas. Failure of 
detection probably results from accelerated degradation of mutant proteins, possibly mediated by 
calpain dependent proteolysis. These findings strongly indicate that the severe form of NF2 (Wishart 
type) results from complete loss of NF2 protein, rather than a dominant negative effect of mutant 
protein over wild-type. The mild form may be explained by some remaining activity of the mutant 
allele, for instance by residual activity of a mutant protein or alternatively by residual wild-type 
splicing of an allele with a splice-site mutation. 
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Neurofibromatosis type 2 is a hereditary disease caused by mutations in the NF2 gene located on 
chromosome 22. The disease is characterised by the occurrence of bilateral vestibular schwannomas. 
These are benign tumours developing from cells of the nerve sheath of the eighth cranial nerve. 
Vestibular schwannomas lead to deafness and balance disorders. Schwannomas may also develop in 
other sites in NF2 patients, in particular on the nerve sheaths of spinal nerve roots. Approximately half 
of the NF2 patients develop meningiomas. These are benign intracranial tumours originating from the 
membranes covering the brain. In addition to schwannomas and meningiomas, NF2 patients develop 
lens opacities at an early age, leading to impaired vision. 
The NF2 gene was cloned in 1993. Mutation analysis of the NF2 gene in tumours and NF2 families 
confirmed its role as a tumour suppressor gene. In the majority of cases the identified mutations 
theoretically should lead to a truncated NF2 protein product. Two major splice variants of the NF2 
gene are known, resulting in either a 595 aminoacid (isoform I) or a 590 aminoacid protein (isoform 
II). The NF2 protein, also known as merlin or schwannomin, is highly homologous to three proteins in 
turn belonging to a superfamily of proteins related to the erythrocyte cytoskeletal protein band 4.1. 
These three proteins, ezrin, radixin and moesin, link integral membrane proteins to the cytoskeleton. 
The similarity of the NF2 protein to these proteins, collectively known as ERM proteins, led to the 
assumption that it likewise would function as a membrane-cytoskeleton linking protein. 
Although initial studies documented NF2 gene expression in many tissues by northern blotting and 
RT-PCR, a detailed analysis of its expression in specific cell types within the various human tissues 
was not yet performed. 
The aim of the work described in this thesis was to gain insight into the mechanisms underlying the 
pathological phenomena observed in NF2. To this end we sought to investigate and characterise the 
association of the NF2 protein with the cytoskeleton. Furthermore, by providing a detailed inventory 
of cells and tissues in which the NF2 gene is expressed the postulated presence of NF2 protein in 
specific tissues is supported. Finally, immunological detection of mutated NF2 protein in tumours may 
speed-up and simplify diagnosis. Therefore, using immunological methods, we sought to detect 
mutated NF2 proteins from meningiomas and schwannomas. 
We generated polyclonal antibodies to synthetic NF2 peptides (Chapter II). With these antibodies we 
investigated the subcellular localisation of the NF2 protein and putative cytoskeletal-NF2 interaction. 
In COS cells transfected with the NF2 eDNA, the spatial arrangement of NF2 protein as determined 
by immunofluorescent staining was compatible with a cytoskeletal interaction. Immunohistochemical 
staining experiments with the polyclonal antibodies revealed expression of the NF2 gene in muscle 
cells, in particular in smooth muscle cells. Immunohistochemical evidence for NF2 protein in 
Schwann cells was also found although staining was weaker than in smooth muscle cells. 
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Monoclonal antibodies were raised to the same synthetic NF2 peptides and an additional N-terminal 
synthetic peptide (Chapter III). Immunofluorescent staining of NF2 transfected COS cells with these 
antibodies, in conjunction with confocal scanning laser microscopy, demonstrated the localisation of 
NF2 protein at the dorsal cell membrane. This localisation is in accordance with an association with 
the cortical actin cytoskeleton. Furthermore, the transfected NF2 protein was resistant to extraction 
with non-ionic detergents, substantiating the postulated cytoskeletal interaction. Imrnunostaining with 
the monoclonal anti-NF2 antibodies confirmed the high level of NF2 expression in smooth muscle 
cells. However, staining of other muscle cells (skeletal and cardiac) was unsuccessful. The 
cytoskeletal association of the NF2 protein was further studied by immunofluorescent staining of 
cultured smooth muscle cells. In these cells co-localisation of NF2 protein with actin stress fibers was 
found. Staining of the human epidermis with the monoclonal anti-NF2 antibodies was also seen. 
Immuno-electron microscopy of the epidermis with a monoclonal antibody showed association of NF2 
protein with keratohyalin granules and intermediate filaments. It is concluded that the NF2 protein 
shares some characteristics with other ERM proteins, in particular as determined by biochemical 
assays. But unlike ERM proteins, the NF2 protein also associates with intermediate filaments. 
Therefore, in comparison with ERM proteins the NF2 protein harbours unique functions. 
The gathered data supports an interaction of NF2 protein with the actin cytoskeleton. It is possible that 
NF2 protein truncation results in impaired cytoskeletal interaction and in this way leads to disease. 
Therefore determination of NF2 protein domains governing cytoskeletal interaction would further our 
understanding of NF2 pathogenesis. To determine the domain of the NF2 protein governing 
cytoskeletal interaction NF2 cDNA constructs with specific mutations were made and transfected to 
COS cells (Chapter IV). The ability of the mutant NF2 protein to resist extraction by non-ionic 
detergents reflected cytoskeletal association. It was found that a cytoskeletal attachment domain was 
present in the N-terminus of the NF2 protein between aminoacids 29-131. A second weaker 
attachment domain was found between aminoacids 321-470. In addition, NF2 mutations found in 
patients did not result in a NF2 protein with impaired cytoskeletal attachment. In conclusion, The NF2 
protein harbours at least 2 cytoskeleton attachment domains that may be common to other ERM 
proteins. However, impairment of cytoskeletal attachment of NF2 protein by itself does not appear 
sufficient to cause disease. 
Early studies of the expression of the human NF2 gene in tissues were largely based on northern 
blotting and RT-PCR analysis. Since these techniques are performed on tissue homogenates they do 
not permit detailed expression studies at the cellular level. In Chapter V application of mRNA-ISH 
and immunohistochemistry with a panel of monoclonal antibodies is described, with generation of 
detailed NF2 expression data in human tissues. Expression of the NF2 gene was found in many human 
tissues, partly overlapping with the other members of the ERM family. The expression of the NF2 
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gene could be confirmed in Schwann cells by immunohistochemistry on frozen sections but not in 
paraffin sections. Detection of NF2 mRNA in Schwann cells, arachnoidal cells and smooth muscle 
cells was not successful. In the epidermis and other epithelia an overlapping mRNA-ISH and 
immunostaining signal was found. 
NF2 mutations theoretically lead to a truncated protein in the majority of cases. Truncating mutations 
are particularly found in patients with a more severe form of NF2. In Chapter VI the detection and 
characterisation of an intronic NF2 mutation in a family with NF2 is described. The mutation results in 
the introduction of a cryptic exon and theoretically in the formation of a 172 aminoacid protein. 
Although detection of mutant protein produced in-vitro from a cDNA construct with the mutation was 
possible, no mutant protein was detected by immunoprecipitation from tumour tissue. The results 
indicate that this truncated protein is unstable and is rapidly degraded. 
To determine the presence of truncated NF2 proteins in tumour tissue, meningiomas and 
schwannomas were subjected to immunoprecipitation. A subset of these tumours harboured previously 
defined NF2 mutations, theoretically leading to truncated proteins with expected molecular weights. 
From 17 of 19 tumours wild-type NF2 protein was precipitated. From 2 schwannomas no product was 
precipitated. No smaller products were seen. The results indicate that truncated NF2 proteins are 
unstable. The detected wild-type protein most likely originated from blood vessel walls. (Chapter 
VII). 
In conclusion, in this thesis evidence for the association of the NF2 protein with the cytoskeleton is 
provided. Moreover, the NF2 protein interacts with the actin cytoskeleton and also with intermediate 
filaments. The conclusions are supported by data from other investigators. However, several points 
remain to be clarified. Exactly which specialized membrane structures is the NF2 protein associated 
with and does it perform an organising role herein? Are there (additional) functional domains present 
in the NF2 protein? To what extent are the functions of ezrin and NF2 protein interchangeable? How 
does the absence of NF2 protein lead to tumorigenesis in Schwann cells? If indeed the NF2 protein is 
an essential part of specialised membrane structures or even induces them, possible effects pertaining 
to growth control may be regulation, relocation or concentration of integral membrane proteins, 
including receptors or regulatory sub-units thereof. However, comparison with other ERM proteins 
fails to reveal a common theme. No neoplastic disease is clearly associated with ERM proteins as yet. 
Therefore tumorigenesis induced by the absence of NF2 protein is likely to be the result of loss of 
interaction with a specific NF2 interacting protein. Conversely, similar to mechanisms proposed for 
ezrin, indirect effects on transcription through cytoskeleton associated signalling proteins 
(Rho/RaclCdc42?) may occur. It is conceivable that these signalling cascades may be secondary to 
morphological aberrations induced by loss of NF2 protein involved. 
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Future investigations should focus on the interaction of the NF2 protein with other proteins. This may 
be achieved by co-immunoprecipitation or other biochemical techniques. However, it must be 
appreciated that the NF2 protein resists solubilisation by non-ionic detergents. Therefore techniques 
relying on solubilisation may fail to identify those proteins that physiologically interact with the NF2 
protein. The downstream effects of loss of NF2 may be more efficiently investigated by focusing on 
the NF2 interacting proteins already identified by other means. 
A second conclusion from the work presented here is that the NF2 gene is expressed in a wide variety 
of human tissues but that gene transcription and the presence of NF2 protein do not always correlate. 
Of note is the finding that in continually proliferating tissue such as epithelia, both protein and mRNA 
is detected, whilst in non-proliferating tissues the protein is detected but detection of transcription 
fails. In general, expression of the NF2 gene in human tissues described here compares with the 
published expression data in rodents. 
Finally, it is concluded that it is not possible to detect truncated NF2 proteins from tumours known to 
harbour NF2 mutations, probably due to accelerated degradation of mutated NF2 protein. This 
conclusion is in accordance with published experimental data documenting the instability of mutated 
NF2 proteins. 
113 
samenvatting en disclls~·ie 
Samenvatting en Discussie 
Neurofibromatose type 2 is een erfelijke aandoening die veroorzaakt wordt door mutaties in het op 
chromosoom 22 gelegen NF2 gen. De ziekte wordt gekenmerkt door bilaterale vestibulaire 
schwannomen. Dit zijn goedaardige gezwellen die ontstaan vanuit cellen van de zenuwschede van de 
achtste hersenzenuw. Vestibulaire schwannomen veroorzaken doofheid en evenwichtsstoornissen. 
Ook op andere plaatsen in het lichaam kunnen schwannomen ontstaan bij NF2 patienten, met name in 
de zenuwscheden van de spinale zenuwwortels. Bij ongeveer de helft van aIle NF2 patienten ontstaan 
ook meningiomen. Dit zijn goedaardige tumoren die ontstaan in de hersenvliezen. Behalve deze 
tumoren krijgen NF2 patienten ook op relatief jonge leeftijd vertroebelingen van de ooglens die tot een 
verminderd gezichtsvermogen leiden. 
Het NF2 gen werd in 1993 ge'l"soleerd. Mu~atie analyse in tumoren en in NF2 families bevestigde de 
rol van het NF2 gen als tumour-suppress~r-gen. In de meerderheid van de gevallen zouden de 
gevonden mutaties theoretisch tot een getrunceerd eiwitprodukt leiden. De twee meest voorkomende 
splice-varianten van het NF2 gen genereren eiwitten van 595 aminozuren (isoform I) en 590 
aminozuren (isoform II). Het NF2 eiwit, ook wei merlin of schwanl10min genoemd, toont sterke 
homologie met drie eiwitten die op hUn beurt behorcn tot een superfamilie van eiwitten gerelateerd 
aan het erytrocyten-cytoskelet eiwit band 4.1. Deze drie eiwitten, ezrin, radix in en moesin verbinden 
eelmembraaneiwitten met het cytoskelet. De gelijkenis van het NF2 eiwit met deze eiwitten, tezamen 
ERM-eiwitten genoemd, leidde tot de veronderstelling dat het NF2 eiwit ook functioneert als brug 
tussen celmembraan en cytoskelet. 
Aanvankelijk werd NF2 gen expressie in veel verschillende humane weefsels beschreven op grond 
van northern-blotting en RT-PCR experimenten. Een gedetailleerde analyse van NF2 expressie in 
specifieke humaan weefsels was nog niet verricht. 
Doel van het werk dat wordt beschreven in dit proefschrift was inzicht verkrijgen in de mechanismen 
die de pathologische verschijnselen veroorzaken in NF2. Om dit te onderzoeken hebben wij getracht 
de samenhang van het NF2 eiwit met het cytoskelet nader te karakteriseren. Verder geven wij een 
gedetailleerd overzieht van humane eellen en weefsels waarin het NF2 gen tot expressie komt. 
Tenslotte zou immunologische deteetie van gemuteerde NF2 eiwitten de diagnostiek van NF2 kunnen 
vereenvoudigen en versnellen. Daartoe hebben wij getracht om met immunologische technieken 
gemuteerde NF2 eiwitten in meningiomen en sehwannomen aan te tonen. 
Wij hebben polyclonaie eiwitten opgewekt tegen synthetische NF2 peptiden (Hoofdstuk II). Met deze 
antilichamen onderzoehten wij de intraeelluiaire lokalisatie van het NF2 eiwit en de mogeJijke 
interaetie van het NF2 eiwit met het cytoskelet. In COS-cellen getransfecteerd met het NF2 eDNA 
werd met behulp van immunofluoresentie gevonden dat de ruimtelijke verdeling van het NF2 eiwit 
verenigbaar was met een associatie met het cytoskelet. Immunohistochemische kleuringen met de 
polyclonale eiwitten toonde expressie van het NF2 gen in spiercellen, met name in glad spierweefsel. 
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Er werd tevens imrnunohistochemisch bewijs gevonden voor de aanwezigheid van het NF2 eiwit in 
Schwann-cellen met immunohistochemie, hoewel de aankleuring zwakker was dan in glad 
spierweefsel. 
Er werden monoklonale antilichamen opgewekt tegen deze1fde synthetische NF2 peptiden en tegen 
een nieuw N-terminaal gelegen synthetisch peptide (Hoofdstuk III). Confocale laser-scanning-
microscopische analyse van NF2 getransfecteerde, en met irnmunofluorescentie gekleurde COS-cellen 
toonde de aanwezigheid van het NF2 eiwit aan de dorsale celmembraan. Deze lokalisatie is in 
overeenstemming met een associatie met het corticale actine-cytoskelet. Het getransfecteerde NF2 
eiwit bleek bovendien resistent te zijn voor extractie met niet-ionogene detergentia. Deze bevinding 
bevestigde de veronderstelde interactie met het cytoskelet. Immunohistochemische kleuringen met de 
monoklonale antilichamen bevestigden de sterke NF2 expressie in gladde spiercellen. Echter, 
immunohistochemisch aankleuren van andere typen spiercellen (skeletspier en hartspier) bleek niet 
mogehjk. De associatie van het NF2 eiwit met het cytoskeJet werd nader onderzocht door 
immunotluorescentie onderzoek van gekweekte gladde spiercellen. In deze cellen bleek het NF2 eiwit 
te co-iokaliseren met actine "stress-fibers". Bovendien werd aankleuring van de humane epidermis 
gezien met monoklonale anti-NF2 antilichamen. In de epidermis werd met behuip van immuno-
elektronenmicroscopie associatie van het NF2 eiwit met keratohyaliene korrels en intermediare 
filamenten gevonden. Geconcludeerd wordt dat het NF2 eiwit gemeenschappelijke biochemische 
eigenschappen toont met andere ERM-eiwitten. Anders dan ERM-eiwitten kan het NF2 eiwit ook 
associeren met intermediare filamenten. Derhalve bezit het NF2 eiwit in vergelijking met andere 
ERM-eiwitten specifieke eigenschappen. 
De verzamelde gegevens ondersteunen een interactie van het NF2 eiwit met het cytoskelet. Het is 
mogelijk dat verkorting van het NF2 eiwit deze interactie verstoort en op deze wijze tot ziekte Icidt. 
Identificatie van domeinen van het NF2 eiwit die van belang zijn voor de interactie met het cytoske1et 
zou derhaive het inzicht in de pathogenese van NF2 kunnen vergroten. Ten einde domeinen in het NF2 
eiwit te identificeren die de interactie met het cytoskelet bewerkstelligen, werden NF2 eDNA 
constructen met specifieke mutaties vervaardigd en in COS-cellen getransfecteerd (Hoofdstuk IV). 
Het vermogen om extractie door niet-ionogene detergentia te weerstaan geeft een indruk van 
cytoskelet interactie. Er werd in het N-terminale deel van het NF2 eiwit eeo cytoskelet bindend 
domein gevonden tussen aminozuren 29-131. Een tweede zwakker cytoskelet bindend domein werd 
gevonden tussen arninozuren 321-470. Bovendien bleken specifieke NF2 mutaties, die werden 
gevonden in patienten, niet tot NF2 eiwitten te lei den met gestoorde cytoskelet binding. In conclusie 
blijkt het NF2 eiwit tenminste twee cytoskelet-bindende dorneinen te bezitten die mogelijk ook 
aanwezig zijn in andere ERM-eiwiuen. Bovendien lijkt het verloren gaan van cytoskelet interactie van 
het NF2 eiwit op zich niet te leiden tot ziekte. 
115 
sameflvatting en discussie 
Onderzaeken naar de expressie van het humane NF2 gen waren aanvankelijk gebaseerd op northern 
blotting en RT-PCR analyse. Omdat deze technieken gebruik maken van gehomogeniseerd weefsel 
laten zij geen gedetailleerde analyse van de expressie van hel gen op eelniveau toe. In Hoofdstuk V 
wordt immunohistoehemie met een panel specifieke monoklonale antilichamen en mRNA-ISH 
beschreven waarbij gedetailleerde data over NF2 expressie in humane weefsels worden verkregen. 
NF2 gen-expressie werd gevonden in vele humane weefsels, deels overlappend met andere ERM-
eiwitten. De expressie van het NF2 gen in Schwann-cellen kon worden bevestigd in vriescoupes maar 
niet in paraffine coupes. Detectie van NF2 mRNA in Schwann-cellen, arachnoidale cellen en gJadde 
spiercellen bleef zonder succes. In de epidermis en andere epithelia werd een overlappend in-situ-
hybridisatie en immunohistochemisch patroon gevonden. 
In een meerderheid van de gevallen resulteren NF2 mutaties theoretisch in een getrunceerd eiwit. 
Mutaties leidend tot een getruneeerd eiwit worden met name gevonden in patienten met een ernstige 
vorm van NF2. In Hoofdstuk VI wordt een mutatie in een intron van het NF2 gen beschreven die 
gevonden werd in een familie met NF2. Het gevolg van deze mutatie is de incorporatie van een 
cryptisch exon waardoor theoretisch een mutant NF2 eiwit van 172 aminozuren gevormd zau worden. 
Hoewel detectie van het in-vitro geproduceerde mutante eiwit goed mogelijk bleek, kon met behulp 
van immunoprecipitatie geen mutant eiwit uit tumorweefsel aangetoond worden. De bevilldingen 
wijzen erop dat het mutante eiwit niet stabie! is en versneld wordt afgebroken. 
Om de te bepalen of getrunceerde NF2 eiwitten in tumoren aangetoond konden worden, werd 
immunoprecipitatie uitgevoerd op meningiomen en schwannomen. Een deel van deze tumoren had een 
NF2 mutatie, waarbij theoretisch gemuteerde NF2 eiwitten met bekende lengte gevormd zouden 
worden. Uit 17 van de 19 onderzochte tumoren werd uitsluitend wild-type NF2 eiwitten gevonden. Uit 
twee schwannomen werd geen produkt verkregen. Getrunceerde NF2 eiwinen werden niet gevonden. 
Deze resuitaten wijzen erop dat getrunceerde NF2 eiwitten niet stabiel zijn. (Hoofdstuk VII) 
Concluderend, in dit proefschrift wordt bewijs geleverd v~~r de interactie van het NF2 eiwit met het 
cytoskelet. Het NF2 eiwit associeert met het actine cytoskelet en met intermediare filamenten. Deze 
conc1usies worden gesteund door bevindingen van andere onderzoekers. Echter, een aantal punten 
behoeven verder onderzoek. Met welke gespecialiseerde celmembraan strukturen is het NF2 eiwit 
geassocieerd en ven'l1It het hierin een organiserende rol? Zijn er nog andere functionele domeinen 
aanwezig in het NF2 eiwit? Tot op welke hoogte zijn de functies van het NF2 eiwit en ezrin 
uitwisselbaar? Hoe leidt de afwezigheid van NF2 eiwit tot tumorvorming in Schwann-celIen? 
Mogelijk effecten op groei regulatie zouden, indien het NF2 eiwit inderdaad een essentieel onderdeei 
van gespecialiseerde membraanstrukturen uitmaakt of deze zeifs induceert, een gevolg kunnen zijn 
van regulatie, relocatie en concentratie van integrale membraaneiwitten, inclusief receptoren en de 
regulerende onderdelen hiervan. Doeh vergelijking met andere ERM-eiwitten toont geen 
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gemeenschappelijk mechanisme. Er is, voor zover bekend, geen neoplastische afwijking geassocieerd 
met andere ERM-eiwitten. Tumorgenese gei'nduceerd door afwezigheid van- NF2 eiwit lijkt derhalve 
een gevolg van een verlies van interactie van NF2 eiwit en een specifiek geassocieerd eiwit. 
Anderzijds, overeenkornstig met mechanismen waarvan gedacht worden dat deze eell rol spelen bij 
ezrin, zouden indirekte effecten op transcriptie door tussenkomst van cytoskelet-geassocieerde 
signaaleiwitten (Rho/Rac/Cdc42?) een roi kunnen speIen. Het is niet ondenkbaar dat deze 
signaalcascaden worden geactiveerd als gevoig van morfologische veranderingen die het gevoig zijn 
van NF2 verlies. 
Toekomstig onderzoek zal zich moeten toespitsen op de interactie van het NF2 eiwit met andere 
eiwitten. Dit zou kunnen plaatsvinden door co-immunoprecipitatie of andere biochemische technieken. 
Er moet echter rekening mee worden gehouden dat het NF2 eiwit niet geextraheerd wordt door niet-
ionogene detergentia. Met technieken die berusten op het extractie met deze stoffen zouden derhalve 
potentieIe NF2 bindende eiwitten kunnen worden gemist. Het lijkt daarom zinvol om effecten van 
NF2 verlies te bestuderen door het onderzoeken van reeds met andere methoden gei'dentificeerde NF2 
geassocieerde eiwitten. 
Ben tweede conclusie van het hier gepresenteerde werk is dat het NF2 gen in veel verschillende 
weefsels tot expressie komt doch dat transcriptie en de aanwezigheid van NFl eiwit niet altijd 
overeenkomen. Opmerkelijk is de bevinding dat in continu vernieuwend weefsel zoals epitheel, zowel 
NF2 mRNA en NF2 eiwit aantoonbaar zijn terwijl in niet delend weefsel NF2 eiwit wei aantoonbaar is 
maar dat transcriptie van het NF2 gen niet is aan te tonen. Over het algemeen is er overeenkomst 
tussen de hier beschreven expressie van het NF2 gen in humaan weefsel en de gepubliceerde gegevens 
in knaagdieren. 
Tensiotte wordt geconcludeerd dat het niet mogelijk is getrunceerde NF2 eiwitten aan te tonen in 
tumoren hoewel dat deze een NF2 mutatie hebben. Vermoedelijk is dit een gevolg van versnelde 
afbraak van het gemuteerde NF2 eiwit. Deze conclusie stemt overeen met gepubliceerde 
experimentele gegevens waaruit de instabiliteit blijkt van mutant NF2 eiwit. 
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